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Measuring universal health coverage based on an index of 
effective coverage of health services in 204 countries and 
territories, 1990–2019: a systematic analysis for the Global 
Burden of Disease Study 2019
GBD 2019 Universal Health Coverage Collaborators*
Summary
Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of 
high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both 
countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and 
WHO’s Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is 
important for understanding whether health services are aligned with countries’ health profiles and are of sufficient 
quality to produce health gains for populations of all ages.
Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC 
effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework 
developed through WHO’s GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing 
health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from 
reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention 
coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; 
outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of 
location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator 
relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and 
population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage 
index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current 
metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of 
UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective 
coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private 
expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion 
target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with 
UHC effective coverage from 2018 to 2023.
Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 
44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 
95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, 
sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 
2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 
2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for 
non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-
communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many 
health systems are not keeping pace with the rising non-communicable disease burden and associated population 
health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita 
(r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is 
potentially achievable relative to their health spending. Under maximum efficiency of translating health spending 
into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita 
(US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 
2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective 
coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. 
Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective 
coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia.
Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting 
improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to 
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accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable 
diseases occurs and countries can better translate health spending into improved performance. Focusing on effective 
coverage and accounting for the world’s evolving health needs lays the groundwork for better understanding how 
close—or how far—all populations are in benefiting from UHC.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Research in context
Evidence before this study
Various approaches have been proposed for monitoring 
universal health coverage (UHC) service coverage, including 
those from WHO (ie, the UHC service coverage index, 
the official UN measure for the Sustainable Development Goal 
indicator 3.8.1) and the World Bank. Currently available service 
coverage metrics are heavily focused on infectious diseases as 
well as reproductive, neonatal, maternal, and child health, 
despite the recognition that advances towards UHC also 
require service provision for non-communicable diseases and 
delivering interventions to a broader range of population-age 
groups. Inconsistent trend estimation across indicators, 
if time series are generated, impedes measurements of 
progress—a priority emphasised in the member-state-led 
Political Declaration for the UN High-Level Meeting on 
Universal Health Coverage in 2019. Although the 2014 WHO 
and World Bank framework for UHC service coverage is 
explicitly focused on health-system effective coverage, 
efforts to date have focused on crude coverage or health-
system resource inputs, or a combination of both. Effective 
coverage at the health-system level, or the fraction of 
potential health gains delivered by a health system, has yet to 
be incorporated into UHC monitoring efforts, even though 
WHO and member states have signalled increasing interest in 
understanding the impact of UHC beyond service coverage 
alone.
Added value of this study
Drawing from the WHO Thirteenth General Programme of 
Work (GPW13) Expert Reference Group and Task Force on 
Metrics recommendations on UHC monitoring and conceptual 
work on effective coverage of health systems, the present 
study offers a new measurement framework for UHC effective 
coverage, representing health needs and corresponding 
service types across the life course while accounting for 
potential health gains delivered to populations. 
The framework mapped 23 effective coverage indicators 
against five health service domains—promotion, prevention, 
treatment, rehabilitation, and palliation—and five population-
age groups (ie, reproductive and newborn, children <5 years, 
children and adolescents aged 5–19 years, adults aged 
20–64 years, and adults aged ≥65 years). Based on estimates 
from the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2019, these 23 effective coverage indicators 
involved either direct measures of intervention coverage 
(eg, antiretroviral therapy coverage) or outcome-based 
indicators, such as mortality-to-incidence ratios, to approximate 
access to quality care. We weighted each effective coverage 
indicator on the basis of potential health gains deliverable by 
health systems, as approximated by the disability-adjusted 
life-years associated with each effective coverage indicator, 
and aggregated them to produce the UHC effective coverage 
index. Three types of validity were assessed (content, known 
groups, and convergent) for the UHC effective coverage index 
and other multi-country service coverage measures (eg, the 
UHC service coverage index for 2017, as estimated by WHO, 
and the GBD 2017 UHC service coverage index for 2017). 
We also quantified relationships between pooled health 
spending per capita (ie, government expenditures, prepaid 
private spending, and development assistance for health) and 
UHC effective coverage performance to examine how well 
countries are currently translating resources into improved 
UHC effective coverage. Last, we estimated the number of 
population equivalents covered by effective health services 
from 2018 to 2023—a key component of WHO’s GPW13—
by assuming a direct translation of the UHC effective coverage 
index to a fractional metric and multiplying country-level 
population estimates.
Implications of all the available evidence
This study offers another step forward in measuring UHC 
effective coverage across settings, developing a measurement 
framework and methods for country and global stakeholders 
to better track progress in effective health service provision at 
the population level. Our results highlight the importance of 
including non-communicable disease indicators alongside 
interventions for reproductive, neonatal, maternal, and child 
health and for infectious diseases, as well as capturing 
potential health gains delivered by health systems at the 
population level. In combination, we expect these analytical 
advances to better identify where countries have improved 
effective health service delivery, and what health needs along 
the life course increasingly threaten further progress. Focusing 
on UHC effective coverage, both in terms of its measurement 
and its capacity for instilling greater accountability for 
improving health outcomes across the development spectrum, 
lays a data-driven path towards achieving UHC for all 
populations.
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Introduction
Universal health coverage (UHC) is viewed as a crucial 
avenue through which improved health for all can be 
attained,1,2 by ensuring all people can receive quality 
health services they need, without experiencing financial 
hardship. Global agendas and actors have amplified calls 
for UHC in recent years, driven at least in part by the 
explicit inclusion of UHC achievement in target 3.8 of 
the UN Sustainable Development Goals (SDGs)3–5 and 
heightened emphasis within recent UN resolutions1 and 
WHO programmatic objectives (eg, the target of 1 billion 
more people benefiting from UHC from 2018 to 2023 as 
part of WHO’s Thirteenth General Programme of Work 
[GPW13]).6,7 Regional and country-driven efforts to elevate 
UHC on policy agendas have occurred as well, both 
building upon long estab lished UHC programmes (eg, in 
Japan,8 much of western Europe,9,10 and many countries 
in Latin America11,12) and galvanising newer commitments 
to UHC implementation (eg, in India, Kenya, and South 
Africa).13 To better understand how actions and investments 
are delivering on the ultimate goal of UHC—improving 
health outcomes—it is essential to quantify and track 
trends in effective health service provision, as well as the 
extent to which advances in service coverage correspond 
with the potential health gains populations should 
experience.
In 2014, WHO and the World Bank published a UHC 
measurement framework in which service coverage 
was defined as a spectrum of services—promotion, 
prevention, treatment, rehabilitation, and palliation—
across the life cycle.14,15 This framework emphasised 
the importance of providing services for individuals’ 
health needs throughout their lifespans and quantifying 
effective coverage of interventions delivered by health 
systems. Conceptually, effective coverage unites inter-
vention need, use, and quality into a single metric, 
representing the proportion of health gain that could 
be potentially received from an intervention relative to 
what is actually experienced.16,17 At the health-system 
level, effective coverage aims to capture the fraction of 
total potential health gains actually delivered relative to 
what a health system could have theoretically delivered.16 
To quantify such population-level health gains, Shengelia 
and colleagues outlined an approach to measure an 
aggregate of health-system effective coverage.16 Effective 
coverage is a powerful measure: this metric not only 
demands accountability of intervention availability and 
use, but also requires that the services received are of 
sufficient quality to provide the health gains they are 
supposed to. Yet in practice, effective coverage has to date 
been rarely measured, particularly across countries and 
over time. Minimal uptake of effective coverage as a 
metric for UHC monitoring is at least partly due to data 
challenges, as most health data systems are not able to 
capture all three intervention components together (ie, 
need, use or receipt, and quality) and few data sources 
can adequately represent these dimensions for conditions 
involving more complex care (eg, cancer or stroke). 
Tracer or proxy indicators of effective coverage exist for 
certain interventions or cause groups (eg, cancers), and 
recent health-system research by Kruk and colleagues 
used mortality-to-incidence rates to garner insights into 
health-care quality in low-income to middle-income 
countries.18 Nevertheless, to date no multi-country UHC 
measure ment effort to our knowledge has sought to 
estimate effective coverage across health service domains 
and population-age groups within a cohesive analytical 
platform.
Following the 2014 WHO/World Bank UHC monitoring 
framework and SDG adoption in 2015, several multi-
country health service coverage indices have been 
developed to inform UHC measurement.19–26 Although 
each effort has shown recognition of prevailing data 
limitations and challenges with operationalising UHC 
service coverage across myriad settings,21,24 they each have 
limitations in how well they capture country-level trends 
and health service needs across the life course.17,27–31 First, 
current indices primarily rely solely on household survey 
point estimates from multi-country survey series, which 
can lead to various measurement limitations (ie, being 
primarily focused on low-income to middle-income 
countries; restricted sets of interventions captured; 
and lags in data availability for understanding trends). 
Second, most indices include either risk factor indicators 
(eg, prevalence of non-smoking and non-raised blood 
pressure in the UHC service coverage index,19–21 the 
SDG indicator 3.8.14) or health-system inputs or process 
indicators (eg, health workers per capita and hospital 
beds per capita in the UHC service coverage index; 
inpatient admission rates for Wagstaff and colleagues’ 
service coverage index23,24), or both. The use of such proxy 
indicators, as well as those influenced by factors outside 
the health system (eg, tobacco prevalence), for service 
coverage measurement could misattribute successes in 
health service provision or misrepresent UHC service 
coverage. With non-communicable diseases accounting 
for at least 60% of early death and disability worldwide,32 
the omission of non-communicable disease indicators 
beyond risk factor prevalence proxies or cancer screening 
is at odds with the reality of countries’ populations and 
health systems. Third, approaches used to construct 
overall indices of UHC service coverage typically involve 
somewhat arbitrary weighting schemes (eg, a series of 
geometric means4,19–21 or weighted geometric means23,24), 
and thus might not capture the alignment of services 
provided given a country’s health and demographic 
profile. Last, none of these approaches explicitly accounts 
for the potential health gains delivered through the 
health system, a limitation that inhibits our collective 
understanding of whether or how gains in UHC are 
improving health outcomes for all.
Recent developments from WHO indicate a revived 
interest in using effective coverage for UHC monitoring; 
these include the WHO GPW13 Expert Reference Group 
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(ERG) Task Force on Metrics recommendations on 
effective service coverage measurement33 and the WHA72 
resolution recommending country pilots on monitoring 
UHC effective coverage.7 The GPW13 ERG also supported 
initial efforts to map health services against population-
age groups within a measurement framework and to 
identify indicator options across the life course in order to 
estimate UHC effective coverage across countries.33 The 
present analysis contributes to this endeavour through 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2019, mapping 23 effective coverage indi-
cators across health service types and population-age 
groups for 204 countries and territories from 1990 to 2019. 
Based on the construct of health-system effective coverage, 
we aggregated individual effective coverage indicators 
to produce an overall index using health gain weights, 
which were derived from country-specific disease burden 
estimates relative to theoretical levels of burden avertable 
given intervention levels and associated effectiveness. We 
compared the performance of this UHC effective coverage 
measure against that of previous multi-country UHC 
service coverage indices21,24,26 on a series of validity tests. We 
then assessed the relationships between pooled health 
spending per capita and index performance, aiming to 
capture how close—or how far—countries were in 
reaching UHC effective coverage frontiers relative to their 
current spending. Finally, we considered applications of 
this index for current global and national UHC priorities, 
such as translating index performance to the number of 
people covered by effective coverage for the GPW13 UHC 
billion target.
Methods
Overview
Our primary analysis involved three main steps: first, to 
use intervention coverage or compute proxy measures of 
effective coverage for 23 indicators; second, to calculate 
the fraction of potential health gains associated with 
each effective coverage indicator based on each location’s 
disease burden profile; and third, to construct the overall 
UHC effective coverage index by weighting each effective 
coverage indicator relative to its health gains fraction. 
We then did secondary analyses, assessing UHC effec-
tive coverage performance relative to health spending 
and current trajectories towards the GPW13 UHC billion 
target. Each step is summarised below and further 
described in appendix 1 (pp 12–61).
This analysis uses estimates from the broader 
GBD 2019,34–36 covering 204 countries and territories from 
1990 to 2019. Details of disease-specific, injury-specific, 
and coverage-specific data inputs and processing, statis-
tical synthesis approaches, and final models are available 
in the accompanying GBD 2019 capstone publications.34–36 
This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
statement,37 with further information provided in the 
appendix 1 (pp 69–72).
Measurement of UHC effective coverage
Framework and indicators
Development of the UHC effective coverage measure-
ment framework and selection of effective coverage 
indicators was based on consultation, methods testing, 
and refinement via the WHO ERG on the GPW13 
from 2017 to 2019;7,33,38,39 the background and details of 
this process are provided in the appendix 1 (pp 12–28). 
The resulting framework (figure 1) and currently 
included effective coverage indicators (table 1) sought to 
represent the range of different health services that 
populations need across their lifespans while recog-
nising present data gaps and appeals for measurement 
parsimony (appendix 1 pp 18–28).
As applied in this analysis, the UHC effective coverage 
measurement framework involves 30 unique cells 
from a matrix of five health service types—promotion, 
prevention, treatment, rehabilitation, and palliation—
against five population-age groups (reproductive and 
newborn, children younger than 5 years, children and 
adolescents aged 5–19 years, adults aged 20–64 years, and 
older adults aged ≥65 years). Treatment is subdivided 
into two separate groups: first, communicable diseases 
and maternal, newborn, and child health; and second, 
non-communicable diseases. Effective coverage indica-
tors were then mapped to these cells to represent needed 
health services across the life course.
23 effective coverage indicators were included in the 
present analysis (table 1). As recognised in previous 
studies,19–26 data for directly measuring effective inter-
vention coverage are rarely available across health services, 
locations, and over time. Subsequently, we used viable 
proxy measures and analytical techniques to approximate 
effective coverage for conditions considered amenable to 
health care.40–43 Criteria set forth by the WHO ERG guided 
selection of effective coverage indica tors and preferred 
measurement approaches (appendix 1 pp 12–28).33 Such 
criteria stipulated that effective coverage indicators should 
be currently measurable (ie, data and methods that 
support indicator measurement today); reflect differences 
in effective health services and not factors outside the 
immediate scope of health systems and UHC (eg, tobacco 
taxation and physical infrastructure such as roads and 
water systems); and use indicators already encompassed 
within the SDGs and GPW13, or draw from data systems 
required for monitoring of SDGs and GPW13. Several 
other indicator candidates were considered from 2017 
to 2019 (appendix 1 pp 12–28), but inadequate data avail-
ability, access, or quality, or a combination of these factors, 
impeded their inclusion in the current analysis.
Four effective coverage indicators were measures 
of intervention coverage and 19 were mortality-based 
measures to proxy access to quality of care (table 1; 
appendix 1 pp 30–32). For the mortality-based measures, 
we primarily used mortality-to-incidence ratios (MIRs) 
and mortality-to-prevalence ratios (MPRs) for chronic or 
longer-term conditions (eg, diabetes or asthma). Without 
See Online for appendix 1
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better data on effective coverage, such mortality-based 
measures are viewed as suitable proxies,33,44–46 providing 
good signals on what access to quality care should, at 
minimum, avert or protect against even if the onset of 
disease cannot be wholly prevented. The main exception 
was ischaemic heart disease, for which GBD input data 
coverage and quality on non-fatal outcomes were less 
robust than data on causes of death and related risks; 
subsequently, we used risk-standardised death rates 
instead of MIRs or MPRs to proxy effective coverage. As 
a statistical approach used in previous GBD analyses41,43 
and further described in the appendix 1 (pp 31–32), 
risk standardisation aims to better isolate variations in 
mortality associated with health-care access and quality 
from differences in underlying risk exposures mainly 
related to factors outside the health system.
Effective coverage indicators for intervention coverage 
were kept on their natural scale (0–100%), whereas the 
19 other effective coverage indicators were transformed 
to values on a 0–100 scale (appendix pp 31–33). Across 
locations and from 1990 to 2019, 0 was set by values at 
the 97·5th percentile or higher (ie, “worst” levels of 
MIRs) and 100 by the 2·5th percentile or lower (ie, “best” 
levels of MIRs).
Figure 1: UHC effective coverage measurement framework
Additional information about the framework development process and selection of effective coverage indicators can be found in appendix 1 (pp 12–28). 
ART=antiretroviral therapy. DTP3=diphtheria-tetanus-pertussis vaccine, 3 doses. IHD=ischaemic heart disease. CKD=chronic kidney disease. COPD=chronic 
obstructive pulmonary disease. LRI=lower respiratory infection. MCV1=measles-containing-vaccine, 1 dose. MNCH=maternal, neonatal, and child health. 
NCDs=non-communicable diseases. TB=tuberculosis. UHC=universal health coverage.
Health service type
Population age group Promotion Prevention Treatment Rehabilitation Palliation
Communicable diseases and MNCH NCDs
Reproductive and 
newborn
Met need for 
family planning 
with modern 
contraception
Antenatal, 
peripartum, and 
postnatal care for 
newborn babies 
Antenatal, 
peripartum, and 
postnatal care for 
mothers
Antenatal, peripartum, and 
postnatal care for newborn 
babies 
Antenatal, peripartum, and 
postnatal care for mothers
Children younger 
than 5 years
Children and 
adolescents 
(5–19 years)
Adults 
(20–64 years)
Older adults 
(≥65 years)
DTP3 coverage 
MCV1 coverage
LRI treatment
Diarrhoea treatment
Acute lymphoid leukaemia 
treatment
ART coverage Acute lymphoid leukaemia 
treatment
Asthma treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
ART coverage
TB treatment
ART coverage
TB treatment
Diabetes treatment
IHD treatment
Stroke treatment
CKD treatment
COPD treatment
Cervical cancer treatment
Breast cancer treatment
Uterine cancer treatment
Colon and rectum cancer 
treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
Diabetes treatment
IHD treatment
Stroke treatment
CKD treatment
COPD treatment
Cervical cancer treatment
Breast cancer treatment
Uterine cancer treatment
Colon and rectum cancer 
treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
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Effective coverage 
indicator
Metric Effective coverage indicator measurement Health gain weight inputs Effectiveness 
category
Numerator Denominator
Reproductive and newborn
Promotion Met need for family 
planning with modern 
contraception
Coverage Females aged 15–49 years with 
demand for family planning met 
with modern contraception
Females aged 15–49 years with 
demand for family planning
50% of DALYs due to maternal 
disorders for females aged 
10–54 years
5
Prevention; 
treatment, 
communicable 
diseases and MNCH
Antenatal, peripartum, 
and postnatal care for 
newborn babies
Early 
neonatal 
mortality rate
All-cause deaths during the 
first 7 days of life
Population of early neonates Early neonatal deaths multiplied 
by life expectancy at birth (on the 
basis of theoretical minimum risk 
life table)
3
Prevention; 
treatment, 
communicable 
diseases and MNCH
Antenatal, peripartum, 
and postnatal care for 
mothers
Maternal 
mortality 
ratio
Deaths due to maternal disorders for 
females aged 10–54 years 
Livebirths among females aged 
10–54 years
50% of DALYs due to maternal 
disorders for females aged 
10–54 years
1
Children younger than 5 years
Prevention DTP3 vaccine coverage Coverage Receipt of three doses of DTP 
vaccine among children aged 
12–23 months
Children aged 12–23 months DALYs due to diphtheria, tetanus, 
and pertussis for children younger 
than 5 years
1
Prevention MCV1 coverage Coverage Receipt of MCV1 among children 
aged 12–23 months
Children aged 12–23 months DALYs due to measles for children 
younger than 5 years
1
Treatment, 
communicable 
diseases and MNCH
LRI treatment MIR Mortality from LRIs for children 
younger than 5 years
Incidence of LRIs for children 
younger than 5 years
DALYs due to LRIs for children 
younger than 5 years
1
Treatment, 
communicable 
diseases and MNCH
Diarrhoea treatment MIR Mortality from diarrhoeal diseases 
for children younger than 5 years
Incidence of diarrhoeal diseases 
for children younger than 5 years
DALYs due to diarrhoeal diseases 
for children younger than 5 years
1
Treatment, NCDs Acute lymphoid 
leukaemia treatment
MIR Mortality from acute lymphoid 
leukaemia for children aged 
1–4 years
Incidence of acute lymphoid 
leukaemia for children aged 
1–4 years
DALYs due to acute lymphoid 
leukaemia for children aged 
1–4 years
1
Children and adolescents (5–19 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Populations aged 5–19 years living 
with HIV/AIDS and on ART
Populations aged 5–19 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged 5–19 years
1
Treatment, NCDs Acute lymphoid 
leukaemia treatment
MIR Mortality from acute lymphoid 
leukaemia for populations aged 
5–19 years
Incidence of acute lymphoid 
leukaemia for populations aged 
5–19 years
DALYs due to acute lymphoid 
leukaemia for populations 
5–19 years
1
Treatment, NCDs Asthma treatment MPR Mortality from asthma for 
populations aged 5–19 years
Prevalence of asthma for 
populations aged 5–19 years
DALYs due to asthma for 
populations aged 5–19 years
1
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged 5–19 years
Prevalence of epilepsy for 
populations aged 5–19
DALYs due to epilepsy for 
populations aged 5–19 years
3
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged 5–19 years
Incidence of appendicitis for 
populations aged 5–19 years
DALYs due to appendicitis for 
populations aged 5–19 years
1
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
1
Adults (20–64 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Population aged 20–64 years living 
with HIV/AIDS and on ART
Population aged 20–64 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged 20–64 years
1
Treatment, 
communicable 
diseases and MNCH
Tuberculosis treatment MIR Mortality from tuberculosis for 
populations aged 20–64 years
Incidence of tuberculosis for 
populations aged 20–64 years
DALYs due to tuberculosis for 
populations aged 20–64 years
1
Treatment, NCDs Diabetes treatment MPR Mortality from diabetes for 
populations aged 20–64 years
Prevalence of diabetes for 
populations aged 20–64 years
DALYs due to diabetes for 
populations aged 20–64 years
3
Treatment, NCDs IHD treatment RSDR Risk-standardised deaths from IHD 
for populations aged 20–64 years
Population aged 20–64 years DALYs due to IHD for 
populations aged 20–64 years
2
Treatment, NCDs Stroke treatment MIR Mortality from stroke for 
populations aged 20–64 years
Incidence of stroke for 
populations aged 20–64 years
DALYs due to stroke for 
populations aged 20–64 years
2
Treatment, NCDs CKD treatment MPR Mortality from CKD for 
populations aged 20–64 years
Incidence of CKD for 
populations aged 20–64 years
DALYs due to CKD for 
populations aged 20–64 years
1
(Table 1 continues on next page)
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Effective coverage 
indicator
Metric Effective coverage indicator measurement Health gain weight inputs Effectiveness 
category
Numerator Denominator
(Continued from previous page)
Treatment, NCDs COPD treatment MPR Mortality from COPD for 
populations aged 20–64 years
Prevalence of COPD for 
populations aged 20–64 years
DALYs due to COPD for 
populations aged 20–64 years
3
Treatment, NCDs Cervical cancer 
treatment
MIR Mortality from cervical cancer for 
females aged 20–64 years
Incidence of cervical cancer for 
females aged 20–64 years
DALYs due to cervical cancer for 
females aged 20–64 years
1
Treatment, NCDs Breast cancer treatment MIR Mortality from breast cancer for 
females aged 20–64 years
Incidence of breast cancer for 
females aged 20–64 years
DALYs due to breast cancer for 
females aged 20–64 years
1
Treatment, NCDs Uterine cancer 
treatment
MIR Mortality from uterine cancer for 
females aged 20–64 years
Incidence of uterine cancer for 
females aged 20–64 years
DALYs due to uterine cancer for 
females aged 20–64 years
1
Treatment, NCDs Colon/rectum cancer 
treatment
MIR Mortality from colon/rectum 
cancer for populations aged 
20–64 years
Incidence of colon/rectum for 
populations aged 20–64 years
DALYs due to colon/rectum 
cancer for populations aged 
20–64 years
1
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged 20–64 years
Prevalence of epilepsy for 
populations aged 20–64 years
DALYs due to epilepsy for 
populations aged 20–64 years
3
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged 20–64 years
Incidence of appendicitis for 
populations aged 20–64 years
DALYs due to appendicitis for 
populations aged 20–64 years
1
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
1
Older adults (≥65 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Population aged ≥65 years living 
with HIV/AIDS and on ART
Population aged ≥65 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged ≥65 years
2
Treatment, 
communicable 
diseases and MNCH
Tuberculosis treatment MIR Mortality from tuberculosis for 
populations aged ≥65 years
Incidence of tuberculosis for 
populations aged ≥65 years
DALYs due to tuberculosis for 
populations aged ≥65 years
2
Treatment, NCDs Diabetes treatment MPR Mortality from diabetes for 
populations aged ≥65 years
Prevalence of diabetes for 
populations aged ≥65 years
DALYs due to diabetes for 
populations aged ≥65 years
4
Treatment, NCDs IHD treatment RSDR Risk-standardised deaths from IHD 
for populations aged ≥65 years
Population aged ≥65 years DALYs due to IHD for 
populations aged ≥65 years
3
Treatment, NCDs Stroke treatment MIR Mortality from stroke for 
populations aged ≥65 years
Incidence of stroke for 
populations aged ≥65 years
DALYs due to stroke for 
populations aged ≥65 years
3
Treatment, NCDs CKD treatment MPR Mortality from CKD for 
populations aged ≥65 years
Incidence of CKD for 
populations aged ≥65 years
DALYs due to CKD for 
populations aged ≥65 years
2
Treatment, NCDs COPD treatment MPR Mortality from COPD for 
populations aged ≥65 years
Prevalence of COPD for 
populations aged ≥65 years
DALYs due to COPD for 
populations aged ≥65 years
4
Treatment, NCDs Cervical cancer 
treatment
MIR Mortality from cervical cancer for 
females aged ≥65 years
Incidence of cervical cancer for 
females aged ≥65 years
DALYs due to cervical cancer for 
females aged ≥65 years
2
Treatment, NCDs Breast cancer 
treatment
MIR Mortality from breast cancer for 
females aged ≥65 years
Incidence of breast cancer for 
females aged ≥65 years
DALYs due to breast cancer for 
females aged ≥65 years
2
Treatment, NCDs Uterine cancer 
treatment
MIR Mortality from uterine cancer for 
females aged ≥65 years
Incidence of uterine cancer for 
females aged ≥65 years
DALYs due to uterine cancer for 
females aged ≥65 years
2
Treatment, NCDs Colon/rectum cancer 
treatment
MIR Mortality from colon/rectum 
cancer for populations aged 
≥65 years
Incidence of colon/rectum 
cancer for populations aged 
≥65 years
DALYs due to colon/rectum 
cancer for populations aged 
≥65 years
2
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged ≥65 years
Prevalence of epilepsy for 
populations aged ≥65 years
DALYs due to epilepsy for 
populations aged ≥65 years
4
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged ≥65 years
Incidence of appendicitis for 
populations aged ≥65 years
DALYs due to appendicitis for 
populations aged ≥65 years
2
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
2
Additional information about the framework development process and selection of effective coverage indicators can be found in appendix 1 (pp 12–28). UHC=universal health coverage. DALYs=disability-
adjusted life-years. MNCH=maternal, neonatal, and child health. DTP3=diphtheria-tetanus-pertussis vaccine, 3 doses. MCV1=measles-containing-vaccine, 1 dose. LRI=lower respiratory infection. 
MIR=mortality-to-incidence ratio. NCDs=non-communicable diseases. ART=antiretroviral therapy. MPR=mortality-to-prevalence ratio. IHD=ischaemic heart disease. RSDR=risk-standardised death rate. 
CKD=chronic kidney disease. COPD=chronic obstructive pulmonary disease.
Table 1: Details of the 23 effective coverage indicators included in the UHC effective coverage index, by health service type
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Construction of UHC effective coverage index
As outlined by previous work,14–17 population-level measures 
of effective coverage should represent the fraction of total 
health gains a health system could potentially provide, 
given currently available interventions, that a health 
system actually delivers. This construct is thus grounded 
in the principle of comparability—all health systems ought 
to maximise potential health gains for their populations—
but also requires accounting for local health needs and 
epidemiological profiles. For instance, if a country 
currently experiences a high burden of diabetes and a 
comparatively lower burden of HIV, at least equal or even 
higher priority in expanding services for diabetes should 
occur relative to HIV in order to further support health 
gains.
To construct the UHC effective coverage index, we 
weighted each effective coverage indicator relative to 
their health gain weights, a metric approximating the 
population health gains potentially deliverable by 
health systems for each location-year. More detail is 
provided in the appendix 1 (pp 32–35), but in brief, 
calculations were based on three inputs for each 
effective coverage indicator and corresponding pop-
ulation-age group: estimates on the 0–100 scale, tar-
geted disease burden, and effectiveness categories of 
associated interventions or services (table 1). For effec-
tiveness, incremental values were assumed by category 
(ie, 90% effectiveness for category 1, 70% for category 2, 
50% for category 3, and so on), as informed by studies 
published in the Cochrane Database of Systematic 
Reviews, the Tufts Cost-Effectiveness Analysis Registry 
and Global Health Cost-Effectiveness Analysis Registry, 
and Disease Control Priorities, third edition (DCP3); 
sensitivity analyses on shifting each effective coverage 
indicator by one category (ie, moving each category 2 
indicator up to category 1 and then down to category 3) 
showed high correlations with current assignments 
(appendix 1 p 35).
As shown in figure 2, UHC effective coverage index 
estimates based on health gain weighting and an 
unweighted average across effective coverage indicators 
were positively associated (r=0·95); however, effects 
differed across countries.
Validation
Since no gold-standard measures of UHC service 
coverage currently exist, we used three types of validity 
testing to compare UHC effective coverage index perfor-
mance to previously published multi-country indices of 
UHC service coverage: the WHO UHC service coverage 
index for 2017;21 UHC service coverage index from 
GBD 2017;26 and service coverage index values from 
the World Bank.24 Further details of these analyses are 
provided in the appendix 1 (pp 38–52), with results 
summarised in table 2.
For content validity, we computed the percentage 
of 30 cells (ie, combinations of health services and 
population-age groups) from the UHC effective 
coverage framework that were represented by indi-
cators for each index. For known-groups validity, we 
assessed how well each index could discriminate 
between 16 country-pairs for which previous studies 
show “country A” as having better performance or 
progress on UHC service coverage than a similar 
“country B”.11,23,47–55 These pairs were selected a priori, 
and for each index we calculated the fraction of pairs 
correctly ordered on the basis of mean estimates 
and accounting for uncertainty where available. For 
convergent validity, we quantified how much variation 
in healthy life expectancy could be explained by each 
index after removing the average relationship between 
each index and overall socio demographic development 
(as measured by Socio-demographic Index [SDI]). In 
general, the UHC effective coverage index based on 
health gain weights showed stronger performance 
across these three validity mea sures than previous 
UHC service coverage measures and the unweighted 
UHC effective coverage index (table 2; appendix 1 
pp 38–52).
Figure 2: Comparing the UHC effective coverage index in 2019 with health gains weighting to the 
unweighted index (unweighted average of effective coverage indicators) in 2019
Locations are colour-coded by GBD super-region, and are abbreviated according to their ISO3 codes. ISO3 codes 
and corresponding location names are listed in appendix 1 (pp 64–68). UHC=universal health coverage. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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For the Cochrane Database of 
Systematic Reviews see 
https://www.cochranelibrary.
com/cdsr/reviews
For the Tufts Cost-Effectiveness 
Analysis Registry see 
https://cevr.tuftsmedicalcenter.
org/databases/cea-registry
For the Global Health Cost-
Effectiveness Analysis Registry 
see https://ghcearegistry.org/
ghcearegistry/
For more on Disease Control 
Priorities, third edition, see 
https://dcp-3.org/
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Relationship between health spending and UHC 
effective coverage
To better understand potential drivers of UHC effective 
coverage, we used stochastic frontier metaregression 
to quantify UHC effective coverage frontiers—esti-
mated maximum levels of UHC effective coverage index 
achieved given any amount of health spending per 
capita—and compared country-level UHC effective 
coverage performance relative to these frontiers. The 
magnitude of these gaps between the frontier and UHC 
effective coverage index values provides insights into 
potential inefficiencies, as well as measurement error, in 
translating health spending into improved UHC effective 
coverage at the population level. Further analytical details 
are in the appendix 1 (pp 53–59).
Since UHC aims to minimise financial hardship 
associated with receiving essential health services, we 
focused on assessing the relationship between pooled 
health spending per capita (ie, government spending, 
prepaid private health spending, and development 
assistance for health)56 and UHC effective coverage 
performance. Alternative analyses, wherein out-of-pocket 
spending was included (ie, total health expenditure) and 
then development assistance for health was excluded 
(ie, pooled domestic health expenditures), were also done 
but are not reported here (appendix 2 pp 6–7).
Counting population equivalents with UHC effective 
coverage
Spurred by the GPW13 UHC billion target,6 which 
calls for 1 billion more people benefiting from UHC 
by 2023, various approaches have been considered 
for translating performance metrics into the number 
of people covered by health services.20,21,57,58 For this 
analysis, we used a similar approach currently recom-
mended by WHO:58 we applied index estimates as 
fractional metrics and multiplied these values by 
populations to approxi mate population equivalents 
with UHC effective coverage.
To assess UHC effective coverage trajectories and 
their contributions towards meeting the UHC 1 billion 
target, we first projected country-level UHC effective 
coverage index estimates through to 2023. These 
projections were based on stochastic frontier meta-
regression modelled relationships between UHC 
effective coverage index and total health spending per 
capita; a related method has been used previously by 
GBD26,59 and is described further in the appendix 1 
(pp 60–61). Taking UHC effective coverage index as a 
fraction, we multiplied these values by country-level 
GBD-based population forecasts through to 2023.60 
Last, we aggregated these estimates globally and by 
GBD super-region, and calculated additional population 
equivalents with UHC effective coverage from 2018 (the 
GPW13 baseline) to 2023.
Uncertainty analysis
GBD aims to propagate sources of uncertainty through 
its estimation process,34–36 resulting in 1000 draws 
from the posterior distribution for each measure by 
location, age, sex, and year. We incorporated uncertainty 
quantified for each effective coverage indicator and 
associated disease burden based on GBD 2019 esti-
mates, and did scaling, index construction, and UHC 
effective coverage index projections at the draw-level to 
reflect uncertainty. We report 95% uncertainty intervals 
(95% UIs) based on the ordinal 25th and 975th draws 
for each measure.
Source Content validity 
(proportion of 
cells covered)
Known-groups validity 
(proportion of 16 country 
pairs)
Convergent validity (variation of HALE 
explained, accounting for SDI)
Based on mean 
values
With 
uncertainty
Beta 
coefficient
Standard 
error
R2
UHC effective coverage index, health 
gains weighted (reported 2019)
GBD 2019 40% 94% 63% 5·00 1·72 0·073
UHC effective coverage index, 
unweighted average (reported 2019)
GBD 2019 40% 94% 56% 4·19 1·49 0·068
UHC service coverage index for SDGs 
(reported 2017)
GBD 2017 33% 94% 69% 4·30 1·76 0·053
UHC service coverage index for SDG 
indicator 3.8.1 (reported 2017)
WHO 2019 20% 75% ·· 4·21 1·88 0·044
Service coverage index (for most recent 
year reported)
World Bank 
2020
17% 56% ·· 1·24 1·18 0·010
Content validity was evaluated on the basis of the percentage of 30 matrix cells of health service types against population-age groups covered by each index. 
Known-groups validity was evaluated on the basis of the percentage of 16 country pairs correctly ranked based on country A’s UHC or health-system performance 
being recognised as better than country B’s performance; details are found in appendix 1 (pp 45–47). Convergent validity was evaluated on the basis of how much 
index performance could explain variation in HALE after controlling for levels of sociodemographic development (as measured by SDI). UHC=Universal health 
coverage. HALE=healthy life expectancy. SDI=Socio-demographic Index. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDGs=UN Sustainable 
Development Goals.
Table 2: Results for content, known-groups, and construct validity across multi-country health service indices for UHC service coverage measurement
See Online for appendix 2
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
National UHC effective coverage patterns in 2019
In 2019, UHC effective coverage performance showed 
some strong geographical patterns (figure 3), but sizeable 
heterogeneities also emerged. Various European coun-
tries, including Iceland, as well as Australia, Canada, 
Japan, Singapore, and South Korea, comprised the highest 
decile, followed by a more geographically diverse group in 
the ninth decile (eg, Costa Rica, Israel, New Zealand, 
Portugal, and the USA). Sub-Saharan Africa had among 
the widest range of UHC effective coverage performances 
in 2019, with two countries ranking in the sixth decile 
(Rwanda and South Africa) and 11 countries in the first 
decile; the countries in the first decile were mainly in 
western or central sub-Saharan Africa, but also spanned 
the continent (eg, Angola, Lesotho, Madagascar, and 
Somalia). Outside of sub-Saharan Africa, ten countries, 
including Afghanistan, Haiti, Pakistan, and Papua New 
Guinea, were also in the lowest decile in 2019. In east, 
southeast, and south Asia, countries largely fell between 
the eighth (China and Thailand) and second deciles 
(Laos), with India and Indonesia occupying the third 
decile. Within Latin America, various countries scored in 
the eighth or seventh deciles (eg, Chile, Colombia, Peru, 
and Brazil) but others saw UHC effective coverage index 
values within the fourth to fifth deciles (eg, Bolivia, 
Guatemala, and Nicaragua).
Performance on the overall UHC effective coverage 
index often corresponded with levels achieved across 
individual effective coverage indicators (figure 4); for 
instance, countries with effective coverage index values 
of 85 or higher generally had the vast majority of effec-
tive coverage indicators exceeding 80. Although high-
performing locations usually had lower values for at least 
some subsets of indicators (eg, met need for family 
planning or antiretroviral therapy coverage), such indi-
cators often represented areas of lower potential health 
gains—especially relative to effective coverage indicators 
proxying health services or interventions for conditions 
with higher potential health gains in these countries 
(eg, cardiovascular diseases, cancers, and diabetes). 
Countries and territories with fairly low overall UHC 
effective coverage index performance in 2019 (ie, <40) 
scored similarly low across most effective coverage 
indicators, although vaccine coverage and proxies for 
lower respiratory infection and diarrhoea treatment were 
among the main exceptions.
Figure 3: Map of the UHC effective coverage index, by decile, in 2019
Deciles are based on the distribution of UHC effective coverage index values in 2019. UHC=universal health coverage.
UHC effective coverage index deciles
22·3 to <41·0
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MediterraneanSoutheast Asia
Northern Europe
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 11
(Figure 4 continues on next page)
68 61 6078 759393 100 99 64 97 8898 8680 75 44 8269 73 70628574Chile
10 4 616 403958 21 25 28 65 2351 1611 8 15 396 28 35311031Chad
5 3 520 374849 21 33 13 42 1920 101 1 9 230 19 317122Central African Republic
75 83 9887 868693 100 100 96 99 10087 7799 99 70 87100 70 681009890Canada
18 9 645 457871 60 45 44 82 6551 2825 24 12 5916 15 45342742Cameroon
26 27 859 799291 97 56 77 87 6750 2840 42 39 4727 34 65245357Cambodia
42 41 1269 83100100 97 86 80 96 9038 5856 44 30 5934 44 52505462Cape Verde
19 12 638 759591 69 72 49 48 4038 1814 12 23 287 18 36261450Burundi
14 16 647 569495 68 6 48 64 3139 3120 20 19 5711 25 36221942Burkina Faso
75 73 4754 789091 99 94 90 92 8132 9584 75 51 7568 59 63279063Bulgaria
65 51 3169 629898 96 94 87 97 8654 6877 76 30 6566 41 54746966Brunei
40 42 2588 638699 98 89 85 68 7766 7673 59 37 6157 44 73657265Brazil
20 32 1078 948485 86 71 66 87 6860 2347 45 14 4529 10 50374958Botswana
93 96 5026 687868 100 100 79 96 8556 10071 69 62 7660 49 66508364Bosnia and Herzegovina
33 22 852 649295 98 80 71 88 5562 6049 42 4 5249 26 56464352Bolivia
21 20 880 6510099 95 70 75 96 8743 2345 40 27 2928 47 54334851Bhutan
81 60 8287 549899 100 99 100 97 9876 8395 83 56 8692 57 91868778Bermuda
9 12 728 568173 77 32 53 75 5151 2720 18 17 5212 30 45332045Benin
48 39 1166 548289 97 85 60 87 7066 5065 52 18 5747 24 52535954Belize
90 92 9986 859996 100 100 96 99 9296 7794 71 72 8691 91 70789887Belgium
85 73 6973 7610097 100 99 80 98 9713 9885 75 98 7380 90 55429470Belarus
47 45 2867 869091 100 95 89 93 7468 6277 64 35 7766 31 60567161Barbados
22 15 779 609294 96 69 79 94 8548 1541 36 52 5124 47 56114354Bangladesh
88 52 4969 7010099 100 100 96 98 9465 4879 66 46 8169 35 67818571Bahrain
60 36 1486 769089 99 91 63 89 7456 6572 63 28 7157 43 65536761 The Bahamas
27 63 1532 838287 97 37 77 96 9413 7261 52 48 6945 44 47187348Azerbaijan
89 97 9981 858894 100 100 95 100 9984 9193 79 61 9595 72 78999986Austria
85 92 8788 859691 100 99 99 100 98100 6998 100 70 92100 78 67888689Australia
60 63 3543 839394 99 78 84 95 9534 10072 62 67 6359 42 89488062Armenia
58 44 2673 558692 99 95 67 95 7079 7866 68 28 6753 53 71517661Argentina
64 50 2683 469294 99 93 100 92 8367 7476 58 26 7765 34 53496860Antigua and Barbuda
18 19 632 224254 80 65 46 79 6350 2819 18 24 5011 28 56382139Angola
100 100 9988 399998 100 100 95 98 9799 7998 93 68 8997 96 749410092Andorra
66 36 1075 578291 99 93 87 88 8642 4450 55 13 2142 40 53565853American Samoa
36 38 2675 809284 99 95 94 96 9746 4770 63 41 6552 72 62606765Algeria
56 81 5810 419892 100 90 92 98 9960 6884 81 70 8165 94 57318870Albania
18 11 543 456562 92 62 60 67 5021 2018 15 9 397 41 23271839Afghanistan
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s 
an
d 
in
te
st
in
al
 o
bs
tr
uc
tio
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Articles
12 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
(Figure 4 continues on next page)
100 100 9069 849494 100 100 93 98 9566 7388 79 87 8780 86 77769382Czech Republic
92 100 9885 339989 100 100 94 100 8977 10098 64 52 7799 66 85699880Cyprus
89 46 4989 769999 100 97 96 90 9052 7088 74 51 7379 85 74638373Cuba
83 91 9139 819189 100 100 90 99 9564 9987 98 75 8582 80 695510079Croatia
7 13 740 547572 86 46 42 78 6051 3119 18 16 4812 25 44431943Côte d’Ivoire
61 55 4286 8597100 99 98 82 92 9580 8089 73 48 7577 84 82888679Costa Rica
100 95 3578 218396 100 98 90 95 9456 7473 73 37 7569 23 79788562Cook Islands
24 14 640 306572 83 83 48 80 6936 3622 21 18 4713 24 62372444Congo
11 24 633 668483 85 60 61 68 5946 3318 20 25 4211 19 50462248Comoros
56 42 3087 799194 99 93 87 91 8973 8384 67 55 6771 76 77808274Colombia
70 75 7296 329998 99 90 97 98 9866 8691 60 61 4186 80 65438870China
16 16 1262 515760 74 71 63 12 460 3521 17 28 3113 14 41312247Ethiopia
28 34 681 938893 79 61 40 79 5656 2026 23 3 4316 1 40322753eSwatini
100 96 8273 8610091 100 99 79 100 9961 8790 93 74 8491 78 537210082Estonia
23 5 630 4595100 73 69 49 55 4041 2813 10 17 378 13 41151342Eritrea
24 24 633 304539 96 82 66 90 8369 4336 31 23 5822 27 78523750Equatorial Guinea
63 50 1782 588797 98 96 81 91 9058 7575 50 10 6958 40 75737462El Salvador
73 51 1285 759697 89 88 86 95 8512 3657 37 28 5942 34 79676755Egypt
51 38 1672 638175 99 92 75 94 8080 7569 61 13 6568 37 65706864Ecuador
27 32 1084 717583 97 92 62 80 9428 3564 54 23 5646 28 55425952Dominican Republic
29 32 1083 479386 98 86 71 85 6264 4762 51 14 5944 38 40515752Dominica
20 8 652 195783 88 60 56 77 6759 3925 20 24 5715 16 53452745Djibouti
82 100 10081 709792 100 100 95 98 9399 8590 91 71 8190 67 66759784Denmark
19 7 623 787382 81 75 40 79 6242 2015 13 22 338 31 46251545Democratic Republic of the Congo
44 35 672 708680 95 84 75 76 7319 640 45 21 926 5 49515445
54 50 1983 249095 100 90 92 96 9728 6363 67 34 3557 55 85817864Guam
45 43 1379 598892 99 87 94 92 6151 6668 55 16 6553 31 54455950Grenada
60 70 2175 759591 100 98 87 94 7571 6567 81 57 5056 67 45726769Greenland
90 90 9761 8610097 100 99 82 99 9467 9992 70 59 8989 98 85549880Greece
17 21 643 379394 89 70 50 67 6145 2732 30 17 4720 25 68383549Ghana
88 90 10083 839797 100 100 97 99 9380 8193 94 61 9791 90 81879886Germany
62 51 2052 838493 99 95 88 96 8231 3766 57 60 7850 55 71187456Georgia
20 4 630 339389 91 72 55 80 5243 3222 20 16 4813 24 37382448The Gambia
29 20 749 727869 92 86 69 88 8345 4034 29 14 5519 21 70463553Gabon
90 85 9992 879790 100 100 87 99 91100 8695 87 83 9792 71 67849991France
100 96 9889 808893 100 100 93 100 9572 94100 94 91 9697 100 68839691Finland
Fiji
55 29 861 126074 98 88 58 75 7216 2236 44 2 230 10 37245234 Federated States of Micronesia
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s 
an
d 
in
te
st
in
al
 o
bs
tr
uc
tio
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 13
(Figure 4 continues on next page)
69 74 9777 769693 100 99 99 99 9677 8592 77 66 9992 81 82809783Malta
3 6 639 417373 75 22 50 73 4256 2018 16 16 4611 25 31312041Mali
41 36 4037 288791 99 97 88 100 10063 5274 71 38 7371 54 60648567Maldives
73 46 2377 769090 100 98 92 95 8243 4866 63 42 5861 64 84597867Malaysia
16 16 672 829293 86 63 46 65 4753 3218 20 40 4310 23 39351956Malawi
18 12 551 128673 59 62 59 64 5339 1815 15 29 378 22 44291540Madagascar
99 85 9988 8310099 100 100 99 100 94100 7895 90 70 9993 100 68829991Luxembourg
93 84 5572 6610090 100 99 80 99 9734 9278 68 97 7669 77 57577470Lithuania
62 55 2167 488787 99 97 89 95 9547 5565 57 40 7847 71 59727466Libya
18 1 547 428992 68 72 59 75 4755 3521 19 16 6313 34 43382248Liberia
12 9 677 629998 73 49 22 71 3051 014 11 2 2810 1 30161839Lesotho
67 67 6966 677681 100 98 93 98 9937 6485 79 53 8768 78 721009175Lebanon
86 72 6171 6810098 100 99 85 100 9839 9280 40 87 7970 69 54459570Latvia
22 21 767 706270 90 52 50 88 6435 329 34 19 4119 33 68264244Laos
37 49 1466 569290 96 75 85 94 9130 8360 54 50 5639 63 31197353Kyrgyzstan
66 89 7385 839895 100 97 99 100 9973 6987 74 66 8081 92 77859182Kuwait
33 13 641 427080 92 85 28 41 2823 119 27 5 015 3 21192936Kiribati
23 11 774 638477 77 67 58 23 863 3222 14 26 4211 19 56422152Kenya
65 68 2979 749595 99 81 86 96 9038 5370 69 57 4355 67 52217859Kazakhstan
47 54 3857 508981 100 93 92 99 9375 6275 63 38 7961 53 76838270Jordan
100 92 9860 789897 95 99 92 100 9899 92100 99 83 96100 100 89989796Japan
36 37 1485 7796100 99 96 79 91 8581 5074 59 27 6759 27 60446357Jamaica
95 93 9970 8210093 100 100 99 98 9896 9797 97 76 9299 81 837410089Italy
95 90 9383 849698 100 100 94 99 9399 7988 84 45 9083 57 72879581Israel
87 97 10080 849591 100 100 93 100 9787 7597 93 80 8797 98 738210090Ireland
44 50 1855 617879 99 94 86 99 9641 5464 53 31 7248 44 67477458Iraq
55 68 4378 409899 99 96 89 96 9852 5277 64 56 6962 62 74688370Iran
32 27 478 487782 89 85 70 43 3238 2343 41 39 4233 9 96335549Indonesia
17 22 1575 729094 80 59 76 47 5334 3236 35 34 2923 54 39264347India
95 100 10087 869194 100 100 98 100 9993 8999 98 88 9999 100 789610095Iceland
92 74 7757 799897 100 99 96 95 9551 8381 69 74 6973 75 79679072Hungary
46 30 878 858993 93 95 59 70 8454 4657 34 13 3339 63 51215854Honduras
15 3 445 557172 75 53 60 44 2015 1928 22 13 3717 30 24161736Haiti
28 22 757 629195 94 83 54 64 5221 4353 43 5 5835 23 36244741Guyana
9 15 648 477480 65 68 13 61 2226 2116 17 5 4010 16 32201436Guinea-Bissau
12 2 621 474549 74 24 36 73 5542 2212 14 12 458 21 34291332Guinea
54 28 968 677882 92 79 59 78 6764 4858 36 16 5136 31 44594952Guatemala
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s 
an
d 
in
te
st
in
al
 o
bs
tr
uc
tio
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Articles
14 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
(Figure 4 continues on next page)
48 66 2960 699287 99 83 88 97 9324 10071 62 85 7162 84 48358462Moldova
50 41 2277 218298 99 82 88 89 9121 3866 58 21 5354 27 60478049Niue
6 15 1439 505461 41 1 65 58 4449 4628 24 30 5818 19 50432938Nigeria
16 9 743 586064 42 26 46 69 2841 2214 12 22 426 18 33281435Niger
58 49 1987 33100100 97 90 82 90 8956 6877 52 6 5359 42 67626957Nicaragua
80 76 9283 799590 100 100 100 99 9983 5799 85 62 8398 72 64768983New Zealand
84 93 10083 809593 100 100 94 98 9499 9097 93 77 8797 81 75829990Netherlands
24 12 762 668695 94 56 71 92 7849 2132 32 25 922 59 29113647Nepal
44 28 953 1899100 98 75 73 78 829 2251 58 5 2543 8 40136642Nauru
27 28 782 9491100 90 80 64 87 6159 1939 33 25 3925 15 52344162Namibia
20 25 878 717384 93 48 76 94 8548 436 42 33 4125 23 5835247Myanmar
14 19 547 509597 84 50 24 56 1751 3016 15 19 488 14 42271544Mozambique
42 34 1273 779691 95 91 79 94 9216 4054 40 34 5732 58 69535758Morocco
85 85 7245 858760 100 99 88 99 9057 10080 80 57 8871 72 86188966Montenegro
44 47 967 459692 97 71 75 76 5430 6450 41 39 4734 55 4706748Mongolia
100 100 10089 3810088 100 100 80 99 9383 8997 98 83 10097 100 918210091Monaco
53 46 2077 767487 98 91 76 74 8064 7178 52 16 6062 33 73817761Mexico
52 46 2475 808585 99 96 85 99 9853 3469 60 11 7063 21 57627256Mauritius
18 3 629 796980 82 73 69 85 6874 5231 27 24 6320 19 62553353Mauritania
46 27 786 376488 98 82 73 68 6711 1629 37 8 418 35 35304344Marshall Islands
69 59 7271 679399 100 99 97 100 9775 6085 69 58 9778 49 95979180Qatar
65 63 6888 678891 100 98 71 98 9580 7694 84 37 7688 48 77978676Puerto Rico
97 86 9680 8698100 100 100 80 97 9598 10094 95 48 8488 81 61609884Portugal
89 95 7547 879592 100 99 93 97 8967 9973 32 80 8451 77 64579173Poland
41 39 357 138184 95 79 86 61 6637 2143 48 16 5233 22 83426055Philippines
50 38 2065 708487 98 91 88 95 8193 7872 69 42 9390 52 83797476Peru
58 34 1380 559297 98 94 76 85 8468 7969 56 17 6550 29 66636963Paraguay
26 16 640 514054 86 36 62 73 8030 823 30 42 718 19 40292938Papua New Guinea
58 39 3176 718294 96 92 73 94 9182 6183 67 41 7367 56 74748171Panama
59 64 2066 19999 100 98 84 96 9447 6665 52 38 6549 40 48517461Palestine
59 33 2267 208189 99 80 87 89 9519 5166 68 8 3460 24 69497345Palau
2 15 1052 418075 79 50 71 36 5134 1727 29 10 2518 33 47223539Pakistan
63 62 5046 498988 100 97 96 99 9941 8979 68 67 5469 43 95628371Oman
99 100 9986 739797 100 100 95 100 9997 9596 94 82 9396 97 751009894Norway
71 37 3378 519397 99 93 95 97 9138 6471 71 15 1966 40 73548360Northern Mariana Islands
61 85 5319 838785 100 98 86 99 8249 9579 60 60 6662 52 72208861North Macedonia
52 45 1286 3010099 98 89 86 95 8841 5653 55 45 3048 57 39247153North Korea
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s 
an
d 
in
te
st
in
al
 o
bs
tr
uc
tio
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 15
(Figure 4 continues on next page)
20 28 1781 816379 71 80 64 72 7179 4842 45 22 5326 21 59594460South Africa
14 7 53 123157 65 29 14 47 3642 162 1 14 231 14 2219124Somalia
40 13 680 378698 94 76 54 74 781 2035 44 22 027 6 2434939Solomon Islands
100 84 9665 859290 100 100 95 100 9797 9986 98 94 9485 89 85769590Slovenia
85 89 7871 889594 100 98 91 98 8850 8585 91 73 8486 78 68669078Slovakia
100 98 9477 759395 99 99 100 100 10077 7999 93 76 9599 100 941008992Singapore
13 1 649 338687 84 20 62 76 4939 2519 18 20 4911 15 39402042Sierra Leone
53 45 1780 638990 99 92 85 92 8051 4562 62 26 6255 62 87667662Seychelles
86 78 6338 828690 100 99 85 97 7953 7376 75 54 8168 61 71368963Serbia
17 6 653 599386 84 70 55 79 5051 2722 18 15 5013 35 45422250Senegal
84 44 4750 239799 100 100 82 98 9548 5580 69 26 6766 70 67628664Saudi Arabia
39 27 758 829494 98 77 70 89 7939 3036 34 6 4820 56 54523555São Tomé and Príncipe
86 99 10088 378987 100 100 92 98 9499 9595 95 89 10094 98 95819993San Marino
58 55 2442 375966 99 90 76 85 8428 3146 54 18 635 28 52416150Samoa
45 37 1182 369398 98 92 70 89 7646 5764 52 21 6445 28 46465349Saint Vincent and the Grenadines
40 36 1868 688788 99 94 67 89 8179 4871 58 25 5955 41 47496859Saint Lucia
44 28 3183 279495 98 91 86 90 7455 6579 57 13 7368 38 57357453Saint Kitts and Nevis
24 15 657 969796 86 73 56 72 6661 3924 23 27 3815 16 44302559Rwanda
78 73 5962 60100100 100 95 90 96 9128 7884 78 92 6966 66 87329869Russia
73 70 5851 868587 100 89 84 97 8847 10077 69 70 7170 79 71388770Romania
16 12 644 759187 93 65 53 71 5959 4123 21 24 5114 15 47392555Tanzania
57 35 652 376868 100 91 76 83 7352 4644 39 23 2137 19 59616052Tonga
78 40 1169 208492 99 94 79 88 8532 4452 58 21 5139 23 56436953Tokelau
14 16 640 628684 51 62 51 77 4740 3424 23 17 5214 18 43382443Togo
26 23 748 486368 94 68 55 89 6237 1531 34 30 3722 41 72333946Timor-Leste
74 49 3489 718992 99 95 92 96 9479 4473 76 43 6868 47 74658472Thailand
30 60 853 7493100 87 45 65 89 7913 9546 36 65 3925 34 2146148Tajikistan
84 75 8896 4698100 100 99 99 99 9790 8993 89 55 5591 44 73829779Taiwan (province of China)
52 63 2056 496876 99 95 92 96 9415 1769 58 43 6653 69 75537858Syria
78 90 10087 869895 100 100 98 99 9799 9097 77 80 9999 93 82939993Switzerland
99 99 10083 829898 100 100 98 100 10087 8798 85 83 10092 83 72939990Sweden
28 30 866 769991 95 84 63 86 3950 5059 49 14 6143 45 47404850Suriname
21 18 931 137784 90 87 77 89 8732 3246 40 33 4829 68 41494752Sudan
68 52 3566 749892 100 97 90 99 9946 3672 69 47 7068 41 68648366Sri Lanka
98 95 9980 879395 100 100 93 99 9599 8296 99 54 8298 93 84829990Spain
9 20 66 316156 71 32 43 60 5363 329 5 26 454 22 5552742South Sudan
100 78 9678 439797 99 100 96 99 96100 9999 99 70 9599 66 76889289South Korea
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s 
an
d 
in
te
st
in
al
 o
bs
tr
uc
tio
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Articles
16 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
Many countries with middle-range performance on 
UHC effective coverage (ie, about 45–70) in 2019 had a 
mixture of fairly high values on most indicators for 
communicable diseases and reproductive, neonatal, 
maternal, and child health but comparatively lower 
scores on many non-communicable diseases, likely 
mirroring their variable epidemiological profiles and 
thus populations’ health needs. For some countries, 
especially those in sub-Saharan Africa (eg, Namibia, 
Rwanda, and Kenya), communicable diseases (eg, HIV) 
and reproductive, neonatal, maternal, and child health 
still ranked among indicators with highest potential 
health gains in 2019, even though non-communicable 
diseases such as cardiovascular diseases and diabetes are 
on the rise.35 With their fairly high levels of coverage or 
services proxied by effective coverage indicators for 
communicable diseases and for reproductive, neonatal, 
maternal, and child health, several of these countries had 
higher UHC effective coverage index performance under 
a health gains weighting approach than under the 
assumption that each effective coverage indicator could 
deliver equal health gains to populations across different 
settings (figure 2). By contrast, in many other countries—
especially those in Latin America, central and eastern 
Europe, and Oceania—non-communicable diseases 
accounted for a greater proportion of potential health 
gains by 2019; consequently, these countries’ relatively 
poor performances on several effective coverage indi-
cators proxying non-communicable disease services 
underpinned lower overall UHC effective coverage index 
values. High levels of vaccine coverage and performance 
on effective coverage indicators such as maternal care 
still contributed to UHC effective coverage performance 
for such countries; however, these health areas generally 
Figure 4: Performance on the UHC effective coverage index and 23 effective coverage indicators, by location, in 2019
Locations are reported in alphabetical order. The UHC effective coverage index and individual effective coverage indicators are reported on a scale of 0–100. 
Four indicators (met need for family planning, MCV1 coverage, DTP3 coverage, and ART coverage) are based on intervention coverage, whereas the remaining 
effective coverage indicators use measures such as mortality-to-incidence ratios to approximate access to quality care; inputs and measurement approaches for each 
indicator and index are further described in appendix 1 (pp 30–32). ART=antiretroviral therapy. CKD=chronic kidney disease. COPD=chronic obstructive pulmonary 
disease. DTP3=diphtheria, tetanus, pertussis vaccine, 3 doses. IHD=ischaemic heart disease. LRI=lower respiratory infection. MCV1=measles-containing vaccine, 
1 dose. TB=tuberculosis. UHC=universal health coverage.
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represented a smaller fraction of population-level health 
gains than many non-communicable diseases in these 
settings. Health gain weights, by country and territory, 
for each effective coverage indicator are available in the 
appendix 2 (pp 11–13) and via online data tools.
Pace of progress on UHC effective coverage
Since 1990, UHC effective coverage performance 
improved, albeit at variable rates of progress over time 
and across GBD super-regions (figure 5). The global 
average increased from 45·8 (95% UI 44·2–47·5) in 1990 
to 60·3 (58·7–61·9) in 2019, while the absolute range in 
performance essentially remained the same (ie, 73·0-point 
difference in 1990 vs 74·0-point difference in 2019). 
By 2019, the UHC effective coverage index spanned 
from 95 or higher in Japan (96·3 [95·0–97·4]) and 
Iceland (95·3 [93·6–96·8]) to lower than 25 in the 
Central African Republic (22·3 [16·3–29·3]) and Somalia 
(23·9 [17·1–31·1]; appendix 2 pp 14–20). Globally, the pace 
of progress on UHC effec tive coverage was somewhat 
slower, albeit not significantly, from 2010 to 2019 (0·9% 
[0·6–1·2] annualised increase) than from 1990 to 2010 
(1·0% [0·8–1·1] annualised increase). Similarly, at the 
global level, annualised rates of change for population 
equivalents with effective coverage were slightly lower 
from 2010 to 2019 (2·0% [1·7–2·3]) than from 1990 to 2010 
(2·3% [2·2–2·4]), although this difference was not 
significant. However, some of these patterns diverged by 
GBD super-region (figure 5), as well as at the country 
level (appendix 2, pp 14–20). For instance, in sub-Saharan 
Africa, UHC effective coverage index performance 
improved at an average of 2·6% (1·9–3·3) per year 
from 2010 to 2019, surpassing its annualised rate of 
change from 1990 to 2010 (1·3% [1·0–1·7] average 
increase per year). Central Europe, eastern Europe, and 
central Asia also had significantly faster progress from 
2010 to 2019 (1·4% [0·8–1·8] average annual increase) 
than from 1990 to 2010 (0·5% [0·4–0·6] annual increase).
Relationship between health expenditure and UHC 
effective coverage
Country-level performance on UHC effective coverage 
widely varied across different levels of pooled health 
spending per capita (figure 6), highlighting how increased 
health spending is necessary but insufficient on its own 
to improve UHC effective coverage. Overall, the UHC 
effective coverage index was associated with pooled 
health spending per capita (r=0·79), but this relationship 
was varied at different levels of spending. Up to about 
$2500 (US$, adjusted for purchasing power parity) in 
pooled health spending per capita, increasingly higher 
expenditures generally paralleled higher performance 
on UHC effective coverage index; beyond that, higher 
expenditures did not correspond as consistently with 
further improvements in UHC effective coverage 
performance.
The UHC effective coverage frontier charts the highest 
UHC effective coverage performances, as achieved by 
countries in 2019, across different levels of pooled health 
spending per capita (figure 6); in other words, this frontier 
represents the relative efficiency—or ineffi ciency—with 
which countries could translate their health spending 
into improved UHC effective coverage. Countries 
including South Korea, Cyprus, Costa Rica, Peru, and 
Figure 5: Annualised rate of change in the UHC effective coverage index (A) and population equivalents with UHC effective coverage (B), globally and by GBD 
super-region, 1990–2010 and 2010–2019
Values reflect the average annualised rate of change on the UHC effective coverage index and population equivalents with UHC effective coverage between each time 
period. Population equivalents are based on taking the UHC effective coverage index as a fraction and multiplying these values by the total population for a given 
location-year to approximate populations covered with UHC effective coverage. UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk 
Factors Study.
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Rwanda were among those setting this performance 
frontier at their corresponding levels of pooled health 
expenditure per capita. Conversely, countries across 
the sociodemographic spectrum (ie, Central African 
Republic, Lesotho, Turkmenistan, Saudi Arabia, and 
the USA) showed large gaps between their estimated 
UHC effective coverage index perfor mances in 2019 and 
what could have been achievable on the UHC effective 
coverage frontier given these countries’ levels of pooled 
health spending. To reach a UHC effective coverage index 
of at least 80, under maximum efficiency, countries would 
need to reach US$1398 in pooled health spending per 
capita (per year). Equivalent analyses and figures for 
total health expendi ture per capita (ie, pooled health 
spending plus out-of-pocket spending) and pooled 
domestic health expenditure per capita (ie, pooled health 
spending minus development assistance for health) are 
provided in appendix 2 (pp 6–7).
Counting population equivalents with effective 
coverage for the UHC billion target 
Based on current projections, an estimated 5·0 billion 
(95% UI 4·8–5·1) population equivalents would have UHC 
effective coverage in 2023 (table 3). This would translate to 
388·9 million (358·6–421·3) more population equivalents 
with UHC effective coverage over the five-year GPW13 
evaluation period (2019–23, with 2018 as the baseline), or 
the equivalent of adding an average of 77·8 million 
(71·7–84·3) population equivalents per year during this 
time. From 2018 to 2023, sub-Saharan Africa was estimated 
to contribute the most additional population equivalents 
with UHC effective coverage (ie, 94·5 million [83·6–104·8]). 
By 2023, an estimated 3·1 billion (3·0–3·2) population 
equivalents would not have UHC effective coverage, with 
nearly a third residing in south Asia (ie, an estimated 
968·1 million [903·5–1040·3]).
Discussion
Summary of the main findings
The present study offers a new approach to monitoring 
progress on UHC service coverage: measuring country-
level effective coverage and thus better representing how 
well health systems are delivering health gains relative to 
their populations’ health needs. Amid global advances 
on the UHC effective coverage index since 1990, our 
findings show a gap of more than 70 points between 
locations with the highest and lowest levels of UHC 
effective coverage remained in 2019. Particularly among 
low-middle to middle-SDI countries, performance of 
effective coverage indicators for non-communicable 
diseases was far lower than levels reached for several 
communicable diseases and maternal and child health 
indicators—a pattern suggesting that many countries’ 
health systems and financing priorities are not moving 
as quickly as their epidemiological and demographic 
transitions. Higher pooled health spending per capita 
generally corresponded with higher UHC effective 
Figure 6: UHC effective coverage index frontier relative to pooled health spending per capita (A) and 
log-transformed pooled health spending per capita (B)
Pooled health spending per capita includes government health expenditures, prepaid private expenditures, and 
development assistance for health. All health spending estimates are for 2017 measured in 2019 PPP-adjusted 
US$ adjusted for inflation. The black line represents the frontier values estimated for UHC effective coverage in 
2019 relative to spending per capita in 2017. Locations are colour-coded by GBD super-region, with a subset 
abbreviated according to their ISO3 codes. ISO3 codes and corresponding location names are listed in appendix 1 
(pp 64–68). UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. 
PPP=purchasing-power parity.
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coverage. Nonetheless, country-level performance varied 
widely and many countries fell well below levels achieved 
by other countries with similar amounts of health 
expenditures, emphasising the importance of increasing 
both health-system efficiencies and funding for UHC. 
To achieve at least 80 on the UHC effective coverage 
index, countries would need to reach $1398 pooled 
spending per capita—and do so under maximum 
efficiency. An estimated 388·9 million more population 
equivalents would have UHC effective coverage between 
2018 and 2023, falling well short of the GPW13 target of 
1 billion more people benefiting from UHC during this 
time. Genuinely advancing toward UHC requires 
prioritising—and thus monitoring—effective coverage 
and health systems’ capacities for improving outcomes 
for all people throughout the world.
Past progress, current challenges, and accelerating 
future gains on UHC effective coverage
By 2019, UHC effective coverage improved substan tially 
for many countries, and for some countries the pace of 
progress has accelerated since 2010. This was particularly 
evident in sub-Saharan Africa; this GBD super-region 
nearly doubled its average annual improve ments from 
2010 to 2019 compared to 1990–2010. Such gains could be 
related to heightened funding—and thus prioritisation—
for HIV, vaccines and childhood infectious diseases, and 
maternal health during the Millennium Development 
Goal (MDG) era.61,62 As further illustrated by the UHC 
effective coverage frontier, up to about $2500 per capita, 
rising levels of UHC effective coverage index generally 
paralleled pooled health spending; this trend highlights 
the important role of increasing funding for UHC to 
jumpstart progress, particularly for countries that still 
have very low UHC effective coverage in 2019. Yet even 
at the frontier, reaching better UHC effective coverage 
performance requires much higher pooled health 
spending per year: an estimated $1398 per capita to reach 
80, and then $2538 per capita to reach 90 and $3424 per 
capita to reach 95. At present, the only countries 
achieving 90 or higher on the UHC effective coverage 
index and such levels of pooled health spending per 
capita are within the high-income GBD super-region. 
Substantially increasing total health spending could be 
one avenue for elevating UHC effective coverage 
performance; however, many countries still have high 
out-of-pocket spending relative to their total spending,56,61 
which is strongly related to household catastrophic 
health expenditures and directly counter to improving 
financial risk protection within UHC. Focusing on 
domestic heath spending while also elevating efficiency 
could be another viable route; our results show that many 
countries would theoretically achieve much higher UHC 
effective coverage if they could better translate current 
amounts of pooled spending per capita into improved 
performance. How to best address such inefficiencies 
will markedly vary across contexts, and will require 
accounting for country-level differences in health-sys-
tem orientations and structures, political stability and 
governance systems, and distribution of health resources 
among populations. Further examination of approaches 
used by countries near or at the UHC effective coverage 
frontier relative to their pooled health spending (eg, 
Rwanda, Peru, South Korea, and Costa Rica) might help 
identify tractable policy pathways to improved efficiency.
Poor performance on various non-communicable 
diseases has severely hindered progress on UHC 
effective coverage in many countries—a trend that is 
likely to only worsen until quality health services for 
non-communicable diseases are better prioritised by 
countries and development partners alike. Especially 
among low-middle SDI to middle-SDI countries, earlier 
advances on UHC effective coverage were mainly 
propelled by improving health services focused on 
communicable diseases, child health, and maternal care. 
As cardiovascular disease, diabetes, cancers, and other 
UHC effective coverage index (95% UIs) Population equivalents with UHC effective coverage (95% UI)*
2018 2023 Added from 2018–23 Covered in 2023 Not covered in 2023
Global 59·8 (58·3 to 61·3) 61·7 (60·1 to 63·3) 388·9 (358·6 to 421·3) 5·0 billion (4·8 to 5·1) 3·1 billion (3·0 to 3·2)
Central Europe, eastern 
Europe, and central Asia
63·2 (61·0 to 65·5) 65·2 (62·7 to 67·6) 9·1 (7·5 to 10·9) 273·0 (262·5 to 282·8) 145·5 (135·7 to 156·1)
High income 85·8 (84·3 to 87·1) 87·1 (85·5 to 88·5) 31·6 (28·8 to 34·3) 958·3 (940·7 to 972·8) 141·5 (127·0 to 159·1)
Latin America and Caribbean 63·2 (61·1 to 65·1) 65·6 (63·3 to 67·8) 33·6 (30·8 to 36·5) 398·5 (384·7 to 412·0) 209·0 (195·6 to 222·8)
North Africa and Middle East 60·0 (57·9 to 61·9) 61·9 (59·6 to 64·0) 43·0 (39·8 to 45·9) 402·3 (387·6 to 416·1) 247·8 (233·9 to 262·5)
South Asia 46·0 (42·6 to 49·2) 48·4 (44·6 to 51·9) 88·9 (73·5 to 102·8) 909·4 (837·2 to 974·0) 968·1 (903·5 to 1040·3)
Southeast Asia, east Asia, and 
Oceania
64·2 (60·7 to 67·6) 66·9 (63·0 to 70·5) 88·2 (74·4 to 102·8) 1·5 billion (1·4 to 1·5) 726·3 (647·9 to 811·6)
Sub-Saharan Africa 43·9 (41·4 to 46·5) 46·2 (43·3 to 49·1) 94·5 (83·6 to 104·8) 555·6 (521·1 to 590·1) 647·1 (612·7 to 681·7)
Population equivalents based on taking the UHC effective coverage index as a fraction and multiplying these values by total population for a given location-year to approximate 
populations covered with UHC effective coverage. UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. 95% UI=95% uncertainty 
interval. *Reported in millions unless otherwise indicated.
Table 3: Projected UHC effective coverage performance in 2023 and additional population equivalents with UHC effective coverage from 2018 to 2023, 
globally and by GBD super-region
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non-communicable diseases became leading causes of 
early death and disability, they also emerged as population 
health needs with the highest potential health gains—
that is, where health systems could increasingly deliver 
the most improved outcomes via effective coverage of 
interventions and services. Re-orienting countries’ health 
systems towards providing effective health services for 
non-communicable disease is not trivial, especially if 
their prior focus (and funding) had a more limited 
scope for the types of services provided, equipment 
used, and health workforce training required. However, 
continued inaction also has likely costs: if health 
systems remain too focused on health problems of the 
past, and fail to effectively respond to where the largest 
potential health gains exist today, it can be increasingly 
difficult to translate current levels of health spending 
into improved UHC effective coverage. For instance, 
only a few high-SDI countries (eg, Japan, Switzerland, 
and South Korea) averaged non-communicable disease 
performance equal to or higher than effective coverage 
indicators focused on communicable diseases and 
maternal and child health by 2019.63 Unless deliberate 
efforts are taken now to recalibrate health-system and 
funding priorities, the ability to alter current trajectories 
for UHC effective coverage could diminish.
To catalyse faster gains in the SDG era, WHO’s 
GPW13 set forth its bold billion targets,6 with the UHC 
target calling for 1 billion more people benefiting from 
UHC by 2023, relative to 2018. Current projections have 
the world falling well short of this ambition, with an 
estimated 388·9 million (358·6–421·3) more population 
equivalents having UHC effective coverage by 2023. 
Even these estimates are likely to be optimistic, as they 
do not account for trends in financial risk protection—
the other key dimension of UHC—nor do they explicitly 
account for populations’ needs for multiple health 
services. Nonetheless, this initial assessment offers 
important considerations for the remaining years of 
GPW13 and then through to 2030. With more than 
3 billion popu lation equivalents estimated to lack UHC 
effective coverage in 2023, targeting populous regions 
or countries that currently have low UHC effective 
coverage and investing in service expansion could be 
one option to accelerating future progress. For instance, 
south Asia, in combination with southeast Asia, east 
Asia, and Oceania, was estimated to have nearly 
1·7 billion population equivalents without UHC 
effective coverage in 2023. However, on the basis of 
current levels of health spending, many countries in 
these regions already fell below their potential UHC 
effective coverage perfor mance in 2019. For most 
countries, heightened health spending alone is unlikely 
to deliver on ambitious UHC targets; rather, a com-
bination of improving alignment of health systems 
with population health needs and bolstering efficiencies 
is likely to chart faster and perhaps more sustained 
gains.
Current challenges and future directions for measuring 
UHC effective coverage
Our measurement framework is grounded in the 
construct of effective coverage at the health-system level,16 
aiming to represent a country’s ability to improve health 
outcomes in accordance with the health needs and disease 
burden of its population. From this perspective, effec-
tive coverage should capture the fraction of potential 
population-level health gains actually delivered by the 
health system, relative to what the health system could 
have provided at maximum performance of current 
interventions or services. As such, we used health gain 
weights to construct the overall UHC effective coverage 
index and to more heavily weight effective coverage 
indicators for which a given country’s health could 
produce greater health gains through available interven-
tions. By contrast, the unweighted average of effective 
coverage indicators implies equal potential health gains 
irrespective of a country’s epidemiological profile or 
effectiveness of the associated interventions or ser vices, or 
a combination of both. Equally weighting interventions 
and their potential for improving health is directly counter 
to the reality of UHC programmes, which are subject to 
each country’s unique health-system structures, political 
demands, and health priorities. To capture what can—or 
should—be achievable through health systems’ provision 
of effective services, we believe the health gains weighting 
approach can better track country-led UHC investments 
and policy implementation. Going forward, assessments 
of UHC effective coverage should strive to apply this 
method beyond the national level, aiming to capture 
inequalities in potential health gains not only by location 
but also within population-age groups, by sex, and across 
other important sociodemographic dimensions (eg, race/
ethnicity and migrant status).
Routinely measuring UHC effective coverage requires 
the existence and maintenance of several functional data 
systems. Many, if not most, indicators or data systems, or 
both, that are needed to measure effective coverage 
indicators are already encompassed within the health-
related SDGs, which UN member states have committed 
to monitoring. These include functional vital registration 
systems that accurately record causes of death; periodic 
household surveys that include biomarker data and 
information on intervention coverage; and disease 
incidence registries based on administrative systems and 
notifications for specific causes (eg, cancers and kidney 
disease).64 Deliberate investments by national govern-
ments, as well as international agencies where appropriate, 
are important for strengthening these data systems and 
identifying how they can be used together to monitor 
trends in effective coverage.
The UHC effective coverage index and corresponding 
UHC effective coverage measurement framework repre-
sent important steps towards capturing a range of needed 
health services across the life course; nonetheless, as 
underscored by its multi-year development process 
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(appendix 1 pp 6–21), considerable gaps persist between 
the breadth of the original candidate effective coverage 
indicators and those used in the present analysis. Minimal 
data on rehabilitative services and palliation across 
countries and over time hindered their direct inclusion or 
the use of suitable proxy effective coverage indicators. 
Recent steps by WHO (ie, publishing its first world report 
on vision65 and upcoming report on hearing,66 and its 
GPW13 indicator on oral morphine availability6) suggest 
that data collection for these areas could be increasingly 
prioritised. A similar paucity of routinely collected data 
on mental health services and substance use disorder 
interventions precluded their use in the current UHC 
effective coverage index. In the future, triangulation of 
data sources including administrative records, health 
facility records, and community-based surveys might 
inform such mea surements.67 Effective coverage indi-
cators on emergency services and trauma care were also 
considered but ultimately excluded because of data 
limitations and ongoing methodological challenges 
(ie, appropriately isolating improvements in effective 
health services from advances in transportation safety).
For non-communicable diseases, we relied on out-
come-based effective coverage indicators, preferring to 
approxi mate access to quality non-communicable disease 
care through measures such as MIRs rather than 
assuming that risk exposure, screening rates, or health-
system inputs, or a combination of these factors, can 
appropriately capture effective service provision for non-
communicable diseases. Many national data systems 
already collect data on cause-specific mortality and 
disease incidence or prevalence, and when analysed 
together they should reflect variations in access to and 
quality of health services and serve as good proxy mea-
sures amid imperfect data realities for non-communicable 
disease services. Conversely, using indicators such as 
non-tobacco use and non-elevated blood pressure4,19,21 or 
inpatient admission rates pushes the world further away 
from understanding improved outcomes delivered by 
health systems and effective service provision. If, or 
when, the quantity and quality of data for measuring 
health services for non-communicable diseases improve, 
we would prefer to use more direct measures of 
effec tive coverage over outcome-based proxy indicators. 
For instance, our ideal effective coverage indicator for 
diabetes treatment would be the proportion of people 
with diabetes on treatment and meeting specified 
treatment targets such as glycated haemoglobin lower 
than 8%. Household surveys such as the WHO STEPwise 
approach to surveillance (STEPS) are increasingly col-
lecting these data, and time series estimates by location 
and population-age group could be easily derived if 
sufficient access to such microdata is possible.
In sum, the indicators included in the present study 
are not meant to be prescriptive; rather, our primary 
objective was to establish a robust, comparable measure-
ment framework from which UHC effective coverage 
could be assessed across settings and inform efforts to 
incorporate effective coverage into UHC monitoring. 
Continuing to advance effective coverage measurement 
of UHC in the future, especially if the main alternative is 
adhering to past measures with known drawbacks and 
narrow operationalisations of health services for all 
populations, is strongly supported by the broader GBD 
study and its collaborators.
Limitations
Our study is subject to limitations beyond those already 
described. First, this analysis draws from GBD 2019 
estimates of outcomes, intervention coverage, and SDG 
indicators,34–36 and thus broader GBD 2019 limitations 
also apply to the present study (eg, availability and quality 
of vital registration data, model coherence between 
cause-specific mortality and non-fatal measures, and 
new modelling approaches for risk factors and related 
outcomes). In the case of ischaemic heart disease, for 
example, new data on the interplay of household air 
pollution, blood pressure, and ischaemic heart disease 
mortality resulted in implausible risk-standardised death 
rates for many low-SDI to low-middle SDI countries 
when we only accounted for joint exposures to metabolic 
risks considered amenable to health care.41,43 We thus 
included household and outdoor air pollution in risk 
standardisation and plan to further examine these risk 
mediation pathways in the future.
Second, health gain weights were based on classifying 
intervention sets into five effectiveness categories, as 
informed by published literature provided by Cochrane, 
the Tufts Cost-Effectiveness Analysis Registry, and 
DCP3.For some effective coverage indicators, especially 
treat ment of more chronic conditions, distilling a wide 
range of reported effectiveness on available interven-
tions into a summary assessment was quite difficult. 
Sensitivity analyses based on shifting each indicator’s 
categorisation up and down one group showed similar 
overall UHC effective coverage index values (appendix 1 
p 35). Formally simulating the range of effectiveness 
across interventions and incorporating this uncertainty 
into health gains weighting is an important future 
avenue for measurement of the UHC effective coverage 
index.
Third, due to limited data quantity or quality (or both), 
we could not include several original candidates for 
effective coverage indicators (appendix 1 pp 12–28), 
including seven expressly recommended by the GPW13 
ERG: HPV vaccination, hepatitis C treatment, effective 
management of hypertension and diabetes, cataract 
surgery, refractive error correction, and dental care.33 
As data availability improves alongside methods for 
estimating these indicators across countries, we plan to 
test the inclusion of these indicators, and thus some 
country-level UHC effective coverage index values and 
rankings might change. Since data are generally more 
easily available for better-funded interventions and health 
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areas, it is possible that our current estimates of UHC 
effective coverage are overly optimistic.
Fourth, we excluded several effective coverage indi-
cators for which high potential health gains could only be 
achieved in select locations because of local exposures 
(ie, malaria and neglected tropical diseases) or current 
introduction status (eg, pneumococcal conjugate vaccine 
[PCV]). Subsequently, our results might under-estimate 
UHC effective coverage in some locations (eg, countries 
with high coverage of effective malaria interventions) or 
over-estimate performance in others (eg, countries that 
have a high pneumonia burden but have yet to introduce 
PCV). Additional methodological testing is needed to 
better incorporate these locally relevant intervention 
needs within a global measurement framework.
Fifth, we did not explicitly account for the effects 
of potential community-level interventions and their 
contribution to potential health gains (eg, herd immunity 
garnered from very high coverage of MCV1 or DTP3). 
Future work should consider whether or how such effects 
can be incorporated into this measurement framework, 
particularly given the toll of recent measles outbreaks 
worldwide.68
Sixth, results of our known-groups validity testing might 
have varied if more or different country-pairs were selected 
(appendix 1 pp 45–47). Showing performance based on 
country means and uncertainty underscores the need to 
further strengthen data collection and overarching mea-
surement for UHC effective coverage at the country level. 
Furthermore, it stresses the importance of estimating and 
reporting uncertainty in monitoring UHC, a limitation of 
current WHO and World Bank service coverage indices.
Seventh, approximating populations with UHC effec-
tive coverage by assuming the UHC effective coverage 
index as a fractional metric and multiplying by popula-
tion does not account for multimorbidities, nor does it 
represent the distribution of needed services received 
within a given population. Measuring UHC effective 
coverage at increasing granularity (ie, subnational loca-
tions and by disaggregated age groups or sex, or both) 
could help improve our understanding of the distribution 
of health services within a given population.
Conclusion
This study provides a new measurement framework and 
metric on UHC effective coverage, supporting country 
and global stakeholders in their efforts to track improved 
performance over time. By striving to capture potential 
health gains delivered by health systems, we hope to 
better diagnose and address challenges that otherwise 
impede the ultimate objective of UHC: improving health 
for all people and leaving no one behind. If current 
trends hold, the world will fall short of delivering on its 
UHC ambitions for the GPW13 and SDGs. Although this 
outcome is not yet inevitable, the window for meaningful 
action and health-system changes is rapidly narrowing. 
By focusing on UHC effective coverage and populations’ 
health needs across the lifespan, we strengthen the 
evidence base for bringing UHC closer to reality for all.
Contributors 
Please see appendix 1 for more detailed information about individual 
authors’ contributions to the research, divided into the following 
categories: managing the estimation process; writing the first draft of 
the manuscript; providing data or critical feedback on data sources; 
developing methods or computational machinery; applying analytical 
methods to produce estimates; providing critical feedback on methods or 
results; drafting the work or revising it critically for important intellectual 
content; extracting, cleaning, or cataloguing data; designing or coding 
figures and tables; and managing the overall research enterprise.
GBD 2019 Universal Health Coverage Collaborators
Rafael Lozano, Nancy Fullman, John Everett Mumford, Megan Knight, 
Celine M Barthelemy, Cristiana Abbafati, Hedayat Abbastabar, 
Foad Abd-Allah, Mohammad Abdollahi, Aidin Abedi, 
Hassan Abolhassani, Akine Eshete Abosetugn, Lucas Guimarães Abreu, 
Michael R M Abrigo, Abdulaziz Khalid Abu Haimed, 
Abdelrahman I Abushouk, Maryam Adabi, Oladimeji M Adebayo, 
Victor Adekanmbi, Jaimie D Adelson, Olatunji O Adetokunboh, 
Davoud Adham, Shailesh M Advani, Ashkan Afshin, Gina Agarwal, 
Pradyumna Agasthi, Seyed Mohammad Kazem Aghamir, 
Anurag Agrawal, Tauseef Ahmad, Rufus Olusola Akinyemi, 
Fares Alahdab, Ziyad Al-Aly, Khurshid Alam, Samuel B Albertson, 
Yihun Mulugeta Alemu, Robert Kaba Alhassan, Muhammad Ali, 
Saqib Ali, Vahid Alipour, Syed Mohamed Aljunid, François Alla, 
Majid Abdulrahman Hamad Almadi, Ali Almasi, Amir Almasi-Hashiani, 
Nihad A Almasri, Hesham M Al-Mekhlafi, Abdulaziz M Almulhim, 
Jordi Alonso, Rajaa M Al-Raddadi, Khalid A Altirkawi, 
Nelson Alvis-Guzman, Nelson J Alvis-Zakzuk, Saeed Amini, 
Mostafa Amini-Rarani, Fatemeh Amiri, Arianna Maever L Amit, 
Dickson A Amugsi, Robert Ancuceanu, Deanna Anderlini, 
Catalina Liliana Andrei, Sofia Androudi, Fereshteh Ansari, 
Alireza Ansari-Moghaddam, Carl Abelardo T Antonio, 
Catherine M Antony, Ernoiz Antriyandarti, Davood Anvari, 
Razique Anwer, Jalal Arabloo, Morteza Arab-Zozani, 
Aleksandr Y Aravkin, Olatunde Aremu, Johan Ärnlöv, Malke Asaad, 
Mehran Asadi-Aliabadi, Ali A Asadi-Pooya, Charlie Ashbaugh, 
Seyyed Shamsadin Athari, Maha Moh’d Wahbi Atout, Marcel Ausloos, 
Leticia Avila-Burgos, Beatriz Paulina Ayala Quintanilla, Getinet Ayano, 
Martin Amogre Ayanore, Getie Lake Aynalem, Yared Asmare Aynalem, 
Muluken Altaye Ayza, Samad Azari, Peter S Azzopardi, Darshan B B, 
Ebrahim Babaee, Ashish D Badiye, Mohammad Amin Bahrami, 
Atif Amin Baig, Mohammad Hossein Bakhshaei, Ahad Bakhtiari, 
Shankar M Bakkannavar, Arun Balachandran, Shelly Balassyano, 
Maciej Banach, Srikanta K Banerjee, Palash Chandra Banik, 
Agegnehu Bante Bante, Simachew Animen Bante, 
Suzanne Lyn Barker-Collo, Till Winfried Bärnighausen, Lope H Barrero, 
Quique Bassat, Sanjay Basu, Bernhard T Baune, Mohsen Bayati, 
Bayisa Abdissa Baye, Neeraj Bedi, Ettore Beghi, Masoud Behzadifar, 
Tariku Tesfaye Tesfaye Bekuma, Michelle L Bell, Isabela M Bensenor, 
Adam E Berman, Eduardo Bernabe, Robert S Bernstein, 
Akshaya Srikanth Bhagavathula, Dinesh Bhandari, Pankaj Bhardwaj, 
Anusha Ganapati Bhat, Krittika Bhattacharyya, Suraj Bhattarai, 
Zulfiqar A Bhutta, Ali Bijani, Boris Bikbov, Ver Bilano, Antonio Biondi, 
Binyam Minuye Birihane, Moses John Bockarie, Somayeh Bohlouli, 
Hunduma Amensisa Bojia, Srinivasa Rao Rao Bolla, Archith Boloor, 
Oliver J Brady, Dejana Braithwaite, Paul Svitil Briant, Andrew M Briggs, 
Nikolay Ivanovich Briko, Sharath Burugina Nagaraja, Reinhard Busse, 
Zahid A Butt, Florentino Luciano Caetano dos Santos, 
Lucero Cahuana-Hurtado, Luis Alberto Cámera, Rosario Cárdenas, 
Giulia Carreras, Juan J Carrero, Felix Carvalho, 
Joao Mauricio Castaldelli-Maia, Carlos A Castañeda-Orjuela, 
Giulio Castelpietra, Franz Castro, Ferrán Catalá-López, Kate Causey, 
Christopher R Cederroth, Kelly M Cercy, Ester Cerin, 
Joht Singh Chandan, Angela Y Chang, Jaykaran Charan, 
Vijay Kumar Chattu, Sarika Chaturvedi, Ken Lee Chin, 
Daniel Youngwhan Cho, Jee-Young Jasmine Choi, Hanne Christensen, 
Dinh-Toi Chu, Michael T Chung, Liliana G Ciobanu, Massimo Cirillo, 
Haley Comfort, Kelly Compton, Paolo Angelo Cortesi, Vera Marisa Costa, 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 23
Ewerton Cousin, Saad M A Dahlawi, Giovanni Damiani, Lalit Dandona, 
Rakhi Dandona, Jiregna Darega Gela, Aso Mohammad Darwesh, 
Ahmad Daryani, Aditya Prasad Dash, Gail Davey, 
Claudio Alberto Dávila-Cervantes, Kairat Davletov, Jan-Walter De Neve, 
Edgar Denova-Gutiérrez, Kebede Deribe, Nikolaos Dervenis, 
Rupak Desai, Samath Dhamminda Dharmaratne, 
Govinda Prasad Dhungana, Mostafa Dianatinasab, Diana Dias da Silva, 
Daniel Diaz, Ilse N Dippenaar, Hoa Thi Do, Fariba Dorostkar, 
Leila Doshmangir, Bruce B Duncan, Andre Rodrigues Duraes, 
Arielle Wilder Eagan, David Edvardsson, Iman El Sayed, 
Maha El Tantawi, Islam Y Elgendy, Iqbal RF Elyazar, Khalil Eskandari, 
Sharareh Eskandarieh, Saman Esmaeilnejad, Alireza Esteghamati, 
Oluchi Ezekannagha, Tamer Farag, Mohammad Farahmand, 
Emerito Jose A Faraon, Carla Sofia e Sá Farinha, Andrea Farioli, 
Pawan Sirwan Faris, Andre Faro, Mehdi Fazlzadeh, Valery L Feigin, 
Eduarda Fernandes, Pietro Ferrara, Garumma Tolu Feyissa, Irina Filip, 
Florian Fischer, James L Fisher, Luisa Sorio Flor, Nataliya A Foigt, 
Morenike Oluwatoyin Folayan, Artem Alekseevich Fomenkov, 
Masoud Foroutan, Joel Msafiri Francis, Weijia Fu, Takeshi Fukumoto, 
João M Furtado, Mohamed M Gad, Abhay Motiramji Gaidhane, 
Emmanuela Gakidou, Natalie C Galles, Silvano Gallus, 
William M Gardner, Biniyam Sahiledengle Geberemariyam, 
Abiyu Mekonnen Gebrehiwot, Gebreamlak Gebremedhn Gebremeskel, 
Leake G Gebremeskel, Hailay Abrha Gesesew, Keyghobad Ghadiri, 
Mansour Ghafourifard, Ahmad Ghashghaee, Nermin Ghith, 
Asadollah Gholamian, Syed Amir Gilani, Paramjit Singh Gill, 
Tiffany K Gill, Themba G Ginindza, Mojgan Gitimoghaddam, 
Giorgia Giussani, Mustefa Glagn, Elena V Gnedovskaya, 
Myron Anthony Godinho, Salime Goharinezhad, Sameer Vali Gopalani, 
Amir Hossein Goudarzian, Bárbara Niegia Garcia Goulart, 
Mohammed Ibrahim Mohialdeen Gubari, Rafael Alves Guimarães, 
Rashid Abdi Guled, Teklemariam Gultie, Yuming Guo, Rahul Gupta, 
Rajeev Gupta, Nima Hafezi-Nejad, Abdul Hafiz, 
Teklehaimanot Gereziher Haile, Randah R Hamadeh, Sajid Hameed, 
Samer Hamidi, Chieh Han, Hannah Han, 
Demelash Woldeyohannes Handiso, Asif Hanif, Graeme J Hankey, 
Josep Maria Haro, Ahmed I Hasaballah, Md. Mehedi Hasan, 
Abdiwahab Hashi, Amr Hassan, Shoaib Hassan, Soheil Hassanipour, 
Hadi Hassankhani, Rasmus J Havmoeller, Simon I Hay, Khezar Hayat, 
Golnaz Heidari, Reza Heidari-Soureshjani, Delia Hendrie, 
Claudiu Herteliu, Thomas R Hird, Hung Chak Ho, Michael K Hole, 
Ramesh Holla, Praveen Hoogar, Kathleen Pillsbury Hopf, 
Nobuyuki Horita, Naznin Hossain, Mostafa Hosseini, 
Mehdi Hosseinzadeh, Mihaela Hostiuc, Sorin Hostiuc, Mowafa Househ, 
Vivian Chia-rong Hsieh, Guoqing Hu, Tanvir M Huda, 
Ayesha Humayun, Bing-Fang Hwang, Ivo Iavicoli, 
Segun Emmanuel Ibitoye, Nayu Ikeda, Olayinka Stephen Ilesanmi, 
Irena M Ilic, Milena D Ilic, Leeberk Raja Inbaraj, Usman Iqbal, 
Seyed Sina Naghibi Irvani, Caleb Mackay Salpeter Irvine, 
M Mofizul Islam, Sheikh Mohammed Shariful Islam, Farhad Islami, 
Hiroyasu Iso, Chidozie C D Iwu, Chinwe Juliana Iwu, Jalil Jaafari, 
Farhad Jadidi-Niaragh, Morteza Jafarinia, Deepa Jahagirdar, 
Mohammad Ali Jahani, Nader Jahanmehr, Mihajlo Jakovljevic, 
Hosna Janjani, Tahereh Javaheri, Achala Upendra Jayatilleke, 
Ensiyeh Jenabi, Ravi Prakash Jha, Vivekanand Jha, John S Ji, Peng Jia, 
Yetunde O John-Akinola, Jost B Jonas, Farahnaz Joukar, 
Jacek Jerzy Jozwiak, Mikk Jürisson, Zubair Kabir, Leila R Kalankesh, 
Rohollah Kalhor, Aruna M Kamath, Tanuj Kanchan, Neeti Kapoor, 
Behzad Karami Matin, Marina Karanikolos, Seyed M. Karimi, 
Nicholas J Kassebaum, Srinivasa Vittal Katikireddi, Gbenga A Kayode, 
Peter Njenga Keiyoro, Yousef Saleh Khader, Mohammad Khammarnia, 
Ejaz Ahmad Khan, Maseer Khan, Young-Ho Khang, Khaled Khatab, 
Amir M Khater, Mona M Khater, Mahalaqua Nazli Khatib, 
Maryam Khayamzadeh, Jagdish Khubchandani, Neda Kianipour, 
Young-Eun Kim, Yun Jin Kim, Ruth W Kimokoti, Yohannes Kinfu, 
Adnan Kisa, Katarzyna Kissimova-Skarbek, Mika Kivimäki, 
Cameron J Kneib, Jonathan M Kocarnik, Sonali Kochhar, Stefan Kohler, 
Jacek A Kopec, Anna V Korotkova, Vladimir Andreevich Korshunov, 
Soewarta Kosen, Anirudh Kotlo, Parvaiz A Koul, Ai Koyanagi, 
Kewal Krishan, Kris J Krohn, Nuworza Kugbey, Vaman Kulkarni, 
G Anil Kumar, Manasi Kumar, Nithin Kumar, Om P Kurmi, 
Dian Kusuma, Hmwe Hmwe Kyu, Carlo La Vecchia, Ben Lacey, 
Dharmesh Kumar Lal, Ratilal Lalloo, Iván Landires, 
Van Charles Lansingh, Anders O Larsson, Savita Lasrado, 
Kathryn Mei-Ming Lau, Paolo Lauriola, Jeffrey V Lazarus, 
Jorge R Ledesma, Paul H Lee, Shaun Wen Huey Lee, Andrew T Leever, 
Kate E LeGrand, James Leigh, Matilde Leonardi, Shanshan Li, 
Lee-Ling Lim, Stephen S Lim, Xuefeng Liu, Giancarlo Logroscino, 
Alan D Lopez, Platon D Lopukhov, Paulo A Lotufo, Alton Lu, Jianing Ma, 
Mohammed Madadin, Phetole Walter Mahasha, Morteza Mahmoudi, 
Azeem Majeed, Jeadran N Malagón-Rojas, Shokofeh Maleki, 
Deborah Carvalho Malta, Borhan Mansouri, 
Mohammad Ali Mansournia, Santi Martini, 
Francisco Rogerlândio Martins-Melo, Ira Martopullo, 
Benjamin Ballard Massenburg, Claudia I Mastrogiacomo, 
Manu Raj Mathur, Colm McAlinden, Martin McKee, 
Carlo Eduardo Medina-Solís, Birhanu Geta Meharie, 
Man Mohan Mehndiratta, Entezar Mehrabi Nasab, Fereshteh Mehri, 
Ravi Mehrotra, Teferi Mekonnen, Addisu Melese, Peter T N Memiah, 
Walter Mendoza, Ritesh G Menezes, George A Mensah, Atte Meretoja, 
Tuomo J Meretoja, Tomislav Mestrovic, Bartosz Miazgowski, 
Irmina Maria Michalek, Erkin M Mirrakhimov, Maryam Mirzaei, 
Mehdi Mirzaei-Alavijeh, Philip B Mitchell, Babak Moazen, 
Masoud Moghadaszadeh, Efat Mohamadi, Dara K Mohammad, 
Yousef Mohammad, Naser Mohammad Gholi Mezerji, 
Abdollah Mohammadian-Hafshejani, Jemal Abdu Mohammed, 
Shafiu Mohammed, Ali H Mokdad, Lorenzo Monasta, 
Stefania Mondello, Masoud Moradi, Maziar Moradi-Lakeh, 
Rahmatollah Moradzadeh, Paula Moraga, Joana Morgado-da-Costa, 
Shane Douglas Morrison, Abbas Mosapour, Jonathan F Mosser, 
Amin Mousavi Khaneghah, Moses K Muriithi, Ghulam Mustafa, 
Ashraf F Nabhan, Mehdi Naderi, Ahamarshan Jayaraman Nagarajan, 
Mohsen Naghavi, Behshad Naghshtabrizi, 
Mukhammad David Naimzada, Vinay Nangia, Jobert Richie Nansseu, 
Vinod C Nayak, Javad Nazari, Rawlance Ndejjo, Ionut Negoi, 
Ruxandra Irina Negoi, Subas Neupane, Kiirithio N Ngari, 
Georges Nguefack-Tsague, Josephine W Ngunjiri, Cuong Tat Nguyen, 
Diep Ngoc Nguyen, Huong Lan Thi Nguyen, Chukwudi A Nnaji, 
Shuhei Nomura, Ole F Norheim, Jean Jacques Noubiap, 
Christoph Nowak, Virginia Nunez-Samudio, Adrian Oțoiu, 
Felix Akpojene Ogbo, Onome Bright Oghenetega, In-Hwan Oh, 
Emmanuel Wandera Okunga, Morteza Oladnabi, Andrew T Olagunju, 
Bolajoko Olubukunola Olusanya, Jacob Olusegun Olusanya, 
Mojisola Morenike Oluwasanu, Ahmed Omar Bali, Muktar Omer Omer, 
Kanyin Liane Ong, Obinna E Onwujekwe, Doris V Ortega-Altamirano, 
Alberto Ortiz, Sergej M Ostojic, Nikita Otstavnov, Stanislav S Otstavnov, 
Simon Øverland, Mayowa O Owolabi, Jagadish Rao Padubidri, 
Smita Pakhale, Raffaele Palladino, Adrian Pana, 
Songhomitra Panda-Jonas, Helena Ullyartha Pangaribuan, Mona Pathak, 
George C Patton, Sagun Paudel, Hamidreza Pazoki Toroudi, 
Spencer A Pease, Amy E Peden, Alyssa Pennini, Emmanuel K Peprah, 
Jeevan Pereira, David M Pigott, Thomas Pilgrim, Tessa M Pilz, 
Marina Pinheiro, Michael A Piradov, Meghdad Pirsaheb, 
Khem Narayan Pokhrel, Maarten J Postma, Hadi Pourjafar, 
Farshad Pourmalek, Reza Pourmirza Kalhori, Akram Pourshams, 
Sergio I Prada, Dimas Ria Angga Pribadi, Elisabetta Pupillo, 
Zahiruddin Quazi Syed, Amir Radfar, Ata Rafiee, Alireza Rafiei, 
Alberto Raggi, Fakher Rahim, Muhammad Aziz Rahman, 
Ali Rajabpour-Sanati, Saleem Muhammad Rana, Chhabi Lal Ranabhat, 
Sowmya J Rao, Davide Rasella, Vahid Rashedi, Goura Kishor Rath, 
Priya Rathi, David Laith Rawaf, Salman Rawaf, Lal Rawal, 
Reza Rawassizadeh, Christian Razo, Vishnu Renjith, 
Andre M N Renzaho, Bhageerathy Reshmi, Nima Rezaei, 
Seyed Mohammad Riahi, Daniel Cury Ribeiro, Jennifer Rickard, 
Nicholas L S Roberts, Leonardo Roever, Michele Romoli, Luca Ronfani, 
Gholamreza Roshandel, Enrico Rubagotti, Godfrey M Rwegerera, 
Siamak Sabour, Perminder S Sachdev, Basema Saddik, Ehsan Sadeghi, 
Masoumeh Sadeghi, Yahya Safari, Rajesh Sagar, Amirhossein Sahebkar, 
Mohammad Ali Sahraian, S. Mohammad Sajadi, 
Mohammad Reza Salahshoor, Hosni Salem, Marwa Rashad Salem, 
Joshua A Salomon, Hossein Samadi Kafil, Abdallah M Samy, 
Juan Sanabria, Milena M Santric-Milicevic, 
Articles
24 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
Sivan Yegnanarayana Iyer Saraswathy, Rodrigo Sarmiento-Suárez, 
Benn Sartorius, Arash Sarveazad, Brijesh Sathian, 
Thirunavukkarasu Sathish, Davide Sattin, Miloje Savic, Susan M Sawyer, 
Deepak Saxena, Alyssa N Sbarra, Lauren E Schaeffer, Silvia Schiavolin, 
Maria Inês Schmidt, Aletta Elisabeth Schutte, David C Schwebel, 
Falk Schwendicke, Soraya Seedat, Feng Sha, Saeed Shahabi, 
Amira A Shaheen, Masood Ali Shaikh, Morteza Shamsizadeh, 
Mohammed Shannawaz, Kiomars Sharafi, Fablina Sharara, 
Hamid Sharifi, David H Shaw, Aziz Sheikh, Abbas Sheikhtaheri, 
B Suresh Kumar Shetty, Kenji Shibuya, 
Wondimeneh Shibabaw Shiferaw, Mika Shigematsu, Jae Il Shin, 
Rahman Shiri, Reza Shirkoohi, K M Shivakumar, Mark G Shrime, 
Kerem Shuval, Soraya Siabani, Radoslaw Sierpinski, 
Inga Dora Sigfusdottir, Rannveig Sigurvinsdottir, 
Diego Augusto Santos Silva, João Pedro Silva, Biagio Simonetti, 
Kyle E Simpson, Jasvinder A Singh, Pushpendra Singh, 
Dhirendra Narain Sinha, Valentin Yurievich Skryabin, 
Emma U R Smith, Amin Soheili, Shahin Soltani, Moslem Soofi, 
Reed J D. Sorensen, Joan B Soriano, Muluken Bekele Sorrie, 
Ireneous N Soyiri, Emma Elizabeth Spurlock, 
Chandrashekhar T Sreeramareddy, Jeffrey D Stanaway, Nicholas Steel, 
Caroline Stein, Mark A Stokes, Mu’awiyyah Babale Sufiyan, 
Hafiz Ansar Rasul Suleria, Iyad Sultan, Lukasz Szumowski, 
Rafael Tabarés-Seisdedos, Takahiro Tabuchi, 
Santosh Kumar Tadakamadla, Biruk Wogayehu Taddele, 
Degena Bahrey Tadesse, Amir Taherkhani, Animut Tagele Tamiru, 
Frank C Tanser, Md Ismail Tareque, Ingan Ukur Tarigan, 
Whitney L Teagle, Fabrizio Tediosi, Yonas Getaye Tefera, 
Freweini Gebrearegay G Tela, Zemenu Tadesse Tessema, 
Bhaskar Thakur, Mariya Vladimirovna Titova, Marcello Tonelli, 
Roman Topor-Madry, Fotis Topouzis, Marcos Roberto Tovani-Palone, 
Bach Xuan Tran, Ravensara S Travillian, Christopher E Troeger, 
Lorainne Tudor Car, Riaz Uddin, Irfan Ullah, 
Chukwuma David Umeokonkwo, Bhaskaran Unnikrishnan, 
Era Upadhyay, Olalekan A Uthman, Marco Vacante, Pascual R Valdez, 
Santosh Varughese, Tommi Juhani Vasankari, Yasser Vasseghian, 
Narayanaswamy Venketasubramanian, Francesco S Violante, 
Vasily Vlassov, Stein Emil Vollset, lAvina Vongpradith, Theo Vos, 
Yasir Waheed, Magdalene K Walters, Richard G Wamai, Haidong Wang, 
Yuan-Pang Wang, Robert G Weintraub, Jordan Weiss, 
Andrea Werdecker, Ronny Westerman, Lauren B Wilner, 
Gebremariam Woldu, Charles D A Wolfe, Ai-Min Wu, 
Sarah Wulf Hanson, Yang Xie, Rixing Xu, 
Seyed Hossein Yahyazadeh Jabbari, Kazumasa Yamagishi, 
Yuichiro Yano, Sanni Yaya, Vahid Yazdi-Feyzabadi, Jamal A Yearwood, 
Yordanos Gizachew Yeshitila, Paul Yip, Naohiro Yonemoto, 
Mustafa Z Younis, Zabihollah Yousefi, Taraneh Yousefinezhadi, 
Hasan Yusefzadeh, Siddhesh Zadey, Telma Zahirian Moghadam, 
Syed Saoud Zaidi, Leila Zaki, Sojib Bin Zaman, Mohammad Zamani, 
Maryam Zamanian, Hamed Zandian, Mikhail Sergeevich Zastrozhin, 
Kaleab Alemayehu Zewdie, Yunquan Zhang, Xiu-Ju George Zhao, 
Yingxi Zhao, Peng Zheng, Cong Zhu, Arash Ziapour, Bianca S Zlavog, 
Sanjay Zodpey, and Christopher J L Murray. 
Affiliations
Institute for Health Metrics and Evaluation (Prof R Lozano MD, 
N Fullman MPH, J Mumford BA, M Knight BS, C M Barthelemy MPH, 
J D Adelson PhD, A Afshin MD, S B Albertson BS, C M Antony MA, 
A Y Aravkin PhD, K Compton BS, Prof L Dandona MD, 
Prof R Dandona PhD, Prof S D Dharmaratne MD, I N Dippenaar BA, 
T Farag PhD, Prof V L Feigin PhD, W Fu MSc, Prof E Gakidou PhD, 
N C Galles BS, W M Gardner AB, C Han BA, H Han MSc, 
Prof S I Hay FMedSci, C M S Irvine BS, D Jahagirdar PhD, 
N J Kassebaum MD, J M Kocarnik PhD, K J Krohn MPH, H H Kyu PhD, 
K M Lau BS, J R Ledesma BA, A T Leever BS, K E LeGrand MPH, 
Prof S S Lim PhD, Prof A D Lopez PhD, A Lu MSc, J Ma MS, 
I Martopullo MPH, C I Mastrogiacomo BS, Prof A H Mokdad PhD, 
J F Mosser MD, Prof M Naghavi MD, K L Ong PhD, S A Pease BS, 
A Pennini MSc, D M Pigott PhD, T M Pilz BA, C Razo PhD, 
N L S Roberts BS, A N Sbarra MPH, L E Schaeffer MSc, F Sharara MS, 
D H Shaw BA, K E Simpson BS, R J D Sorensen MPH, E E Spurlock BA, 
J D Stanaway PhD, R S Travillian PhD, C E Troeger MPH, 
Prof S Vollset DrPH, A Vongpradith BA, Prof T Vos PhD, 
M K Walters BS, H Wang PhD, L B Wilner MPH, S Wulf Hanson PhD, 
R Xu BS, J A Yearwood BS, P Zheng PhD, B S Zlavog BS, 
Prof C J L Murray PhD), Department of Health Metrics Sciences, School 
of Medicine (Prof R Lozano MD, A Afshin MD, A Y Aravkin PhD, 
Prof R Dandona PhD, Prof S D Dharmaratne MD, Prof E Gakidou PhD, 
Prof S I Hay FMedSci, N J Kassebaum MD, H H Kyu PhD, 
Prof S S Lim PhD, Prof A D Lopez PhD, Prof A H Mokdad PhD, 
Prof M Naghavi MD, D M Pigott PhD, Prof B Sartorius PhD, 
J D Stanaway PhD, Prof S Vollset DrPH, Prof T Vos PhD, H Wang PhD, 
Prof C J L Murray PhD), Department of Applied Mathematics 
(A Y Aravkin PhD), Division of Plastic Surgery (D Y Cho MD, 
C J Kneib MD), Department of Anesthesiology (A M Kamath MD), 
Department of Anesthesiology & Pain Medicine (N J Kassebaum MD), 
Department of Global Health (S Kochhar MD, R J D Sorensen MPH), 
Division of Plastic and Reconstructive Surgery (B B Massenburg MD, 
S D Morrison MD), University of Washington, Seattle, WA, USA 
(A Y Chang DSc); Department of Juridical and Economic Studies 
(C Abbafati PhD), La Sapienza University, Rome, Italy; Advanced 
Diagnostic and Interventional Radiology Research Center 
(H Abbastabar PhD), The Institute of Pharmaceutical Sciences (TIPS) 
(Prof M Abdollahi PhD), School of Pharmacy (Prof M Abdollahi PhD), 
Research Center for Immunodeficiencies (H Abolhassani PhD, 
Prof N Rezaei PhD), Urology Research Center (Prof S Aghamir PhD), 
Department of Health Policy, Management, and Economics 
(A Bakhtiari PhD), Multiple Sclerosis Research Center 
(S Eskandarieh PhD, Prof M Sahraian MD), Endocrinology and 
Metabolism Research Center (Prof A Esteghamati MD), School of Public 
Health (M Farahmand PhD), Department of Environmental Health 
Engineering (M Fazlzadeh PhD, H Janjani PhD), School of Medicine 
(N Hafezi-Nejad MD), School of Nursing and Midwifery 
(R Heidari-Soureshjani MSc), Department of Epidemiology and 
Biostatistics (Prof M Hosseini PhD, M Mansournia PhD), Pediatric 
Chronic Kidney Disease Research Center (Prof M Hosseini PhD), 
Tehran Heart Center (E Mehrabi Nasab MD), Health Equity Research 
Center (E Mohamadi PhD), Digestive Diseases Research Institute 
(Prof A Pourshams MD), Metabolomics and Genomics Research Center 
(F Rahim PhD), Cancer Research Institute (R Shirkoohi PhD), Cancer 
Biology Research Center (R Shirkoohi PhD), Tehran University of 
Medical Sciences, Tehran, Iran; Department of Neurology 
(Prof F Abd-Allah MD, A Hassan MD), National Hepatology and Tropical 
Medicine Research Institute (A M Khater MD), Department of Medical 
Parasitology (M M Khater MD), Department of Urology 
(Prof H Salem MD), Department of Public Health and Community 
Medicine (M R Salem MD), Cairo University, Cairo, Egypt; Department 
of Orthopaedic Surgery (A Abedi MD), University of Southern 
California, Los Angeles, CA, USA; Karolinska University Hospital, 
Huddinge, Sweden (H Abolhassani PhD); Department of Public Health 
(A E Abosetugn MPH), Department of Nursing (Y A Aynalem MSc, 
W S Shiferaw MSc), Debre Berhan University, Debre Berhan, Ethiopia; 
Department of Pediatric Dentistry (Prof L G Abreu PhD), Department of 
Maternal and Child Nursing and Public Health (Prof D C Malta PhD), 
Federal University of Minas Gerais, Belo Horizonte, Brazil; Department 
of Research (M R M Abrigo PhD), Philippine Institute for Development 
Studies, Quezon City, Philippines; Internal Medicine Department 
(A K Abu Haimed MBBS), College of Medicine (A M Almulhim MBBS), 
Environmental Health Department (S M A Dahlawi PhD), Pathology 
Department (M Madadin MD), Forensic Medicine Division 
(Prof R G Menezes MD), Imam Abdulrahman Bin Faisal University, 
Dammam, Saudi Arabia; Harvard Medical School (A I Abushouk MD), 
T.H. Chan School of Public Health (Prof T W Bärnighausen MD), 
Center for Primary Care (S Basu PhD), Department of Global Health 
and Social Medicine (A W Eagan MSW), Cardiology Department 
(I Y Elgendy MD), Department of Global Health and Population 
(Prof O F Norheim PhD), Division of General Internal Medicine 
(Prof A Sheikh MD), Massachusetts Veterans Epidemiology Research 
and Information Center (MAVERIC) & CSP Coordinating Center 
(B Thakur PhD), Harvard University, Boston, MA, USA 
(M G Shrime MD); Department of Medicine (A I Abushouk MD), 
Department of Obstetrics and Gynecology (Prof A F Nabhan PhD), 
Department of Entomology (A M Samy PhD), Ain Shams University, 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 25
Cairo, Egypt; Department of Anesthesiology (M Bakhshaei MD), Autism 
Spectrum Disorders Research Center (E Jenabi PhD), Department of 
Biostatistics (N Mohammad Gholi Mezerji MSc), Department of 
Cardiology (B Naghshtabrizi MD), Research Center for Molecular 
Medicine (A Taherkhani PhD), Hamedan University of Medical 
Sciences, Hamadan, Iran (M Adabi PhD); College of Medicine 
(O M Adebayo MD), Department of Community Medicine 
(O S Ilesanmi PhD), Department of Medicine (Prof M O Owolabi DrM), 
University College Hospital, Ibadan, Ibadan, Nigeria; School of Medicine 
(V Adekanmbi PhD), Cardiff University, Cardiff, UK; Centre of 
Excellence for Epidemiological Modelling and Analysis 
(O O Adetokunboh PhD), Department of Global Health 
(O O Adetokunboh PhD, C J Iwu PhD), Department of Psychiatry 
(Prof S Seedat PhD), Stellenbosch University, Cape Town, South Africa; 
School of Health (D Adham PhD), Department of Environmental Health 
Engineering (M Fazlzadeh PhD), Social Determinants of Health 
Research Center (T Zahirian Moghadam PhD, H Zandian PhD), 
Department of Community Medicine (H Zandian PhD), Ardabil 
University of Medical Science, Ardabil, Iran; Social Behavioral Research 
Branch (S M Advani PhD), National Eye Institute (W L Teagle BA), 
National Institute of Health, Bethesda, MD, USA; Department of 
Oncology (S M Advani PhD), Georgetown University, Washington DC, 
USA; Department of Family Medicine (Prof G Agarwal PhD), 
Department of Medicine (O P Kurmi PhD), Department of Psychiatry 
and Behavioural Neurosciences (A T Olagunju MD), Population Health 
Research Institute (T Sathish PhD), McMaster University, Hamilton, 
ON, Canada; Department of Cardiovascular Medicine (P Agasthi MD), 
Mayo Clinic, Scottsdale, AZ, USA; Institute of Genomics and Integrative 
Biology (Prof A Agrawal PhD), Council of Scientific & Industrial 
Research, Delhi, India; Internal Medicine (Prof A Agrawal PhD), Baylor 
College of Medicine, Houston, TX, USA; Department of Epidemiology 
and Health Statistics (T Ahmad MS), Southeast University, Nanjing, 
China; Institute for Advanced Medical Research and Training 
(R O Akinyemi PhD), Department of Health Promotion and Education 
(S E Ibitoye MPH, Y O John-Akinola PhD, M M Oluwasanu PhD), 
Department of Community Medicine (O S Ilesanmi PhD), Department 
of Obstetrics and Gynecology (O B Oghenetega MSc), Department of 
Medicine (Prof M O Owolabi DrM), University of Ibadan, Ibadan, 
Nigeria; Institute of Neuroscience (R O Akinyemi PhD), Newcastle 
University, Newcastle upon Tyne, UK; Mayo Evidence-based Practice 
Center (F Alahdab MSc), Mayo Clinic Foundation for Medical Education 
and Research, Rochester, MN, USA; John T. Milliken Department of 
Internal Medicine (Z Al-Aly MD), Washington University in St. Louis, 
St. Louis, MO, USA; Clinical Epidemiology Center (Z Al-Aly MD), 
Department of Veterans Affairs, St Louis, MO, USA; Murdoch Business 
School (K Alam PhD), Murdoch University, Perth, WA, Australia; 
Department of Epidemiology and Biostatistics (Y Alemu MPH), 
Department of Midwifery (S A Bante MSc), Department of Medical 
Laboratory Sciences (A Melese MSc), Bahir Dar University, Bahir Dar, 
Ethiopia; Institute of Health Research (R K Alhassan PhD), Department 
of Health Policy Planning and Management (M A Ayanore PhD), 
Department of Family and Community Health (N Kugbey PhD), 
University of Health and Allied Sciences, Ho, Ghana; Department of 
Biotechnology (M Ali PhD), Quaid-i-Azam University, Islamabad, 
Pakistan; Department of Information Systems, College of Economics 
and Political Science (S Ali PhD), Sultan Qaboos University, Muscat, 
Oman; Health Management and Economics Research Center 
(V Alipour PhD, J Arabloo PhD, S Azari PhD, A Ghashghaee BSc), 
Health Economics Department (V Alipour PhD), Preventive Medicine 
and Public Health Research Center (M Asadi-Aliabadi MSc, 
E Babaee PhD, S Goharinezhad PhD, M Moradi-Lakeh MD), Faculty of 
Allied Medicine (F Dorostkar PhD), Student Research Committee 
(A Ghashghaee BSc), Nutrition Health Research Center (F Mehri PhD), 
Department of Physiology (H Pazoki Toroudi PhD), Physiology Research 
Center (H Pazoki Toroudi PhD), Tehran Institute of Psychiatry 
(V Rashedi PhD), Colorectal Research Center (A Sarveazad PhD), 
Health Information Management (A Sheikhtaheri PhD), Iran University 
of Medical Sciences, Tehran, Iran; Department of Health Policy and 
Management (Prof S M Aljunid PhD), Kuwait University, Safat, Kuwait; 
International Centre for Casemix and Clinical Coding 
(Prof S M Aljunid PhD), National University of Malaysia, 
Bandar Tun Razak, Malaysia; Bordeaux School of Public Health 
(Prof F Alla PhD), University of Bordeaux, Bordeaux, France; College of 
Medicine (M A H Almadi FRCPC), Pediatric Intensive Care Unit 
(K A Altirkawi MD), Internal Medicine Department (Y Mohammad MD), 
King Saud University, Riyadh, Saudi Arabia; Division of 
Gastroenterology & Hepatology (M A H Almadi FRCPC), McGill 
University, Montreal, QC, Canada; Department of Environmental Health 
Engineering (Prof A Almasi PhD), Department of Radiology and Nuclear 
Medicine (F Amiri MSc), Infectious Disease Research Center 
(Prof K Ghadiri MD), Pediatric Department (Prof K Ghadiri MD), 
Research Center for Environmental Determinants of Health 
(Prof B Karami Matin PhD, M Moradi PhD, Prof M Pirsaheb PhD, 
Prof E Sadeghi PhD, Y Safari PhD, K Sharafi PhD, S Soltani PhD, 
Y Vasseghian PhD), Department of Public Health (N Kianipour MA), 
Clinical Research Development Center (S Maleki MSc, M Naderi PhD), 
Substance Abuse Prevention Research Center (B Mansouri PhD), 
Department of Rehabilitation and Sports Medicine (M Mirzaei MSc), 
Social Development and Health Promotion Research Center 
(M Mirzaei-Alavijeh PhD, M Soofi PhD), Department of Emergency 
Medicine (R Pourmirza Kalhori PhD), Department of Anatomical 
Sciences (M R Salahshoor PhD), Department of Health Education and 
Health Promotion (S Siabani PhD, A Ziapour PhD), Kermanshah 
University of Medical Sciences, Kermanshah, Iran (H Janjani PhD); 
Department of Epidemiology (A Almasi-Hashiani PhD, 
R Moradzadeh PhD, M Zamanian PhD), Health Services Management 
Department (S Amini PhD), Department of Pediatrics (J Nazari MD), 
Arak University of Medical Sciences, Arak, Iran; Physiotherapy 
Department (Prof N A Almasri PhD), The University of Jordan, Amman, 
Jordan; Medical Research Center (H M Al-Mekhlafi PhD), Epidemiology 
Department (M Khan MD), Jazan University, Jazan, Saudi Arabia 
(Prof N Bedi MD); Department of Parasitology (H M Al-Mekhlafi PhD), 
Sana’a University, Sana’a, Yemen; Research Program of Epidemiology 
and Public Health (J Alonso MD), Pompeu Fabra University, Barcelona, 
Spain; Department of Experimental and Health Sciences (J Alonso MD), 
Biomedical Research Networking Center in Epidemiology and Public 
Health (CiberESP), Madrid, Spain; Department of Community Medicine 
(R M Al-Raddadi PhD), King Abdulaziz University, Jeddah, Saudi Arabia; 
Research Group in Health Economics (Prof N Alvis-Guzman PhD), 
University of Cartagena, Cartagena, Colombia; Research Group in 
Hospital Management and Health Policies (Prof N Alvis-Guzman PhD), 
Universidad de la Costa, Barranquilla, Colombia; Department of 
Economic Sciences (N J Alvis-Zakzuk MSc), University of the Coast, 
Barranquilla, Colombia; Colombian National Health Observatory 
(N J Alvis-Zakzuk MSc, C A Castañeda-Orjuela MD), Department of 
Public Health Research (J N Malagón-Rojas MSc), National Institute of 
Health, Bogota, Colombia; Health Management and Economics 
Reasearch Center (M Amini-Rarani PhD), Department of Immunology 
(M Jafarinia MSc), Cardiac Rehabilitation Research Center 
(Prof M Sadeghi MD), Isfahan University of Medical Sciences, Isfahan, 
Iran; Department of Epidemiology and Biostatistics (A L Amit BS), 
Department of Health Policy and Administration (C T Antonio MD, 
E A Faraon MD), University of the Philippines Manila, Manila, 
Philippines; School of Public Health (A L Amit BS), Department of 
Radiology and Radiological Sciences (N Hafezi-Nejad MD), Johns 
Hopkins University, Baltimore, MD, USA; Maternal and Child 
Wellbeing (D A Amugsi PhD), African Population and Health Research 
Center, Nairobi, Kenya; Department of Pharmacy (R Ancuceanu PhD), 
Department of Cardiology (C Andrei PhD), Department of Internal 
Medicine (M Hostiuc PhD), Department of Legal Medicine and 
Bioethics (S Hostiuc PhD), Department of General Surgery 
(I Negoi PhD), Department of Anatomy and Embryology 
(R I Negoi PhD), Carol Davila University of Medicine and Pharmacy, 
Bucharest, Romania; Centre for Sensorimotor Performance 
(D Anderlini MD), School of Health and Rehabilitation Sciences 
(R Uddin PhD), The University of Queensland, Brisbane, Australia; 
Neurology Department (D Anderlini MD), Royal Brisbane and Women’s 
Hospital, Brisbane, QLD, Australia; Department of Medicine 
(S Androudi PhD), University of Thessaly, Volos, Greece; Research 
Center for Evidence Based Medicine (F Ansari PhD), Department of 
Health Policy and Management (L Doshmangir PhD), Department of 
Medical Surgical Nursing (M Ghafourifard PhD), School of Nursing and 
Articles
26 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
Midwifery (H Hassankhani PhD), Department of Immunology 
(F Jadidi-Niaragh PhD), Health Services Management Research Center 
(L R Kalankesh PhD), Biotechnology Research Center 
(M Moghadaszadeh PhD), Molecular Medicine Research Center 
(M Moghadaszadeh PhD), Drug Applied Research Center 
(H Samadi Kafil PhD), Tabriz University of Medical Sciences, Tabriz, 
Iran; Razi Vaccine and Serum Research Institute (F Ansari PhD), 
Agricultural Research, Education, and Extension Organization (AREEO), 
Tehran, Iran; Department of Epidemiology and Biostatistics 
(Prof A Ansari-Moghaddam PhD), Health Promotion Research Center 
(M Khammarnia PhD), Zahedan University of Medical Sciences, 
Zahedan, Iran; Department of Applied Social Sciences 
(C T Antonio MD), School of Nursing (P H Lee PhD), Hong Kong 
Polytechnic University, Hong Kong, China; Agribusiness Study Program 
(E Antriyandarti DrAgrSc), Sebelas Maret University, Surakarta, 
Indonesia; Department of Parasitology (D Anvari PhD), Toxoplasmosis 
Research Center (Prof A Daryani PhD), Faculty of Nursing and 
Midwifery (A Goudarzian MSc), Department of Immunology 
(Prof A Rafiei PhD), Molecular and Cell Biology Research Center 
(Prof A Rafiei PhD), Department of Environmental Health 
(Prof Z Yousefi PhD), Mazandaran University of Medical Sciences, Sari, 
Iran; Department of Parasitology (D Anvari PhD), Iranshahr University 
of Medical Sciences, Iranshahr, Iran; Department of Pathology 
(R Anwer PhD), Imam Mohammad Ibn Saud Islamic University, 
Riyadh, Saudi Arabia; Social Determinants of Health Research Center 
(M Arab-Zozani PhD), Faculty of Medicine (A Rajabpour-Sanati MD), 
Cardiovascular Diseases Research Center (S Riahi PhD), Birjand 
University of Medical Sciences, Birjand, Iran; Department of Public 
Health (O Aremu PhD), Birmingham City University, Birmingham, UK; 
Department of Neurobiology, Care Sciences and Society 
(Prof J Ärnlöv PhD, C Nowak PhD), Department of Medical 
Epidemiology and Biostatistics (Prof J J Carrero PhD), Department of 
Physiology and Pharmacology (C R Cederroth PhD), Department of 
Medicine (D K Mohammad PhD), Karolinska Institutet, Stockholm, 
Sweden; School of Health and Social Studies (Prof J Ärnlöv PhD), 
Dalarna University, Falun, Sweden; Department of Plastic Surgery 
(M Asaad MD), University of Texas, Houston, TX, USA; Epilepsy 
Research Center (Prof A A Asadi-Pooya MD), Department of Healthcare 
Management and Education (M Bahrami PhD), Health Human 
Resources Research Center (M Bayati PhD), Department of 
Epidemiology (M Dianatinasab MSc), Health Policy Research Center 
(S Shahabi PhD), Shiraz University of Medical Sciences, Shiraz, Iran; 
Neurology Department (Prof A A Asadi-Pooya MD), Thomas Jefferson 
University, Philadelphia, PA, USA; Department of Immunology 
(S Athari MPH), Zanjan University of Medical Sciences, Zanjan, Iran; 
Faculty of Nursing (M M W Atout PhD), Philadelphia University, 
Amman, Jordan; School of Business (Prof M Ausloos PhD), University 
of Leicester, Leicester, UK; Department of Statistics and Econometrics 
(Prof M Ausloos PhD, Prof C Herteliu PhD, A Oțoiu PhD, A Pana MD), 
Bucharest University of Economic Studies, Bucharest, Romania; Center 
for Health Systems Research (L Avila-Burgos ScD), Center for Nutrition 
and Health Research (E Denova-Gutiérrez DSc), Health Systems 
Research Center (D V Ortega-Altamirano DrPH), National Institute of 
Public Health, Cuernavaca, Mexico; The Judith Lumley Centre 
(B Ayala Quintanilla PhD), School of Nursing and Midwifery 
(Prof D Edvardsson PhD, M Rahman PhD), Department of Public 
Health (M Islam PhD), La Trobe University, Melbourne, VIC, Australia; 
School of Public Health (G Ayano MSc, D Hendrie PhD), School of 
Physiotherapy and Exercise Science (Prof A M Briggs PhD), Curtin 
University, Perth, WA, Australia; Department of Clinical Midwifery 
(G L Aynalem MSc), Department of Midwifery (A T Tamiru MSc), 
Department of Clinical Pharmacy (Y G Tefera MSc), Department of 
Epidemiology and Biostatistics (Z T Tessema MSc), University of 
Gondar, Gondar, Ethiopia; Department of Pharmacology and Toxicology 
(M A Ayza MSc), Department of Nursing (G G Gebremeskel MSc), 
Department of Pharmacy (L G Gebremeskel MSc), Department of 
Epidemiology (H A Gesesew PhD), School of Public Health 
(F G G Tela BHlthSci), School of Pharmacy (K A Zewdie MSc), Mekelle 
University, Mekelle, Ethiopia; Global Adolescent Health Group 
(P S Azzopardi PhD), Burnet Institute, Melbourne, VIC, Australia; 
Wardliparingga Aboriginal Research Unit (P S Azzopardi PhD), 
South Australian Health and Medical Research Institute, Adelaide, SA, 
Australia; Department of Community Medicine (D B B MD, 
V Kulkarni MD, N Kumar MD), Department of Forensic Medicine and 
Toxicology (S M Bakkannavar MD, Prof V C Nayak MD, 
Prof B K Shetty MD), Department of Health Information Management 
(R Bhageerathy PhD), Department of Internal Medicine (A Boloor MD), 
Kasturba Medical College (R Holla MD, Prof B Unnikrishnan MD), 
Centre for Bio Cultural Studies (CBiCS) (P Hoogar PhD), Department of 
Forensic Medicine (J Padubidri MD), Kasturba Medical College, 
Mangalore (P Rathi MD), Manipal Academy of Higher Education, 
Mangalore, India (R Bhageerathy PhD, Prof V Jha MD); Department of 
Forensic Science (A D Badiye MSc, N Kapoor MSc), Government 
Institute of Forensic Science, Nagpur, India; Unit of Biochemistry 
(A A Baig PhD), Sultan Zainal Abidin University, Kuala Terengganu, 
Malaysia; Department of Demography (A Balachandran MSc), 
University Medical Center Groningen (Prof M J Postma PhD), School of 
Economics and Business (Prof M J Postma PhD), University of 
Groningen, Groningen, Netherlands; Population Research Centre 
(A Balachandran MSc), Institute for Social and Economic Change, 
Bengaluru, India; Department of Hypertension (Prof M Banach PhD), 
Medical University of Lodz, Lodz, Poland; Polish Mothers’ Memorial 
Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); School 
of Health Sciences (Prof S K Banerjee PhD), Walden University, 
Minneapolis, MN, USA; Department of Non-communicable Diseases 
(P C Banik MPhil), Bangladesh University of Health Sciences, Dhaka, 
Bangladesh; Department of Nursing (A B Bante MSc, 
Y G Yeshitila MSc), Department of Public Health (M Glagn MPH, 
M B Sorrie MPH), Department of Midwifery (T Gultie MSc), 
Arba Minch University, Arba Minch, Ethiopia; School of Psychology 
(Prof S L Barker-Collo PhD), University of Auckland, Auckland, 
New Zealand; Heidelberg Institute of Global Health (HIGH) 
(Prof T W Bärnighausen MD, J De Neve MD, S Kohler MD, 
B Moazen MSc, S Mohammed PhD), Department of Ophthalmology 
(Prof J B Jonas MD, S Panda-Jonas MD), Heidelberg University, 
Heidelberg, Germany; Department of Industrial Engineering 
(Prof L H Barrero DSc), Pontifical Javeriana University, Bogota, 
Colombia; Barcelona Institute for Global Health (Prof Q Bassat MD), 
Research Unit (J M Haro MD), University of Barcelona, Barcelona, 
Spain; Catalan Institution for Research and Advanced Studies (ICREA), 
Barcelona, Spain (Prof Q Bassat MD, A Koyanagi MD); School of Public 
Health (S Basu PhD), Imperial College Business School 
(D Kusuma DSc), Department of Primary Care and Public Health 
(Prof A Majeed MD, R Palladino MD, Prof S Rawaf MD), WHO 
Collaborating Centre for Public Health Education and Training 
(D L Rawaf MD), Imperial College London, London, UK; Department of 
Psychiatry (Prof B T Baune PhD), University of Münster, Münster, 
Germany; Department of Psychiatry (Prof B T Baune PhD), Melbourne 
Medical School, Melbourne, VIC, Australia; Department of Public 
Health (B A Baye MPH, J Darega Gela MPH), Ambo University, Ambo, 
Ethiopia; Department of Community Medicine (Prof N Bedi MD), 
Gandhi Medical College Bhopal, Bhopal, India; Department of 
Neuroscience (E Beghi MD, E Pupillo PharmD), Department of 
Environmental Health Sciences (S Gallus DSc), Laboratory of 
Neurological Disorders (G Giussani PhD), Mario Negri Institute for 
Pharmacological Research, Milan, Italy (B Bikbov MD); Social 
Determinants of Health Research Center (M Behzadifar PhD), Lorestan 
University of Medical Sciences, Khorramabad, Iran; Department of 
Public Health (T T Bekuma MPH), Wollega University, Nekemte, 
Ethiopia; School of the Environment (Prof M L Bell PhD), Yale 
University, New Haven, CT, USA; Department of Internal Medicine 
(I M Bensenor PhD), Department of Psychiatry 
(Prof J Castaldelli-Maia PhD, Y Wang PhD), Division of Ophthalmology 
(J M Furtado MD), Department of Medicine (Prof P A Lotufo DrPH), 
Department of Pathology and Legal Medicine (M R Tovani-Palone PhD), 
University of São Paulo, São Paulo, Brazil; Department of Medicine 
(A E Berman MD), Medical College of Georgia at Augusta University, 
Augusta, GA, USA; Faculty of Dentistry, Oral & Craniofacial Sciences 
(E Bernabe PhD), Institute for Population Health (Prof K Shibuya MD), 
School of Population Health and Environmental Sciences 
(Prof C D A Wolfe MD), King’s College London, London, UK; Hubert 
Department of Global Health (R S Bernstein MD), Emory University, 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 27
Atlanta, GA, USA; Department of Internal Medicine 
(A S Bhagavathula PharmD), United Arab Emirates University, Al Ain, 
United Arab Emirates; Department of Social and Clinical Pharmacy 
(A S Bhagavathula PharmD), Charles University, Prague, Czech 
Republic; School of Public Health (D Bhandari MSc), Adelaide Medical 
School (L G Ciobanu PhD, T K Gill PhD), Centre for Heart Rhythm 
Disorders (J Noubiap MD), University of Adelaide, Adelaide, SA, 
Australia; Public Health Research Laboratory (D Bhandari MSc), 
Tribhuvan University, Kathmandu, Nepal; Department of Community 
Medicine and Family Medicine (P Bhardwaj MD), Department of 
Pharmacology (J Charan MD), Department of Forensic Medicine and 
Toxicology (T Kanchan MD), Department of Radiation Oncology 
(Prof G K Rath MD), Department of Psychiatry (Prof R Sagar MD), 
All India Institute of Medical Sciences, New Delhi, India; Division of 
General Internal Medicine (A G Bhat MD), University of Massachusetts 
Medical School, Springfield, MA, USA; Department of Statistical and 
Computational Genomics (K Bhattacharyya MSc), National Institute of 
Biomedical Genomics, Kalyani, India; Department of Statistics 
(K Bhattacharyya MSc), University of Calcutta, Kolkata, India; 
Department of Global Health (S Bhattarai MD), Global Institute for 
Interdisciplinary Studies, Kathmandu, Nepal; Centre for Global Child 
Health (Prof Z A Bhutta PhD), Department of Medicine (V Chattu MD), 
University of Toronto, Toronto, ON, Canada; Centre of Excellence in 
Women & Child Health (Prof Z A Bhutta PhD), Aga Khan University, 
Karachi, Pakistan; Social Determinants of Health Research Center 
(A Bijani PhD, M A Jahani PhD), Department of Clinical Biochemistry 
(A Mosapour PhD), Student Research Committee (M Zamani MD), 
Babol University of Medical Sciences, Babol, Iran; Health Economics 
and Outcomes Research (V Bilano PhD), Creativ-Ceutical, London, UK; 
Department of General Surgery and Medical-Surgical Specialties 
(Prof A Biondi PhD, M Vacante PhD), University of Catania, Catania, 
Italy; Ethiopian Public Health Institute, Addis Ababa, Ethiopia 
(B M Birihane MSc); Department of Nursing (B M Birihane MSc), 
Debre Tabor University, Debretabor, Ethiopia; European & Developing 
Countries Clinical Trials Partnership, Cape Town, South Africa 
(Prof M J Bockarie MSc); Department of Medicine 
(Prof M J Bockarie MSc, G A Mensah MD), School of Public Health and 
Family Medicine (C A Nnaji MPH), University of Cape Town, 
Cape Town, South Africa; Department of Veterinary Medicine 
(S Bohlouli PhD), Tehran Medical Sciences Branch 
(S Esmaeilnejad PhD), Young Researchers and Elite Club 
(A Gholamian MSc), Department of Biology (A Gholamian MSc), 
Islamic Azad University, Kermanshah, Iran; School of Pharmacy 
(H A Bojia BPharm), Department of Medical Laboratory Sciences 
(A M Gebrehiwot PhD), Haramaya University, Harar, Ethiopia; 
Department of Biomedical Sciences (S R Bolla PhD), Nazarbayev 
University, Nur-Sultan City, Kazakhstan; Department of Infectious 
Disease Epidemiology (O J Brady PhD), MSc Epidemiology Programme 
(A Hafiz PhD), European Observatory on Health Systems and Policies 
(M Karanikolos PhD), Department of Health Services Research and 
Policy (M Karanikolos PhD, Prof M McKee DSc), Faculty of Infectious 
and Tropical Diseases (Prof B Sartorius PhD), London School of Hygiene 
& Tropical Medicine, London, UK; Division of Hematology and 
Oncology (D Braithwaite PhD), Georgetown University, Washington, 
DC, USA; Department of Epidemiology and Evidence Based Medicine 
(Prof N I Briko DSc), N. A. Semashko Department of Public Health and 
Healthcare (Prof M Jakovljevic PhD), Department of Epidemiology and 
Evidence-Based Medicine (V A Korshunov PhD, P D Lopukhov PhD), 
I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 
Department of Community Medicine (Prof S Burugina Nagaraja MD), 
Employee State Insurance Post Graduate Institute of Medical Sciences 
and Research, Bangalore, India; Department of Health Care 
Management (Prof R Busse PhD), Technical University of Berlin, Berlin, 
Germany; School of Public Health and Health Systems (Z A Butt PhD), 
University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public 
Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, 
Pakistan; Institute of Microengineering (F Caetano dos Santos PhD), 
Federal Polytechnic School of Lausanne, Lausanne, Switzerland; School 
of Public Health and Administration (L Cahuana-Hurtado PhD), 
Peruvian University Cayetano Heredia, Lima, Peru; Internal Medicine 
Department (Prof L A Cámera MD), Hospital Italiano de Buenos Aires, 
Buenos Aires, Argentina; Board of Directors (Prof L A Cámera MD), 
Argentine Society of Medicine, Buenos Aires, Argentina 
(Prof P R Valdez MEd); Department of Health Care 
(Prof R Cárdenas DSc), Metropolitan Autonomous University, Mexico 
City, Mexico; Institute for Cancer Research, Prevention and Clinical 
Network, Florence, Italy (G Carreras PhD); Research Unit on Applied 
Molecular Biosciences (UCIBIO) (Prof F Carvalho PhD, V M Costa PhD, 
J P Silva PhD), Laboratory of Toxicology (Prof D Dias da Silva PhD), 
Associated Laboratory for Green Chemistry (LAQV) 
(Prof E Fernandes PhD), University Hospital Center of Porto 
(J Morgado-da-Costa MSc), Department of Chemistry (M Pinheiro PhD), 
University of Porto, Porto, Portugal; Epidemiology and Public Health 
Evaluation Group (C A Castañeda-Orjuela MD), National University of 
Colombia, Bogota, Colombia; Department of Medicine 
(G Castelpietra PhD), University of Udine, Udine, Italy; Department of 
Mental Health (G Castelpietra PhD), Healthcare Agency “Friuli 
Occidentale”, Pordenone, Italy; Gorgas Memorial Institute for Health 
Studies, Panama City, Panama (F Castro MD); National School of Public 
Health (F Catalá-López PhD), Institute of Health Carlos III, Madrid, 
Spain; Clinical Epidemiology Program (F Catalá-López PhD), 
Department of Medicine (S Pakhale MD), Ottawa Hospital Research 
Institute, Ottawa, ON, Canada; National Institute of Health Research 
Nottingham Biomedical Research Centre (C R Cederroth PhD), 
University of Nottingham, Nottingham, UK; Mary MacKillop Institute 
for Health Research (Prof E Cerin PhD), Australian Catholic University, 
Melbourne, VIC, Australia; School of Public Health (Prof E Cerin PhD), 
Department of Urban Planning and Design (H Ho PhD), Centre for 
Suicide Research and Prevention (Prof P Yip PhD), Department of Social 
Work and Social Administration (Prof P Yip PhD), University of Hong 
Kong, Hong Kong, China; Institute of Applied Health Research 
(J S Chandan MFPH), Institute of Occupational and Environmental 
Medicine (O P Kurmi PhD), University of Birmingham, Birmingham, 
UK; Research Department (S Chaturvedi PhD), Dr D Y Patil University, 
Pune, India; Department of Epidemiology and Preventive Medicine 
(K L Chin PhD), School of Public Health and Preventive Medicine 
(S Li PhD), The School of Clinical Sciences at Monash Health 
(S Zaman MPH), Monash University, Melbourne, VIC, Australia; 
Melbourne Medical School (K L Chin PhD), Melbourne School of 
Population and Global Health (Prof A D Lopez PhD), School of Health 
Sciences (A Meretoja MD), Department of Pediatrics 
(Prof G C Patton MD, Prof S M Sawyer MD), Department of Agriculture 
and Food Systems (H Suleria PhD), University of Melbourne, 
Melbourne, VIC, Australia; Biomedical Informatics (J J Choi PhD), Seoul 
National University Hospital, Seoul, South Korea; Bispebjerg Hospital 
(Prof H Christensen DMSci), University of Copenhagen, Copenhagen, 
Denmark; Faculty of Biology (D Chu PhD), Hanoi National University of 
Education, Hanoi, Vietnam; Department of Otolaryngology 
(M T Chung MD), Wayne State University, Detroit, MI, USA; School of 
Pharmacy and Medical Sciences (L G Ciobanu PhD), University of South 
Australia, Adelaide, SA, Australia; Department of Public Health 
(Prof M Cirillo MD, Prof I Iavicoli PhD, R Palladino MD), University of 
Naples Federico II, Naples, Italy; School of Medicine and Surgery 
(P A Cortesi PhD), Research Center on Public Health (P Ferrara MD), 
University of Milan Bicocca, Monza, Italy; Postgraduate Program in 
Epidemiology (E Cousin PhD, Prof B B Duncan PhD, 
Prof B N G Goulart DSc, Prof M I Schmidt PhD, C Stein PhD), Federal 
University of Rio Grande do Sul, Porto Alegre, Brazil; Clinical 
Dermatology, IRCCS Istituto Ortopedico Galeazzi (G Damiani MD), 
Department of Clinical Sciences and Community Health 
(Prof C La Vecchia MD), University of Milan, Milan, Italy; Department of 
Dermatology (G Damiani MD), Department of Nutrition and Preventive 
Medicine (Prof J Sanabria MD), Case Western Reserve University, 
Cleveland, OH, USA; Health Policy Research (M R Mathur PhD), Indian 
Institute of Public Health (Prof S Zodpey PhD), Public Health 
Foundation of India, Gurugram, India (Prof L Dandona MD, 
Prof R Dandona PhD, G Kumar PhD, D K Lal MD); India Cancer 
Research Consortium (Prof R Mehrotra DPhil), Indian Council of 
Medical Research, New Delhi, India (Prof L Dandona MD); Department 
of Information Technology (A M Darwesh PhD), Department of 
Computer Science (M Hosseinzadeh PhD), University of Human 
Development, Sulaymaniyah, Iraq; Central University Tami Nadu, 
Articles
28 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
Thiruvarur, India (Prof A P Dash DSc); Department of Global Health 
and Infection (Prof G Davey MD), Wellcome Trust Brighton and Sussex 
Centre for Global Health Research (K Deribe PhD), Brighton and Sussex 
Medical School, Brighton, UK; School of Public Health 
(Prof G Davey MD, K Deribe PhD), Addis Ababa University, Addis 
Ababa, Ethiopia; Department of Population and Development 
(C A Dávila-Cervantes PhD), Latin American Faculty of Social Sciences 
Mexico, Mexico City, Mexico; Health Research Institute 
(K Davletov PhD), Al Farabi Kazakh National University, Almaty, 
Kazakhstan; St Paul’s Eye Unit (N Dervenis MD), Royal Liverpool 
University Hospital, Liverpool, UK; Department of Ophthalmology 
(N Dervenis MD), 1st Department of Ophthalmology 
(Prof F Topouzis PhD), Aristotle University of Thessaloniki, 
Thessaloniki, Greece; Division of Cardiology (R Desai MBBS), Atlanta 
Veterans Affairs Medical Center, Decatur, GA, USA; Department of 
Community Medicine (Prof S D Dharmaratne MD), University of 
Peradeniya, Peradeniya, Sri Lanka; Department of Microbiology 
(G P Dhungana MSc), Far Western University, Mahendranagar, Nepal; 
Department of Epidemiology and Biostatistics (M Dianatinasab MSc), 
Shahroud University of Medical Sciences, Shahroud, Iran; Center of 
Complexity Sciences (Prof D Diaz PhD), National Autonomous 
University of Mexico, Mexico City, Mexico; Faculty of Veterinary 
Medicine and Zootechnics (Prof D Diaz PhD), Autonomous University 
of Sinaloa, Culiacan Rosales, Mexico; Center of Excellence in Public 
Health Nutrition (H T Do MD), Nguyen Tat Thanh University, 
Ho Chi Minh City, Vietnam; School of Medicine (Prof A R Duraes PhD), 
Institute of Collective Health (Prof D Rasella PhD), Federal University of 
Bahia, Salvador, Brazil; Department of Internal Medicine 
(Prof A R Duraes PhD), Escola Bahiana de Medicina e Saúde Pública, 
Salvador, Brazil; Department of Social Services (A W Eagan MSW), 
Tufts Medical Center, Boston, MA, USA; Department of Nursing 
(Prof D Edvardsson PhD), Umeå University, Umea, Sweden; Biomedical 
Informatics and Medical Statistics Department (I El Sayed PhD), 
Pediatric Dentistry and Dental Public Health Department 
(Prof M El Tantawi PhD), Alexandria University, Alexandria, Egypt; 
Division of Cardiology (I Y Elgendy MD), Massachusetts General 
Hospital, Boston, MA, USA; Eijkman-Oxford Clinical Research Unit 
(I R Elyazar PhD), Eijkman Institute for Molecular Biology, Jakarta, 
Indonesia; Department of Medicinal Chemistry (K Eskandari PhD), 
Pharmaceutics Research Center (K Eskandari PhD), HIV/STI 
Surveillance Research Center, and WHO Collaborating Center for HIV 
Surveillance (Prof H Sharifi PhD), Health Services Management 
Research Center (V Yazdi-Feyzabadi PhD), Department of Health 
Management, Policy, and Economics (V Yazdi-Feyzabadi PhD), Kerman 
University of Medical Sciences, Kerman, Iran; Department of Physiology 
(S Esmaeilnejad PhD), Department of Clinical Biochemistry 
(A Mosapour PhD), Department of Parasitology and Entomology 
(L Zaki PhD), Tarbiat Modares University, Tehran, Iran; Independent 
Consultant, Awka, Nigeria (O Ezekannagha PhD); International Institute 
for Tropical Agriculture, Ibadan, Nigeria (O Ezekannagha PhD); 
Dissemination Division (C S e Farinha MSc), National Institute of 
Statistics, Lisbon, Portugal; Activity Planning and Control Unit 
(C S e Farinha MSc), Directorate-General of Health (DGS), Lisbon, 
Portugal; Department of Medical and Surgical Sciences (A Farioli PhD, 
Prof F S Violante MD), University of Bologna, Bologna, Italy; 
Department of Biology and Biotechnology “Lazzaro Spallanzani” 
(P S Faris PhD), University of Pavia, Pavia, Italy; Department of Biology 
(P S Faris PhD), Department of Forestry (D K Mohammad PhD), 
Salahaddin University-Erbil, Erbil, Iraq; Department of Psychology 
(Prof A Faro PhD), Federal University of Sergipe, São Cristóvão, Brazil; 
National Institute for Stroke and Applied Neurosciences 
(Prof V L Feigin PhD), Auckland University of Technology, Auckland, 
New Zealand; Third Department of Neurology (E V Gnedovskaya PhD), 
Research Center of Neurology, Moscow, Russia (Prof V L Feigin PhD, 
Prof M A Piradov DSc); Department of Health Education and Behavioral 
Sciences (G T Feyissa PhD), Jimma University, Jimma, Ethiopia; 
Psychiatry Department (I Filip MD), Kaiser Permanente, Fontana, CA, 
USA; School of Health Sciences (I Filip MD), A.T. Still University, Mesa, 
AZ, USA; Institute of Gerontological Health Services and Nursing 
Research (F Fischer PhD), Ravensburg-Weingarten University of Applied 
Sciences, Weingarten, Germany; James Cancer Hospital 
(J L Fisher PhD), Ohio State University, Columbus, OH, USA; 
Sergio Arouca National School of Public Health, Rio de Janeiro, Brazil 
(L S Flor MPH); Federal University of Espírito Santo, Vitória, Brazil 
(L S Flor MPH); Institute of Gerontology (N A Foigt PhD), National 
Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; Department of 
Child Dental Health (Prof M O Folayan FWACS), Obafemi Awolowo 
University, Ile-Ife, Nigeria; Department of Cell Biology and 
Biotechnology (A A Fomenkov PhD), Timiryazev Institute of Plant 
Physiology, Moscow, Russia; Abadan Faculty of Medical Sciences 
(M Foroutan PhD), Abadan School of Medical Sciences, Abadan, Iran; 
Department of Family Medicine and Primary Care (J M Francis PhD), 
University of the Witwatersrand, Johannesburg, South Africa; 
Department of Dermatology (T Fukumoto PhD), Kobe University, Kobe, 
Japan; Department of Cardiovascular Medicine (M M Gad MD), 
Cleveland Clinic, Cleveland, OH, USA; Gillings School of Global Public 
Health (M M Gad MD), University of North Carolina Chapel Hill, 
Chapel Hill, NC, USA; Department of Community Medicine 
(Prof A M Gaidhane MD, Prof Z Quazi Syed PhD, Prof D Saxena PhD), 
Global Evidence Synthesis Initiative (Prof M Khatib PhD), Datta Meghe 
Institute of Medical Sciences, Wardha, India; Department of Public 
Health (B S Geberemariyam MPH), Madda Walabu University, Bale 
Robe, Ethiopia; Department of Nursing (G G Gebremeskel MSc, 
T G Haile MSc, D B Tadesse MSc), School of Pharmacy 
(L G Gebremeskel MSc, G Woldu MSc), Aksum University, Aksum, 
Ethiopia; College of Medicine and Public Health (H A Gesesew PhD), 
Flinders University, Adelaide, SA, Australia; Research Group for 
Genomic Epidemiology (N Ghith PhD), Technical University of 
Denmark, Copenhagen, Denmark; Faculty of Allied Health Sciences 
(Prof S Gilani PhD), University Institute of Public Health 
(S Hameed MPH, A Hanif PhD, Prof S M Rana PhD), The University of 
Lahore, Lahore, Pakistan; Afro-Asian Institute, Lahore, Pakistan 
(Prof S Gilani PhD); Medical School (Prof P S Gill DM), Division of 
Health Sciences (O A Uthman PhD), University of Warwick, Coventry, 
UK; Discipline of Public Health Medicine (T G Ginindza PhD), 
University of KwaZulu-Natal, Durban, South Africa 
(Prof F C Tanser PhD); Department of Pediatrics 
(M Gitimoghaddam MD), School of Population and Public Health 
(J A Kopec PhD, F Pourmalek PhD), University of British Columbia, 
Vancouver, BC, Canada; School of Public Health and Community 
Medicine (M A Godinho MBBS, A E Peden PhD), The George Institute 
for Global Health (Prof V Jha MD), School of Psychiatry 
(Prof P B Mitchell MD, Prof P S Sachdev MD), University of New South 
Wales, Sydney, NSW, Australia; Hudson College of Public Health 
(S V Gopalani MPH), University of Oklahoma Health Sciences Center, 
Oklahoma City, OK, USA; Department of Health and Social Affairs 
(S V Gopalani MPH), Government of the Federated States of Micronesia, 
Palikir, Federated States of Micronesia; Department of Family and 
Community Medicine (M I M Gubari PhD), University Of Sulaimani, 
Sulaimani, Iraq; Institute of Tropical Pathology and Public Health 
(IPTSP) (R A Guimarães MSc), Federal University of Goias, Goiânia, 
Brazil; College of Medicine and Health Science (R A Guled PhD), 
Department of Public Health (A Hashi PhD, M O Omer MSc), Jigjiga 
University, Jijiga, Ethiopia; Department of Epidemiology 
(Prof Y Guo PhD), Binzhou Medical University, Yantai City, China; 
Medical Resources (Prof R Gupta MD), March of Dimes, Arlington, VA, 
USA; Health Policy, Management and Leadership (Prof R Gupta MD), 
West Virginia University School of Public Health, Morgantown, WV, 
USA; Department of Preventive Cardiology (Prof R Gupta MD), Eternal 
Heart Care Centre & Research Institute, Jaipur, India; Department of 
Medicine (Prof R Gupta MD), Mahatma Gandhi University Medical 
Sciences, Jaipur, India; College of Medicine (A Hafiz PhD), Umm AL 
Qura University, Makkah, Saudi Arabia; Department of Family and 
Community Medicine (Prof R R Hamadeh PhD), Arabian Gulf 
University, Manama, Bahrain; School of Health and Environmental 
Studies (Prof S Hamidi DrPH), Hamdan Bin Mohammed Smart 
University, Dubai, United Arab Emirates; Department of Public Health 
(D Handiso MPH), Wachemo University, Hossana, Ethiopia; Medical 
School (Prof G J Hankey MD), University of Western Australia, Perth, 
WA, Australia; Department of Neurology (Prof G J Hankey MD), 
Sir Charles Gairdner Hospital, Perth, WA, Australia; Carlos III Health 
Institute (Prof R Tabarés-Seisdedos PhD), Biomedical Research 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 29
Networking Center for Mental Health Network (CiberSAM), Barcelona, 
Spain (J M Haro MD); Department of Zoology and Entomology 
(A I Hasaballah PhD), Al Azhar University, Cairo, Egypt; Institute for 
Social Science Research (M Hasan MPH), ARC Centre of Excellence for 
Children and Families over the Life Course (M Hasan MPH), School of 
Dentistry (R Lalloo PhD), The University of Queensland, Brisbane, QLD, 
Australia; Center for International Health (CIH) and Bergen Center for 
Ethics and Priority Setting (BCEPS) (S Hassan MPhil), Department of 
Global Public Health and Primary Care (Prof O F Norheim PhD), 
Department of Psychosocial Science (Prof S Øverland PhD), University 
of Bergen, Bergen, Norway; Gastrointestinal and Liver Diseases 
Research Center (S Hassanipour PhD, F Joukar PhD), Caspian Digestive 
Disease Research Center (S Hassanipour PhD, F Joukar PhD), 
Department of Environmental Health Engineering (J Jaafari PhD), 
Guilan University of Medical Sciences, Rasht, Iran; Independent 
Consultant, Tabriz, Iran (H Hassankhani PhD); Skaane University 
Hospital (R J Havmoeller PhD), Skaane County Council, Malmoe, 
Sweden; Institute of Pharmaceutical Sciences (K Hayat MS), University 
of Veterinary and Animal Sciences, Lahore, Pakistan; Department of 
Pharmacy Administration and Clinical Pharmacy (K Hayat MS), Xian 
Jiaotong University, Xian, China; Independent Consultant, Santa Clara, 
CA, USA (G Heidari MD); School of Business (Prof C Herteliu PhD), 
London South Bank University, London, UK; Department for Health 
(T R Hird PhD), Department of Mathematical Sciences (P Moraga PhD), 
University of Bath, Bath, UK; Department of Pediatrics (M K Hole MD), 
University of Texas Austin, Austin, TX, USA; Independent Consultant, 
Virginia Beach, VA, USA (K P Hopf MPH); Metrics and Evaluation 
(K P Hopf MPH), Operation Smile, Virginia Beach, VA, USA; 
Department of Pulmonology (N Horita PhD), Yokohama City University, 
Yokohama, Japan; National Human Genome Research Institute 
(NHGRI) (N Horita PhD), Center for Translation Research and 
Implementation Science (G A Mensah MD), National Institutes of 
Health, Bethesda, MD, USA; Department of Pharmacology 
(N Hossain MPhil), Bangladesh Industrial Gases Limited, Tangail, 
Bangladesh; Institute of Research and Development 
(M Hosseinzadeh PhD), Institute for Global Health Innovations 
(C T Nguyen MPH, D N Nguyen MA, H L T Nguyen MPH), Faculty of 
Pharmacy (D N Nguyen MA), Duy Tan University, Da Nang, Vietnam; 
Clinical Legal Medicine Department (S Hostiuc PhD), National Institute 
of Legal Medicine Mina Minovici, Bucharest, Romania; Division of 
Information and Computing Technology (Prof M Househ PhD), 
Hamad Bin Khalifa University, Doha, Qatar; Department of Health 
Services Administration (V Hsieh PhD), Department of Occupational 
Safety and Health (Prof B Hwang PhD), China Medical University, 
Taichung, Taiwan; Department of Epidemiology and Health Statistics 
(Prof G Hu PhD), Central South University, Changsha, China; School of 
Public Health (T M Huda PhD), Sydney Medical School (S Islam PhD), 
Asbestos Diseases Research Institute (J Leigh MD), Institute of Bone 
and Joint Research (IBJR) (E U R Smith PhD), Pain Management 
Research Institute (PMRI) (E U R Smith PhD), University of Sydney, 
Sydney, NSW, Australia; Maternal and Child Health Division 
(T M Huda PhD, S Zaman MPH), International Centre for Diarrhoeal 
Disease Research, Bangladesh, Dhaka, Bangladesh; Department of 
Public Health and Community Medicine (Prof A Humayun PhD), 
Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan; 
International Center for Nutrition and Information (N Ikeda PhD), 
National Institutes of Biomedical Innovation, Health and Nutrition, 
Tokyo, Japan; Faculty of Medicine (I M Ilic PhD, 
Prof M M Santric-Milicevic PhD), School of Public Health and Health 
Management (Prof M M Santric-Milicevic PhD), University of Belgrade, 
Belgrade, Serbia; Department of Epidemiology (Prof M D Ilic PhD), 
Department of Global Health, Economics and Policy 
(Prof M Jakovljevic PhD), University of Kragujevac, Kragujevac, Serbia; 
Division of Community Health and Family Medicine (L R Inbaraj MD), 
Bangalore Baptist Hospital, Bangalore, India; College of Public Health 
(U Iqbal PhD), Taipei Medical University, Taipei, Taiwan; Research 
Institute for Endocrine Sciences (S N Irvani MD), School of 
Management and Medical Education (N Jahanmehr PhD), Safety 
Promotion and Injury Prevention Research Center (N Jahanmehr PhD), 
Department of Epidemiology (S Sabour PhD), Injury Prevention and 
Safety Promotion Research Center (T Yousefinezhadi PhD), Shahid 
Beheshti University of Medical Sciences, Tehran, Iran 
(M Khayamzadeh MD); Institute for Physical Activity and Nutrition 
(S Islam PhD, R Uddin PhD), Department of Psychology 
(M A Stokes PhD), Deakin University, Burwood, VIC, Australia; 
Surveillance and Health Services Research (F Islami PhD), American 
Cancer Society, Atlanta, GA, USA; Department of Social Medicine 
(Prof H Iso MD), Graduate School of Medicine (Prof K Yamagishi MD), 
Osaka University, Suita-city, Japan; Department of Biochemistry and 
Microbiology (C C D Iwu MSc), University of Fort Hare, Alice, 
South Africa; Grants, Innovation and Product Development Unit 
(P W Mahasha PhD), South African Medical Research Council, 
Cape Town, South Africa (C J Iwu PhD, C A Nnaji MPH); Health 
Informatic Lab (T Javaheri PhD), Department of Computer Science 
(R Rawassizadeh PhD), Boston University, Boston, MA, USA; 
Postgraduate Institute of Medicine (A U Jayatilleke PhD), University of 
Colombo, Colombo, Sri Lanka; Faculty of Graduate Studies 
(A U Jayatilleke PhD), Institute for Violence and Injury Prevention, 
Colombo, Sri Lanka; Department of Community Medicine 
(R P Jha MSc), Dr. Baba Saheb Ambedkar Medical College & Hospital, 
Delhi, India; Department of Community Medicine (R P Jha MSc), 
Banaras Hindu University, Varanasi, India; Environmental Research 
Center (J S Ji DSc), Duke Kunshan University, Kunshan, China; Nicholas 
School of the Environment (J S Ji DSc), Department of Family Medicine 
and Community Health (Y Yano MD), Duke Global Health Institute 
(S Zadey MS), Duke University, Durham, NC, USA; Department of 
Earth Observation Science (P Jia PhD), University of Twente, Enschede, 
Netherlands; Beijing Institute of Ophthalmology (Prof J B Jonas MD), 
Beijing Tongren Hospital, Beijing, China; Department of Family 
Medicine and Public Health (J J Jozwiak PhD), University of Opole, 
Opole, Poland; Institute of Family Medicine and Public Health 
(M Jürisson PhD), University of Tartu, Tartu, Estonia; School of Public 
Health (Z Kabir PhD), University College Cork, Cork, Ireland; Institute 
for Prevention of Non-communicable Diseases (R Kalhor PhD), Health 
Services Management Department (R Kalhor PhD), Qazvin University of 
Medical Sciences, Qazvin, Iran; Department of Health Management and 
System Sciences (S M Karimi PhD), University of Louisville, Louisville, 
KY, USA; Center for Health Equity (S M Karimi PhD), Louisville Metro 
Department of Public Health & Wellness, Louisville, KY, USA; 
MRC/CSO Social and Public Health Sciences Unit (S V Katikireddi PhD), 
University of Glasgow, Glasgow, UK; International Research Center of 
Excellence (G A Kayode PhD), Institute of Human Virology Nigeria, 
Abuja, Nigeria; Julius Centre for Health Sciences and Primary Care 
(G A Kayode PhD), Utrecht University, Utrecht, Netherlands; Open, 
Distance and eLearning Campus (Prof P N Keiyoro PhD), Department of 
Psychiatry (M Kumar PhD), School of Economics (M K Muriithi PhD), 
School of Public Health (R G Wamai PhD), University of Nairobi, 
Nairobi, Kenya; Department of Public Health (Prof Y S Khader PhD), 
Jordan University of Science and Technology, Irbid, Jordan; Department 
of Epidemiology and Biostatistics (E A Khan MPH), Health Services 
Academy, Islamabad, Pakistan; Department of Health Policy and 
Management (Prof Y Khang MD), Institute of Health Policy and 
Management (Prof Y Khang MD), Seoul National University, Seoul, 
South Korea; Faculty of Health and Wellbeing (K Khatab PhD), Sheffield 
Hallam University, Sheffield, UK; College of Arts and Sciences 
(K Khatab PhD), Ohio University, Zanesville, OH, USA; The Iranian 
Academy of Medical Sciences, Tehran, Iran (M Khayamzadeh MD); 
Department of Nutrition and Health Science (Prof J Khubchandani PhD), 
Ball State University, Muncie, IN, USA; Department of Preventive 
Medicine (Y Kim PhD), Korea University, Seoul, South Korea; School of 
Traditional Chinese Medicine (Y Kim PhD), Xiamen University 
Malaysia, Sepang, Malaysia; Department of Nutrition 
(R W Kimokoti MD), Simmons University, Boston, MA, USA; Faculty of 
Health (Y Kinfu PhD), University of Canberra, Canberra, ACT, Australia; 
College of Medicine (Y Kinfu PhD), Qatar University, Doha, Qatar; 
School of Health Sciences (Prof A Kisa PhD), Kristiania University 
College, Oslo, Norway; Global Community Health and Behavioral 
Sciences (Prof A Kisa PhD), Tulane University, New Orleans, LA, USA; 
Department of Health Economics and Social Security 
(K Kissimova-Skarbek PhD), Jagiellonian University Medical College, 
Krakow, Poland; Department of Epidemiology and Public Health 
(Prof M Kivimäki PhD), Division of Psychology and Language Sciences 
Articles
30 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
(M Kumar PhD), University College London, London, UK; Department 
of Public Health (Prof M Kivimäki PhD), University of Helsinki, 
Helsinki, Finland (T J Meretoja MD); Public Health Sciences Division 
(J M Kocarnik PhD), Fred Hutchinson Cancer Research Center, Seattle, 
WA, USA; Global Healthcare Consulting, New Delhi, India 
(S Kochhar MD); Arthritis Research Canada, Richmond, BC, Canada 
(J A Kopec PhD); Federal Research Institute for Health Organization and 
Informatics of the Ministry of Health (FRIHOI), Moscow, Russia 
(A V Korotkova PhD); Independent Consultant, Jakarta, Indonesia 
(S Kosen MD); Department of Global Health (A Kotlo MS), Vancouver 
Virology Centre, Vancouver, BC, Canada; Department of Internal and 
Pulmonary Medicine (Prof P A Koul MD), Sheri Kashmir Institute of 
Medical Sciences, Srinagar, India; Biomedical Research Networking 
Center for Mental Health Network (CIBERSAM) (A Koyanagi MD), 
San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; 
Department of Anthropology (K Krishan PhD), Panjab University, 
Chandigarh, India; Faculty of Public Health (D Kusuma DSc), University 
of Indonesia, Depok, Indonesia; Nuffield Department of Population 
Health (B Lacey PhD), The George Institute for Global Health 
(Prof S Yaya PhD), Nuffield Department of Medicine (Y Zhao MPH), 
University of Oxford, Oxford, UK; National Institute for Health Research 
(NIHR) Oxford Biomedical Research Centre, Oxford, UK (B Lacey PhD); 
Unit of Genetics and Public Health (Prof I Landires MD), Unit of 
Microbiology and Public Health (V Nunez-Samudio PhD), Institute of 
Medical Sciences, Las Tablas, Panama; Department of Public Health 
(V Nunez-Samudio PhD), Ministry of Health, Herrera, Panama 
(Prof I Landires MD); Medical Director (Prof V C Lansingh PhD), 
HelpMeSee, New York, NY, USA; General Director 
(Prof V C Lansingh PhD), Mexican Institute of Ophthalmology, 
Queretaro, Mexico; Department of Medical Sciences 
(Prof A O Larsson PhD), Uppsala University, Uppsala, Sweden; 
Department of Clinical Chemistry and Pharmacology 
(Prof A O Larsson PhD), Uppsala University Hospital, Uppsala, Sweden; 
Department of Otorhinolaryngology (S Lasrado MS), Father Muller 
Medical College, Mangalore, India; Institute of Clinical Physiology 
(P Lauriola MD), National Research Council, Pisa, Italy; Barcelona 
Institute for Global Health, Barcelona, Spain (Prof J V Lazarus PhD); 
School of Pharmacy (S W H Lee PhD), Monash University, Selangor, 
Malaysia; School of Pharmacy (S W H Lee PhD), Taylor’s University 
Lakeside Campus, Subang Jaya, Malaysia; Neurology, Public Health and 
Disability Unit (M Leonardi MD, A Raggi PhD, D Sattin PsyD, 
S Schiavolin MSc), Carlo Besta Neurological Institute IRCCS, Milan, 
Italy; Department of Medicine (L Lim MRCP), University of Malaya, 
Kuala Lumpur, Malaysia; Department of Medicine and Therapeutics 
(L Lim MRCP), The Chinese University of Hong Kong, Shatin, NT, 
China; Department of Systems, Populations, and Leadership 
(X Liu PhD), University of Michigan, Ann Arbor, MI, USA; Department 
of Basic Medical Sciences, Neuroscience and Sense Organs 
(Prof G Logroscino PhD), University of Bari Aldo Moro, Bari, Italy; 
Department of Clinical Research in Neurology (Prof G Logroscino PhD), 
Fondazione Cardinale Giovanni Panico Hospital, Tricase, Italy; Radiology 
and Precision Health Program (M Mahmoudi PhD), Michigan State 
University, East Lansing, MI, USA; Faculty of Medicine 
(J N Malagón-Rojas MSc), El Bosque University, Bogota, Colombia; 
Faculty of Public Health (S Martini PhD), Airlangga University, 
Surabaya, Indonesia; Indonesian Public Health Association, Surabaya, 
Indonesia (S Martini PhD); Campus Caucaia (F R Martins-Melo PhD), 
Federal Institute of Education, Science and Technology of Ceará, 
Caucaia, Brazil; Institute of Population Health Sciences 
(M R Mathur PhD), University of Liverpool, Liverpool, UK; Department 
of Ophthalmology (C McAlinden PhD), Singleton Hospital, Swansea, 
UK; Academic Area of Dentistry (C E Medina-Solís MSc), Autonomous 
University of Hidalgo State, Pachuca, Mexico; Department of Pharmacy 
(B Meharie MSc), Wollo University, Dessie, Ethiopia; Neurology 
Department (Prof M Mehndiratta MD), Janakpuri Super Specialty 
Hospital Society, New Delhi, India; Department of Neurology 
(Prof M Mehndiratta MD), Govind Ballabh Institute of Medical 
Education and Research, New Delhi, India; Department of Nutrition 
(T Mekonnen MPH), University of Oslo, Oslo, Norway; Institute of 
Human Virology (P T N Memiah DrPH), University of Maryland, 
Baltimore, MD, USA; Peru Country Office (W Mendoza MD), 
United Nations Population Fund (UNFPA), Lima, Peru; Neurology Unit 
(A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), Helsinki 
University Hospital, Helsinki, Finland; Clinical Microbiology and 
Parasitology Unit (T Mestrovic PhD), Dr. Zora Profozic Polyclinic, 
Zagreb, Croatia; University Centre Varazdin (T Mestrovic PhD), 
University North, Varazdin, Croatia; Center for Innovation in Medical 
Education (B Miazgowski MD), Pomeranian Medical University, 
Szczecin, Poland (B Miazgowski MD); Department of Women-Mother-
Child (I Michalek PhD), Vaud University Hospital Center, Lausanne, 
Switzerland; Internal Medicine Programme 
(Prof E M Mirrakhimov PhD), Kyrgyz State Medical Academy, Bishkek, 
Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease 
(Prof E M Mirrakhimov PhD), National Center of Cardiology and 
Internal Disease, Bishkek, Kyrgyzstan; Institute of Addiction Research 
(ISFF) (B Moazen MSc), Frankfurt University of Applied Sciences, 
Frankfurt, Germany; Department of Epidemiology and Biostatistics 
(A Mohammadian-Hafshejani PhD), Shahrekord University of Medical 
Sciences, Shahrekord, Iran; Department of Public Health 
(J A Mohammed MPH), Samara University, Semera, Ethiopia; Health 
Systems and Policy Research Unit (S Mohammed PhD), Department of 
Community Medicine (M B Sufiyan MD), Ahmadu Bello University, 
Zaria, Nigeria; Clinical Epidemiology and Public Health Research Unit 
(L Monasta DSc, L Ronfani PhD), Burlo Garofolo Institute for Maternal 
and Child Health, Trieste, Italy; Department of Biomedical and Dental 
Sciences and Morphofunctional Imaging (Prof S Mondello MD), 
Messina University, Messina, Italy; Department of Food Science 
(Prof A Mousavi Khaneghah PhD), University of Campinas (Unicamp), 
Campinas, Brazil; Department of Pediatric Medicine 
(Prof G Mustafa MD), The Children’s Hospital & The Institute of Child 
Health, Multan, Pakistan; Department of Pediatrics & Pediatric 
Pulmonology (Prof G Mustafa MD), Institute of Mother & Child Care, 
Multan, Pakistan; Knowledge Translation and Utilization Unit 
(Prof A F Nabhan PhD), Egyptian Center for Evidence Based Medicine, 
Cairo, Egypt; Research and Analytics Department 
(A J Nagarajan MTech), Initiative for Financing Health and Human 
Development, Chennai, India; Department of Research and Analytics 
(A J Nagarajan MTech), Bioinsilico Technologies, Chennai, India; 
Laboratory of Public Health Indicators Analysis and Health 
Digitalization (M Naimzada MD, N Otstavnov BA, S S Otstavnov PhD, 
M V Titova PhD), Moscow Institute of Physics and Technology, 
Dolgoprudny, Russia; Experimental Surgery and Oncology Laboratory 
(M Naimzada MD), Kursk State Medical University, Kursk, Russia; 
Suraj Eye Institute, Nagpur, India (V Nangia MD); Department for the 
Control of Disease, Epidemics, and Pandemics (J Nansseu MD), 
Ministry of Public Health, Yaoundé, Cameroon; Department of Public 
Heath (J Nansseu MD), Department of Public Health 
(G Nguefack-Tsague PhD), University of Yaoundé I, Yaoundé, 
Cameroon; Disease Control and Environmental Health (R Ndejjo MSc), 
Makerere University, Kampala, Uganda; Department of General Surgery 
(I Negoi PhD), Emergency Hospital of Bucharest, Bucharest, Romania; 
Cardio-Aid, Bucharest, Romania (R I Negoi PhD); Department of Health 
Sciences (S Neupane PhD), University of Tampere, Tampere, Finland; 
Research & Statistics Unit (K N Ngari MSc), Synotech Consultants, 
Nairobi, Kenya; Department of Biological Sciences (J W Ngunjiri DrPH), 
University of Embu, Embu, Kenya; Department of Health Policy and 
Management (S Nomura PhD), Keio University, Tokyo, Japan; 
Department of Global Health Policy (S Nomura PhD), University of 
Tokyo, Tokyo, Japan; Translational Health Research Institute 
(F A Ogbo PhD, Prof A M N Renzaho PhD), School of Social Sciences 
and Psychology (Prof A M N Renzaho PhD), Western Sydney University, 
Sydney, NSW, Australia; Department of Preventive Medicine (I Oh PhD), 
Kyung Hee University, Dongdaemun-gu, South Korea; Disease 
Surveillance and Epidemic Response (E W Okunga MSc), Ministry of 
Health, Nairobi, Kenya; Gorgan Congenital Malformations Research 
Center (M Oladnabi PhD), Golestan Research Center of 
Gastroenterology and Hepatology (GRCGH) (G Roshandel PhD), 
Golestan University of Medical Sciences, Gorgan, Iran; Department of 
Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; 
Centre for Healthy Start Initiative, Lagos, Nigeria (B O Olusanya PhD, 
J O Olusanya MBA); Diplomacy and Public Relations Department 
(A Omar Bali PhD), University of Human Development, Sulaimaniyah, 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 31
Iraq; Department of Pharmacology and Therapeutics 
(Prof O E Onwujekwe PhD), University of Nigeria Nsukka, Enugu, 
Nigeria; Department of Medicine (Prof A Ortiz MD), Princess University 
Hospital (Prof J B Soriano MD), Autonomous University of Madrid, 
Madrid, Spain; Department of Nephrology and Hypertension 
(Prof A Ortiz MD), The Institute for Health Research Foundation 
Jiménez Díaz University Hospital, Madrid, Spain; Department of 
Biomedical Sciences (Prof S M Ostojic PhD), University of Novi Sad, 
Novi Sad, Serbia; Department of Project Management 
(S S Otstavnov PhD), Department of Health Care Administration and 
Economics (Prof V Vlassov MD), National Research University Higher 
School of Economics, Moscow, Russia; Division of Mental and Physical 
Health (Prof S Øverland PhD), Norwegian Institute of Public Health, 
Bergen, Norway; Department of Health Metrics (A Pana MD), Center for 
Health Outcomes & Evaluation, Bucharest, Romania; National Institute 
of Health Research and Development (H U Pangaribuan MSc), Ministry 
of Health, Jakarta, Indonesia; Research & Development Department 
(M Pathak PhD), Kalinga Institute of Medical Sciences, Bhubaneswar, 
India; Population Health Theme (Prof G C Patton MD), Centre for 
Adolescent Health (Prof S M Sawyer MD), Critical Care and 
Neurosciences (Prof R G Weintraub MB), Murdoch Childrens Research 
Institute, Melbourne, VIC, Australia; Public Health Youth Society of 
Nepal, Pokhara, Nepal (S Paudel MPH); Public Health Update, Pokhara, 
Nepal (S Paudel MPH); College of Public Health, Medical, and 
Veterinary Sciences (A E Peden PhD), James Cook University, 
Townsville, NSW, Australia; School of Global Public Health 
(E K Peprah PhD), New York University, New York, NY, USA; 
Department of Orthopedics (J Pereira MS), Yenepoya Medical College, 
Mangalore, India; Department of Cardiology (T Pilgrim MD), University 
of Bern, Bern, Switzerland; HIV and Mental Health Department 
(K N Pokhrel PhD), Integrated Development Foundation Nepal, 
Kathmandu, Nepal; Department of Nutrition and Food Sciences 
(H Pourjafar PhD), Maragheh University of Medical Sciences, 
Maragheh, Iran; Dietary Supplements and Probiotic Research Center 
(H Pourjafar PhD), Alborz University of Medical Sciences, Karaj, Iran; 
Clinical Research Center (S I Prada PhD), Valle del Lili Foundation, Cali, 
Colombia; Center for Studies in Social Protection and Health Economics 
(S I Prada PhD), ICESI University, Cali, Colombia; Health Sciences 
Department (D R A Pribadi MSc), Muhammadiyah University of 
Surakarta, Sukoharjo, Indonesia; College of Medicine (A Radfar MD), 
University of Central Florida, Orlando, FL, USA; Department of 
Medicine (A Rafiee MSc), University of Alberta, Edmonton, AB, Canada; 
Thalassemia and Hemoglobinopathy Research Center (F Rahim PhD), 
Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; School 
of Nursing and Healthcare Professions (M Rahman PhD), Federation 
University Australia, Berwick, VIC, Australia; Public Health Department 
(Prof S M Rana PhD), University of Health Sciences, Lahore, Pakistan; 
Research Department (C L Ranabhat PhD), Policy Research Institute, 
Kathmandu, Nepal; Health and Public Policy Department 
(C L Ranabhat PhD), Global Center for Research and Development, 
Kathmandu, Nepal; Department of Oral Pathology (S Rao MDS), 
Srinivas Institute of Dental Sciences, Mangalore, India; University 
College London Hospitals, London, UK (D L Rawaf MD); Academic 
Public Health England (Prof S Rawaf MD), Public Health England, 
London, UK (Prof N Steel PhD); School of Health, Medical and Applied 
Sciences (L Rawal PhD), CQ University, Sydney, NSW, Australia; School 
of Nursing and Midwifery (V Renjith PhD), Royal College of Surgeons in 
Ireland - Bahrain, Muharraq Governorate, Bahrain; Network of 
Immunity in Infection, Malignancy and Autoimmunity (NIIMA) 
(Prof N Rezaei PhD), Universal Scientific Education and Research 
Network (USERN), Tehran, Iran; School of Physiotherapy 
(D C Ribeiro PhD), University of Otago, Dunedin, New Zealand; 
Department of Surgery (J Rickard MD), University of Minnesota, 
Minneapolis, MN, USA; Department of Surgery (J Rickard MD), 
University Teaching Hospital of Kigali, Kigali, Rwanda; Department of 
Clinical Research (L Roever PhD), Federal University of Uberlândia, 
Uberlândia, Brazil; Department of Neuroscience (M Romoli MD), 
University of Perugia, Perugia, Italy; Department of Neurology 
(M Romoli MD), Rimini “Infermi” Hospital - AUSL Romagna, Rimini, 
Italy; Agrosavia, Palmira, Colombia (E Rubagotti PhD); Department of 
Internal Medicine (G M Rwegerera MD), University of Botswana, 
Gaborone, Botswana; Neuropsychiatric Institute (Prof P S Sachdev MD), 
Prince of Wales Hospital, Randwick, NSW, Australia; Department of 
Family and Community Medicine (B Saddik PhD), University of 
Sharjah, Sharjah, United Arab Emirates; Halal Research Center of IRI 
(A Sahebkar PhD), Food and Drug Administration of the Islamic 
Republic of Iran, Tehran, Iran; Neurogenic Inflammation Research 
Center (A Sahebkar PhD), Mashhad University of Medical Sciences, 
Mashhad, Iran; Department of Phytochemistry (Prof S Sajadi PhD), 
Soran University, Soran, Iraq; Department of Nutrition 
(Prof S Sajadi PhD), Cihan University-Erbil, Kurdistan Region, Iraq; 
Center for Health Policy & Center for Primary Care and Outcomes 
Research (Prof J A Salomon PhD), Stanford University, Stanford, CA, 
USA; Department of Surgery (Prof J Sanabria MD), Marshall University, 
Huntington, WV, USA; Department of Community Medicine 
(S Y Saraswathy PhD), PSG Institute of Medical Sciences and Research, 
Coimbatore, India; PSG-FAIMER South Asia Regional Institute, 
Coimbatore, India (S Y Saraswathy PhD); Faculty of Medicine 
(Prof R Sarmiento-Suárez MPH), University of Applied and 
Environmental Sciences, Bogota, Colombia; National School of Public 
Health (Prof R Sarmiento-Suárez MPH), Carlos III Health Institute, 
Madrid, Spain; Department of Geriatrics and Long Term Care 
(B Sathian PhD), Hamad Medical Corporation, Doha, Qatar; Faculty of 
Health & Social Sciences (B Sathian PhD), Bournemouth University, 
Bournemouth, UK; GSK Biologicals, Wavre, Belgium (M Savic PhD); 
Department of Epidemiology (Prof D Saxena PhD), Indian Institute of 
Public Health, Gandhinagar, India; Unit for Hypertension and 
Cardiovascular Disease (Prof A E Schutte PhD), North-West University, 
Potchefstroom, South Africa; The George Institute for Global Health 
(Prof A E Schutte PhD), University of New South Wales, Sydney, NSW, 
Australia; Department of Psychology (D C Schwebel PhD), School of 
Medicine (Prof J A Singh MD), University of Alabama at Birmingham, 
Birmingham, AL, USA; Oral Diagnosis, Digital Health and Health 
Services Research (Prof F Schwendicke PhD), Charité University 
Medical Center Berlin, Berlin, Germany; Center for Biomedical 
Information Technology (F Sha PhD), Shenzhen Institutes of Advanced 
Technology, Shenzhen, China; Public Health Division 
(A A Shaheen PhD), An-Najah National University, Nablus, Palestine; 
Independent Consultant, Karachi, Pakistan (M A Shaikh MD); Faculty of 
Caring Science, Work Life, and Social Welfare (M Shamsizadeh MSc), 
University of Borås, Borås, Sweden; Department of Community 
Medicine (M Shannawaz PhD), BLDE University, Vijayapur, India; 
Centre for Medical Informatics (Prof A Sheikh MD), University of 
Edinburgh, Edinburgh, UK; National Institute of Infectious Diseases, 
Tokyo, Japan (M Shigematsu PhD); College of Medicine 
(Prof J Shin MD), Yonsei University, Seoul, South Korea; Finnish 
Institute of Occupational Health, Helsinki, Finland (R Shiri PhD); 
Faculty of Dental Sciences (Prof K M Shivakumar PhD), Krishna 
Institute of Medical Sciences, Karad, India; School of Public Health 
(K Shuval PhD), University of Haifa, Haifa, Israel; School of Health 
(S Siabani PhD), University of Technology Sydney, Sydney, NSW, 
Australia; Medical Research Agency, Warsaw, Poland (R Sierpinski PhD); 
School of Medicine (R Sierpinski PhD), Cardinal Wyszynski University, 
Warsaw, Poland; Department of Psychology (Prof I D Sigfusdottir PhD, 
R Sigurvinsdottir PhD), Reykjavik University, Reykjavik, Iceland; 
Department of Health and Behavior Studies (Prof I D Sigfusdottir PhD), 
Columbia University, New York, NY, USA; Department of Physical 
Education (Prof D A S Silva PhD), Federal University of Santa Catarina, 
Florianopolis, Brazil; Department of Law, Economics, Management and 
Quantitative Methods (Prof B Simonetti PhD), University of Sannio, 
Benevento, Italy; WSB University in Gdańsk, Gdańsk, Poland 
(Prof B Simonetti PhD); Medicine Service (Prof J A Singh MD), 
US Department of Veterans Affairs (VA), Birmingham, AL, USA; 
Department of Humanities and Social Sciences (P Singh MSc), Indian 
Institute of Technology, Roorkee, Roorkee, India; Department of 
Epidemiology (D N Sinha PhD), School of Preventive Oncology, Patna, 
India; Department of Epidemiology (D N Sinha PhD), Healis Sekhsaria 
Institute for Public Health, Mumbai, India; Department No.16 
(V Y Skryabin MD), Laboratory of Genetics and Genomics 
(Prof M S Zastrozhin PhD), Moscow Research and Practical Centre on 
Addictions, Moscow, Russia; Nursing Care Research Center 
(A Soheili PhD), Semnan University of Medical Sciences, Semnan, Iran; 
Articles
32 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
Centro de Investigación Biomédica en Red Enfermedades Respiratorias 
(CIBERES, Center for Biomedical Research in Respiratory Diseases 
Network), Madrid, Spain (Prof J B Soriano MD); Hull York Medical 
School (I N Soyiri PhD), University of Hull, Hull City, UK; Division of 
Community Medicine (C T Sreeramareddy MD), International Medical 
University, Kuala Lumpur, Malaysia; Department of Primary Care and 
Public Health (Prof N Steel PhD), University of East Anglia, Norwich, 
UK; Pediatric Services (I Sultan MD), King Hussein Cancer Center, 
Amman, Jordan; Pediatrics Department (I Sultan MD), University of 
Jordan, Amman, Jordan; Minister of Health (L Szumowski MD), 
Institute of Cardiology, Warsaw, Poland; Department of Medicine 
(Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; 
Cancer Control Center (T Tabuchi MD), Osaka International Cancer 
Institute, Osaka, Japan; School of Dentistry and Oral Health 
(S K Tadakamadla PhD), Griffith University, Gold Coast, QLD, Australia; 
Department of Pharmacy (B W Taddele MPH), Arbaminch College of 
Health Sciences, Arbaminch, Ethiopia; Africa Health Research Institute, 
Berea, South Africa (Prof F C Tanser PhD); Department of Population 
Science and Human Resource Development (Prof M I Tareque PhD), 
University of Rajshahi, Rajshahi, Bangladesh; Research and 
Development Center for Humanities and Health Management 
(I U Tarigan PhD), National Institute of Health Research & 
Development, Jakarta, Indonesia; University of Basel, Basel, Switzerland 
(F Tediosi PhD); Division of Biostatistics and Epidemiology 
(B Thakur PhD), Texas Tech University, El Paso, TX, USA; Timiryazev 
Institute of Plant Physiology (M V Titova PhD), Russian Academy of 
Sciences, Moscow, Russia; Department of Medicine 
(Prof M Tonelli MD), University of Calgary, Calgary, AB, Canada; 
Institute of Public Health (R Topor-Madry PhD), Jagiellonian University 
Medical College, Kraków, Poland; Agency for Health Technology 
Assessment and Tariff System, Warsaw, Poland (R Topor-Madry PhD); 
Modestum LTD, London, UK (M R Tovani-Palone PhD); Department of 
Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, 
Vietnam; Lee Kong Chian School of Medicine (L Tudor Car PhD), 
Nanyang Technological University, Singapore, Singapore; Department of 
Microbiology (I Ullah PhD), Iqra National University, Peshawar, 
Pakistan; TB Culture Laboratory (I Ullah PhD), Mufti Mehmood 
Memorial Teaching Hospital, Dera Ismail Khan, Pakistan; Department 
of Community Medicine (C D Umeokonkwo MPH), Alex Ekwueme 
Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria; 
Amity Institute of Biotechnology (E Upadhyay PhD), Amity University 
Rajasthan, Jaipur, India; Velez Sarsfield Hospital, Buenos Aires, 
Argentina (Prof P R Valdez MEd); Department of Nephrology 
(Prof S Varughese FRCP), Christian Medical College and Hospital 
(CMC), Vellore, India; UKK Institute, Tampere, Finland 
(Prof T J Vasankari MD); Raffles Neuroscience Centre 
(Prof N Venketasubramanian MBBS), Raffles Hospital, Singapore, 
Singapore; Yong Loo Lin School of Medicine 
(Prof N Venketasubramanian MBBS), National University of Singapore, 
Singapore, Singapore; Occupational Health Unit (Prof F S Violante MD), 
Sant’Orsola Malpighi Hospital, Bologna, Italy; Foundation University 
Medical College (Prof Y Waheed PhD), Foundation University 
Islamabad, Islamabad, Pakistan; Cultures, Societies and Global Studies, 
& Integrated Initiative for Global Health (R G Wamai PhD), 
Northeastern University, Boston, MA, USA; Cardiology Department 
(Prof R G Weintraub MB), Royal Children’s Hospital, Melbourne, VIC, 
Australia; Leonard Davis Institute of Health Economics (J Weiss MA), 
Population Studies Center (J Weiss MA), University of Pennsylvania, 
Philadelphia, PA, USA; Demographic Change and Aging Research Area 
(A Werdecker PhD), Competence Center of Mortality-Follow-Up of the 
German National Cohort (R Westerman DSc), Federal Institute for 
Population Research, Wiesbaden, Germany; NIHR Biomedical Research 
Centre (Prof C D A Wolfe MD), Guy’s and St.Thomas’ Hospital and 
Kings College London, London, UK; Department of Orthopaedics 
(Prof A Wu MD), Wenzhou Medical University, Wenzhou, China; 
Department of Behavior and Operation Management (Y Xie MD), 
Beijing Advanced Innovation Center for Big Data-based Precision 
Medicine, Beijing, China; Clinical Cancer Research Center 
(S Yahyazadeh Jabbari MD), Milad General Hospital, Tehran, Iran; 
Research and Development Center for Health Services 
(Prof K Yamagishi MD), University of Tsukuba, Tsukuba, Japan; School 
of International Development and Global Studies (Prof S Yaya PhD), 
University of Ottawa, Ottawa, ON, Canada; Department of 
Neuropsychopharmacology (N Yonemoto MPH), National Center of 
Neurology and Psychiatry, Kodaira, Japan; Department of Public Health 
(N Yonemoto MPH), Juntendo University, Tokyo, Japan; Department of 
Health Policy and Management (Prof M Z Younis PhD), Jackson State 
University, Jackson, MS, USA; School of Medicine 
(Prof M Z Younis PhD), Tsinghua University, Beijing, China; 
Department of Health care Management and Economics 
(H Yusefzadeh PhD), Urmia University of Medical Science, Urmia, Iran; 
Department of Pharmaceutics (S Zaidi PhD), Dow University of Health 
Sciences, Karachi, Pakistan; Addictology Department 
(Prof M S Zastrozhin PhD), Russian Medical Academy of Continuous 
Professional Education, Moscow, Russia; School of Public Health 
(Y Zhang PhD), Hubei Province Key Laboratory of Occupational Hazard 
Identification and Control (Y Zhang PhD), Wuhan University of Science 
and Technology, Wuhan, China; School of Biology and Pharmaceutical 
Engineering (X G Zhao PhD), Wuhan Polytechnic University, Wuhan, 
China; School of Health Sciences (X G Zhao PhD), Wuhan University, 
Wuhan, China; Department of Epidemiology, Human Genetics, and 
Environmental Sciences (C Zhu MPH), University of Texas Health 
Science Center at Houston, Houston, TX, USA.
Declaration of interests
Ali Almasi reports a patent null pending. Robert Ancuceanu reports 
receiving consultancy and speakers’ fees from various pharmaceutical 
companies. Ettore Beghi reports grants from the Italian Ministry of 
Health, grants from SOBI, and personal fees from Arvelle Therapeutics, 
outside the submitted work. Hanne Christensen reports personal fees 
from Bristol-Myers Squibb, Bayer, Boehringer-Ingelheim, outside the 
submitted work. Vivekanand Jha reports grants from GlaxoSmithKline, 
grants from Baxter Healthcare, personal fees from NephroPlus, grants 
from Biocon, grants from Zydus Cadilla, outside the submitted work. 
Jacek Jerzy Jozwiak reports personal fees from Amgen, Alab, Teva, 
Synexus, and Boehringer Ingelheim, outside the submitted work. 
Srinivasa Vittal Katikireddi reports support from the Medical Research 
Council and from the Scottish Government Chief Scientist Office, during 
the conduct of the study. Walter Mendoza is Program Analyst in 
Population and Development at the United Nations Population Fund-
UNFPA Country Office in Peru, an institution which does not necessarily 
endorse this study. Jonathan F Mosser reports grants from the Bill and 
Melinda Gates Foundation, during the conduct of the study. 
Shuhei Nomura reports grants from the Ministry of Education, Culture, 
Sports, Science, and Technology of Japan. Thomas Pilgrim reports grants 
and personal fees from Biotronik and Boston Scientific, grants from 
Edwards Lifesciences, and personal fees from HighLife SAS for his work 
as a member of clinical event committee for a study sponsored by 
HighLife Sas, outside the submitted work. Maarten J Postma reports 
grants and personal fees from MSD, GlaxoSmithKline, Pfizer, 
Boehringer Ingelheim, Novavax, Bristol-Myers Squibb, AstraZeneca, 
Sanofi, IQVIA, and Seqirus; personal fees from Quintiles, Novartis, 
and Pharmerit; 2% of stocks from Ingress Health, 100% of stocks from 
PAG, being an advisor to Asc Academics; and grants from Bayer, 
BioMerieux, WHO, the EU, FIND, Antilope, DIKTI, LPDP, and Budi, 
outside the submitted work. Elisabetta Pupillo reports grants from AIFA, 
outside the submitted work. Miloje Savic is an employee of 
GlaxoSmithKline Biologicals, Wavre, Belgium, and holds GlaxoSmithKline 
restricted shares. Aletta Elisabeth Schutte reports personal fees from 
Omron Healthcare, Servier, Novartis, Takeda, and Abbott, outside the 
submitted work. Mark G Shrime reports grants from Mercy Ships and 
Damon Runyon Cancer Research Foundation, outside the submitted 
work. Jasvinder A Singh reports personal fees from Crealta/Horizon, 
Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care 
options, Clearview healthcare partners, Putnam associates, Spherix, 
Practice Point communications, the National Institutes of Health and the 
American College of Rheumatology; personal fees from Simply 
Speaking, holding stock in Amarin pharmaceuticals and Viking 
pharmaceuticals, non-financial support from the FDA Arthritis Advisory 
Committee, non-financial support from Steering committee of 
OMERACT, an international organization that develops measures for 
clinical trials and receives arm’s length funding from 12 pharmaceutical 
companies, non-financial support from the Veterans Affairs 
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 33
Rheumatology Field Advisory Committee, and non-financial support 
from the Editor and the Director of the UAB Cochrane Musculoskeletal 
Group Satellite Center on Network Meta-analysis, outside the submitted 
work. Jeffrey D Stanaway reports grants from the Bill and Melinda Gates 
Foundation, during the conduct of the study. Fotis Topouzis reports 
grants from Pfizer, Thea, Rheon, Pharmaten, Bayer, and Bausch & Lomb; 
and grants and personal fees from Novartis and Omikron, outside the 
submitted work. Riaz Uddin worked as a visiting fellow at Deakin 
University Institute for Physical Activity and Nutrition (IPAN), which 
paid for his travel (including flights and transport), accommodation, 
and meals from Deakin University, outside the submitted work.
Data sharing
To download the data used in these analyses, please visit the Global Health 
Data Exchange at http://ghdx.healthdata.org/gbd-2019. 
Acknowledgments
Lucas Guimarães Abreu acknowledges support from Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior - Brasil (Capes) - Finance 
Code 001, Conselho Nacional de Desenvolvimento Científico e 
Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado de 
Minas Gerais (FAPEMIG). Olatunji O Adetokunboh acknowledges South 
African Department of Science & Innovation, and National Research 
Foundation. Anurag Agrawal acknowledges support from the Wellcome 
Trust DBT India Alliance Senior Fellowship IA/CPHS/14/1/501489. 
Rufus Olusola Akinyemi acknowledges Grant U01HG010273 from the 
National Institutes of Health (NIH) as part of the H3Africa Consortium. 
Rufus Olusola Akinyemi is further supported by the FLAIR fellowship 
funded by the UK Royal Society and the African Academy of Sciences. 
Syed Mohamed Aljunid acknowledges the Department of Health Policy 
and Management, Faculty of Public Health, Kuwait University and 
International Centre for Casemix and Clinical Coding, Faculty of 
Medicine, National University of Malaysia for the approval and support to 
participate in this research project. Marcel Ausloos, Claudiu Herteliu, 
and Adrian Pana acknowledge partial support by a grant of the Romanian 
National Authority for Scientific Research and Innovation, CNDS-
UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. Till Winfried 
Bärnighausen acknowledges support from the Alexander von Humboldt 
Foundation through the Alexander von Humboldt Professor award, 
funded by the German Federal Ministry of Education and Research. 
Juan J Carrero was supported by the Swedish Research Council 
(2019-01059). Felix Carvalho acknowledges UID/MULTI/04378/2019 and 
UID/QUI/50006/2019 support with funding from FCT/MCTES through 
national funds. Vera Marisa Costa acknowledges support from grant 
(SFRH/BHD/110001/2015), received by Portuguese national funds 
through Fundação para a Ciência e a Tecnologia (FCT), IP, under the 
Norma TransitÃ³ria DL57/2016/CP1334/CT0006. Jan-Walter De Neve 
acknowledges support from the Alexander von Humboldt Foundation. 
Kebede Deribe acknowledges support by Wellcome Trust grant number 
201900/Z/16/Z as part of his International Intermediate Fellowship. 
Claudiu Herteliu acknowledges partial support by a grant co-funded by 
European Fund for Regional Development through Operational Program 
for Competitiveness, Project ID P_40_382. Praveen Hoogar 
acknowledges the Centre for Bio Cultural Studies (CBiCS), Manipal 
Academy of Higher Education(MAHE), Manipal and Centre for Holistic 
Development and Research (CHDR), Kalghatgi. Bing-Fang Hwang 
acknowledges support from China Medical University (CMU108-MF-95), 
Taichung, Taiwan. Mihajlo Jakovljevic acknowledges the Serbian part of 
this GBD contribution was co-funded through the Grant OI175014 of 
the Ministry of Education Science and Technological Development of the 
Republic of Serbia. Aruna M Kamath acknowledges funding from the 
National Institutes of Health T32 grant (T32GM086270). Srinivasa Vittal 
Katikireddi acknowledges funding from the Medical Research Council 
(MC_UU_12017/13 & MC_UU_12017/15), Scottish Government Chief 
Scientist Office (SPHSU13 & SPHSU15) and an NRS Senior Clinical 
Fellowship (SCAF/15/02). Yun Jin Kim acknowledges support from the 
Research Management Centre, Xiamen University Malaysia 
(XMUMRF/2018-C2/ITCM/0001). Kewal Krishan acknowledges support 
from the DST PURSE grant and UGC Center of Advanced Study 
(CAS II) awarded to the Department of Anthropology, Panjab University, 
Chandigarh, India. Manasi Kumar acknowledges support from K43 
TW010716 Fogarty International Center/NIMH. Ben Lacey acknowledges 
support from the NIHR Oxford Biomedical Research Centre and the 
BHF Centre of Research Excellence, Oxford. Iván Landires is a member 
of the Sistema Nacional de InvestigaciÃ³n (SNI), which is supported by 
the Secretaría Nacional de Ciencia Tecnología e Innovación (SENACYT), 
Panamá. Jeffrey V Lazarus acknowledges support by a Spanish Ministry 
of Science, Innovation and Universities Miguel Servet grant (Instituto de 
Salud Carlos III/ESF, European Union [CP18/00074]). Peter T N Memiah 
acknowledges CODESRIA; HISTP. Subas Neupane acknowledges partial 
support from the Competitive State Research Financing of the Expert 
Responsibility area of Tampere University Hospital. Shuhei Nomura 
acknowledges support from the Ministry of Education, Culture, Sports, 
Science, and Technology of Japan (18K10082). Alberto Ortiz 
acknowledges support by ISCIII PI19/00815, DTS18/00032, 
ISCIII-RETIC REDinREN RD016/0009 Fondos FEDER, FRIAT, 
Comunidad de Madrid B2017/BMD-3686 CIFRA2-CM. These funding 
sources had no role in the writing of the manuscript or the decision to 
submit it for publication. George C Patton acknowledges support from a 
National Health & Medical Research Council Fellowship. Marina 
Pinheiro acknowledges support from FCT for funding through program 
DL 57/2016 - Norma transitÃ³ria. Alberto Raggi, David Sattin, and 
Silvia Schiavolin acknowledge support by a grant from the Italian 
Ministry of Health (Ricerca Corrente, Fondazione Istituto Neurologico C 
Besta, Linea 4 - Outcome Research: dagli Indicatori alle Raccomandazioni 
Cliniche). Daniel Cury Ribeiro acknowledges support from the 
Sir Charles Hercus Health Research Fellowship - Health Research 
Council of New Zealand (18/111). Perminder S Sachdev acknowledges 
funding from the NHMRC Australia. Abdallah M Samy acknowledges 
support from a fellowship from the Egyptian Fulbright Mission Program. 
Milena M Santric-Milicevic acknowledges support from the Ministry of 
Education, Science and Technological Development of the Republic of 
Serbia (Contract No. 175087). Rodrigo Sarmiento-Suárez acknowledges 
institutional support from University of Applied and Environmental 
Sciences in Bogota, Colombia, and Carlos III Institute of Health in 
Madrid, Spain. Maria Inês Schmidt acknowledges grants from the 
Foundation for the Support of Research of the State of Rio Grande do Sul 
(IATS and PrInt) and the Brazilian Ministry of Health. 
Sheikh Mohammed Shariful Islam acknowledges a fellowship from the 
National Heart Foundation of Australia and Deakin University. 
Aziz Sheikh acknowledges support from Health Data Research UK. 
Kenji Shibuya acknowledges Japan Ministry of Education, Culture, 
Sports, Science and Technology. Joan B Soriano acknowledges support by 
Centro de Investigación en Red de Enfermedades Respiratorias 
(CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 
Rafael Tabarés-Seisdedos acknowledges partial support from grant 
PI17/00719 from ISCIII-FEDER. Santosh Kumar Tadakamadla 
acknowledges support from the National Health and Medical Research 
Council Early Career Fellowship, Australia. Marcello Tonelli 
acknowledges the David Freeze Chair in Health Services Research at the 
University of Calgary, AB, Canada.
Editorial note: the Lancet Group takes a neutral position with respect to 
territorial claims in published maps and institutional affiliations.
References
1 UNGA. Resolution 74/2: political declaration of the high-level 
meeting on universal health coverage. Oct 18, 2019. https://undocs.
org/en/A/RES/74/2 (accessed Nov 15, 2019).
2 Schmidt H, Gostin LO, Emanuel EJ. Public health, universal health 
coverage, and Sustainable Development Goals: can they coexist? 
Lancet 2015; 386: 928–30.
3 UN. Transforming our world: the 2030 Agenda for Sustainable 
Development. UN, 2015. https://sustainabledevelopment.un.org/
post2015/transformingourworld/publication (accessed 
March 25, 2020).
4 UN Statistical Commission. SDG indicator 3·8.1 metadata. 2018. 
https://unstats.un.org/sdgs/metadata/files/Metadata-03–08–01.pdf 
(accessed March 25, 2020).
5 UN Statistical Commission. SDG indicator 3.8.2 metadata. 2019. 
https://unstats.un.org/sdgs/metadata/files/Metadata-03-08-02.pdf 
(accessed April 22, 2020).
6 WHO. Thirteenth General Programme of Work 2019–2023: 
promote health, keep the world safe, serve the vulnerable. Geneva: 
World Health Organization, 2019.
Articles
34 www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9
7 WHO. Resolution A72/5. Thirteenth General Programme of Work, 
2019–2023. WHO Impact Framework. Geneva: World Health 
Organization, 2019.
8 Naoki Ikegami. Universal health coverage for inclusive and 
sustainable development: lessons from Japan. A World Bank study. 
Washington, DC: World Bank, 2014.
9 McKee M, Balabanova D, Basu S, Ricciardi W, Stuckler D. 
Universal health coverage: a quest for all countries but under threat 
in some. Value Health 2013; 16: S39–45.
10 Hurst JW. Reforming health care in seven European nations. 
Health Aff 1991; 10: 7–21.
11 Atun R, de Andrade LOM, Almeida G, et al. Health-system reform 
and universal health coverage in Latin America. Lancet 2015; 
385: 1230–47.
12 Dmytraczenko T, Almeida G. Toward universal health coverage and 
equity in Latin America and the Caribbean: evidence from selected 
countries. Washington, DC: World Bank, 2015.
13 Cotlear D, Nagpal S, Smith O, Tandon A, Cortez R. Going 
universal: how 24 developing countries are implementing 
universal health coverage from the bottom up. Washington, DC: 
World Bank, 2015.
14 WHO, World Bank. Monitoring progress towards universal health 
coverage at country and global levels: framework, measures, 
and targets. Geneva; Washington, DC: WHO, World Bank, 2014.
15 Boerma T, Eozenou P, Evans D, Evans T, Kieny M-P, Wagstaff A. 
Monitoring progress towards universal health coverage at country 
and global Levels. PLoS Med 2014; 11: e1001731.
16 Shengelia B, Tandon A, Adams OB, Murray CJL. Access, 
utilization, quality, and effective coverage: an integrated conceptual 
framework and measurement strategy. Soc Sci Med 2005; 
61: 97–109.
17 Ng M, Fullman N, Dieleman JL, Flaxman AD, Murray CJL, Lim SS. 
Effective coverage: a metric for monitoring universal health 
coverage. PLoS Med 2014; 11: e1001730.
18 Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, 
Salomon JA. Mortality due to low-quality health systems in the 
universal health coverage era: a systematic analysis of amenable 
deaths in 137 countries. Lancet 2018; 392: 2203–12.
19 Hogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring 
universal health coverage within the Sustainable Development 
Goals: development and baseline data for an index of essential 
health services. Lancet Glob Health 2018; 6: e152–68.
20 WHO, World Bank. Tracking universal health coverage: 2017 global 
monitoring report. Geneva; Washington, DC: WHO, World Bank, 
2017.
21 WHO. Primary health care on the road to universal health coverage: 
2019 monitoring report. Geneva: World Health Organization, 2019.
22 Leegwater A, Wong W, Avila C. A concise, health service coverage 
index for monitoring progress towards universal health coverage. 
BMC Health Serv Res 2015; 15: 230.
23 Wagstaff A, Dmytraczenko T, Almeida G, et al. Assessing 
Latin America’s progress toward achieving universal health 
coverage. Health Aff 2015; 34: 1704–12.
24 Wagstaff A, Neelsen S. A comprehensive assessment of universal 
health coverage in 111 countries: a retrospective observational study. 
Lancet Glob Health 2020; 8: e39–49.
25 Fullman N, Barber RM, Abajobir AA, et al. Measuring progress and 
projecting attainment on the basis of past trends of the health-
related Sustainable Development Goals in 188 countries: an analysis 
from the Global Burden of Disease Study 2016. Lancet 2017; 
390: 1423–59.
26 Lozano R, Fullman N, Abate D, et al. Measuring progress from 
1990 to 2017 and projecting attainment to 2030 of the health-related 
Sustainable Development Goals for 195 countries and territories: 
a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet 2018; 392: 2091–138.
27 Bergen N, Ruckert A, Labonté R. Monitoring frameworks for 
universal health coverage: what about high-income countries? 
Int J Health Policy Manag 2019; 8: 387–93.
28 Ataguba JE, Ingabire M-G. Universal health coverage: assessing 
service coverage and financial protection for all. Am J Public Health 
2016; 106: 1780–81.
29 The Lancet. Ensuring and measuring universality in UHC. Lancet 
2019; 393: 1.
30 Fullman N, Lozano R. Towards a meaningful measure of universal 
health coverage for the next billion. Lancet Glob Health 2018; 
6: e122–23.
31 Fullman N, Lozano R. Measurement matters: who and what counts 
on the road to universal health coverage. Lancet Glob Health 2020; 
8: e2–3.
32 Kyu HH, Abate D, Abate KH, et al. Global, regional, and national 
disability-adjusted life-years (DALYs) for 359 diseases and injuries 
and healthy life expectancy (HALE) for 195 countries and territories, 
1990–2017: a systematic analysis for the Global Burden of Disease 
Study 2017. Lancet 2018; 392: 1859–922.
33 WHO Expert Reference Group on the Draft GPW 13. Preliminary 
report 2018: metrics for the GPW13. May, 2018. https://www.who.int/
docs/default-source/documents/about-us/expert-reference-group-
preliminary-report.pdf?sfvrsn=27a03101_2 (accessed March 27, 2020).
34 GBD 2019 Demographics Collaborators. Global age-sex-specific 
fertility, mortality, healthy life expectancy (HALE), and population 
estimates in 204 countries and territories, 1950–2019: 
a comprehensive demographic analysis for the Global Burden of 
Disease Study 2019. Lancet (in press).
35 GBD 2019 Diseases and Injuries Collaborators. Global burden of 
369 diseases and injuries in 204 countries and territories, 
1990–2019: a systematic analysis for the Global Burden of Disease 
Study 2019. Lancet (in press). 
36 GBD 2019 Risk Factors Collaborators. Global burden of 87 risk 
factors in 204 countries and territories, 1990–2019: a systematic 
analysis for the Global Burden of Disease Study 2019. Lancet 
(in press).
37 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and 
transparent health estimates reporting: the GATHER statement. 
Lancet 2016; 388: e19–23.
38 WHO. Expert Reference Group on the Draft GPW 13 Impact 
Framework 2019–2023. https://www.who.int/about/what-we-do/
thirteenth-general-programme-of-work-2019-2023/expert-reference-
group-on-the-draft-gpw-13-impact-framework-2019-2023 (accessed 
Feb 25, 2020).
39 WHO. An updated method for the essential health services 
coverage index. Jan 17, 2019. https://unstats.un.org/sdgs/files/
meetings/webex-17jan2019/1_3.8.1_Tier%20Reclassification%20
Request_WHO.pdf (accessed March 27, 2020).
40 Nolte E, McKee M. Does healthcare save lives? Avoidable mortality 
revisited. London: London School of Hygiene & Tropical Medicine, 
2004. https://researchonline.lshtm.ac.uk/15535/1/does-healthcare-
save-lives-mar04.pdf (accessed March 27, 2020).
41 Fullman N, Yearwood J, Abay SM, et al. Measuring performance on 
the Healthcare Access and Quality Index for 195 countries and 
territories and selected subnational locations: a systematic analysis 
from the Global Burden of Disease Study 2016. Lancet 2018; 
391: 2236–71.
42 Nolte E, McKee CM. Measuring the health of nations: updating an 
earlier analysis. Health Aff 2008; 27: 58–71.
43 Barber RM, Fullman N, Sorensen RJD, et al. Healthcare Access and 
Quality Index based on mortality from causes amenable to personal 
health care in 195 countries and territories, 1990–2015: a novel 
analysis from the Global Burden of Disease Study 2015. Lancet 2017; 
390: 231–66.
44 Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in 
five continents: a worldwide population-based study (CONCORD). 
Lancet Oncol 2008; 9: 730–56.
45 De Angelis R, Sant M, Coleman MP, et al. Cancer survival in 
Europe 1999–2007 by country and age: results of EUROCARE-5— 
a population-based study. Lancet Oncol 2014; 15: 23–34.
46 Allemani C, Matsuda T, Carlo VD, et al. Global surveillance of 
trends in cancer survival 2000–14 (CONCORD-3): analysis of 
individual records for 37 513 025 patients diagnosed with one of 
18 cancers from 322 population-based registries in 71 countries. 
Lancet 2018; 391: 1023–75.
47 Marten R, McIntyre D, Travassos C, et al. An assessment of 
progress towards universal health coverage in Brazil, Russia, 
India, China, and South Africa (BRICS). Lancet 2014; 
384: 2164–71.
48 Aguilera X, Castillo-Laborde C, Ferrari MN-D, Delgado I, Ibañez C. 
Monitoring and evaluating progress towards universal health 
coverage in Chile. PLoS Med 2014; 11: e1001676.
Articles
www.thelancet.com   Published online August 27, 2020   https://doi.org/10.1016/S0140-6736(20)30750-9 35
49 de Andrade LOM, Filho AP, Solar O, et al. Social determinants of 
health, universal health coverage, and sustainable development: 
case studies from Latin American countries. Lancet 2015; 385: 1343–51.
50 Reich MR, Harris J, Ikegami N, et al. Moving towards universal 
health coverage: lessons from 11 country studies. Lancet 2016; 
387: 811–16.
51 Nyonator F, Ofosu A, Segbafah M, d’Almeida S. Monitoring and 
evaluating progress towards universal health coverage in Ghana. 
PLoS Med 2014; 11: e1001691.
52 Chemouni B. The political path to universal health coverage: 
power, ideas and community-based health insurance in Rwanda. 
World Dev 2018; 106: 87–98.
53 Tan KB, Tan WS, Bilger M, Ho CWL. Monitoring and evaluating 
progress towards universal health coverage in Singapore. PLoS Med 
2014; 11: e1001695.
54 Tangcharoensathien V, Limwattananon S, Patcharanarumol W, 
Thammatacharee J. Monitoring and evaluating progress towards 
universal health coverage in Thailand. PLoS Med 2014; 11: e1001726.
55 Savedoff WD, Smith AL. Achieving universal health coverage: 
learning from Chile, Japan, Malaysia, and Sweden. Results for 
Development (R4D), 2011. https://www.r4d.org/resources/achieving-
universal-health-coverage-learning-chile-japan-malaysia-sweden/ 
(accesed March 27, 2020).
56 Global Burden of Disease Health Financing Collaborator Network. 
Health sector spending and spending on HIV/AIDS, tuberculosis, 
and malaria, and development assistance for health: progress 
towards Sustainable Development Goal 3. Lancet 2020; published 
online April 23. http://doi.org/10.1016/S0140-6736(20)30608-5.
57 Stevens G, Hogan D. Service coverage within universal health 
coverage: how large is the gap? Technical note. Geneva: World 
Health Organization, 2017.
58 WHO. Methods for the 13th General Programme of Work (GPW13) 
Impact Measurement. Draft for consultation. Version 1.3.1. 
Jan 30, 2020. Geneva: World Health Organization, 2020.
59 Dieleman JL, Sadat N, Chang AY, et al. Trends in future health 
financing and coverage: future health spending and universal 
health coverage in 188 countries, 2016–40. Lancet 2018; 391: 1783–98.
60 Vollset SE, Goren E, Yuan C-W, et al. Fertility, mortality, migration, 
and population scenarios for 195 countries and territories from 2017 
to 2100: a forecasting analysis for the Global Burden of Disease 
Study. Lancet 2020; published online July 14. https://doi.org/10.1016/
S0140-6736(20)30677-2. 
61 Chang AY, Cowling K, Micah AE, et al. Past, present, and future of 
global health financing: a review of development assistance, 
government, out-of-pocket, and other private spending on health for 
195 countries, 1995–2050. Lancet 2019; 393: 2233–60.
62 Dieleman JL, Schneider MT, Haakenstad A, et al. Development 
assistance for health: past trends, associations, and the future of 
international financial flows for health. Lancet 2016; 387: 2536–44.
63 GBD 2019 Viewpoint Collaborators. Five insights from the Global 
Burden of Disease Study 2019. Lancet (in press).
64 Asma S, Lozano R, Chatterji S, et al. Monitoring the health-related 
Sustainable Development Goals: lessons learned and 
recommendations for improved measurement. Lancet 2019; 
395: 240–46.
65 WHO. World report on vision. Geneva: World Health Organization, 
2019.
66 WHO. World report on hearing. 2020. http://www.who.int/
deafness/world-report-hearing/en/ (accessed May 27, 2020).
67 De Silva MJ, Lee L, Fuhr DC, et al. Estimating the coverage of 
mental health programmes: a systematic review. Int J Epidemiol 
2014; 43: 341–53.
68 WHO. Measles—global situation. Nov 27, 2019. http://www.who.
int/csr/don/26-november-2019-measles-global_situation/en/ 
(accessed March 3, 2020).
